drug1_db stringlengths 7 7 | drug2_db stringlengths 7 7 | drug1_id int64 0 1.69k | drug2_id int64 0 1.69k | drug_pair listlengths 2 2 | drug1_name stringlengths 4 85 | drug2_name stringlengths 4 85 | drug1_desc stringlengths 27 1.09k | drug2_desc stringlengths 27 6.14k | label stringclasses 3 values | label_idx int64 0 2 | all_paths listlengths 1 10 | all_paths_str listlengths 1 10 | path_str stringlengths 0 3.57k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB01037 | DB01309 | 1,161 | 1,254 | [
"DDInter1653",
"DDInter933"
] | Selegiline | Insulin glulisine | A selective, irreversible inhibitor of Type B monoamine oxidase. It is used in newly diagnosed patients with Parkinson's disease. It may slow progression of the clinical disease and delay the requirement for levodopa therapy. It also may be given with levodopa upon onset of disability. (From AMA Drug Evaluations Annual, 1994, p385) The compound without isomeric designation is Deprenyl. | Insulin glulisine is a short-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas that promotes glucose metabolism. Insulin is released from the pancreas following a meal to promote the uptake of glucose from the blood into internal organs and tissues such as the liver, fat cells, and skeletal muscle. Absorption of glucose into cells allows for its transformation into glycogen or fat for storage. Insulin also inhibits hepatic glucose production, enhances protein synthesis, and inhibits lipolysis and proteolysis among many other functions. Insulin is an important treatment in the management of Type 1 Diabetes (T1D) which is caused by an autoimmune reaction that destroys the beta cells of the pancreas, resulting in the body not being able to produce or synthesize the insulin needed to manage circulating blood sugar levels. As a result, people with T1D rely primarily on exogenous forms of insulin, such as insulin glulisine, to lower glucose levels in the blood. Insulin is also used in the treatment of Type 2 Diabetes (T2D), another form of diabetes mellitus that is a slowly progressing metabolic disorder caused by a combination of genetic and lifestyle factors that promote chronically elevated blood sugar levels. Without treatment or improvement in non-pharmacological measures such as diet and exercise to lower blood glucose, high blood sugar eventually causes cellular resistance to endogenous insulin, and in the long term, damage to pancreatic islet cells. Insulin is typically prescribed later in the course of T2D, after trying several oral medications such as , , or have been tried, when sufficient damage has been caused to pancreatic cells that the body is no longer able to produce insulin on its own. Marketed as the brand name product Apidra, insulin glulisine begins to exert its effects within 15 minutes of subcutaneous administration, while peak levels occur 30 to 90 minutes after administration. Due to its duration of action of around 5 hours, Apidra is considered "bolus insulin" as it provides high levels of insulin in a short period of time to mimic the release of endogenous insulin from the pancreas after meals. Bolus insulin is often combined with once daily, long-acting "basal insulin" such as , , and to provide low concentrations of background insulin that can keep blood sugar stable between meals or overnight. Use of basal and bolus insulin together is intended to mimic the pancreas' production of endogenous insulin, with a goal of avoiding any periods of hypoglycemia. Insulin glulisine is a biosynthetic, rapid-acting human insulin analogue produced in a non-pathogenic laboratory strain of _Escherichia coli_ (K12). This recombinant hormone differs from native human insulin in that the amino acid asparagine at position B3 is replaced by lysine and the lysine at position B29 is replaced by glutamic acid. These structural modifications decrease hexamer formation, stabilize insulin glulisine monomers and increase the rate of absorption and onset of action compared to human insulin. Without an adequate supply of insulin to promote absorption of glucose from the bloodstream, blood sugar levels can climb to dangerously high levels and can result in symptoms such as fatigue, headache, blurred vision, and increased thirst. If left untreated, the body starts to break down fat, instead of glucose, for energy which results in a build-up of ketone acids in the blood and a syndrome called ketoacidosis, which is a life-threatening medical emergency. In the long term, elevated blood sugar levels increase the risk of heart attack, stroke, and diabetic neuropathy. | Moderate | 1 | [
[
[
1161,
24,
1254
]
],
[
[
1161,
63,
274
],
[
274,
23,
1254
]
],
[
[
1161,
24,
1033
],
[
1033,
63,
1254
]
],
[
[
1161,
1,
280
],
[
280,
... | [
[
[
"Selegiline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin glulisine"
]
],
[
[
"Selegiline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phentolamine"
],... | Selegiline may cause a moderate interaction that could exacerbate diseases when taken with Phentolamine and Phentolamine may cause a minor interaction that can limit clinical effects when taken with Insulin glulisine
Selegiline may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib and Alpelisib may cause a moderate interaction that could exacerbate diseases when taken with Insulin glulisine
Selegiline (Compound) resembles Mephentermine (Compound) and Mephentermine may cause a moderate interaction that could exacerbate diseases when taken with Insulin glulisine
Selegiline may cause a moderate interaction that could exacerbate diseases when taken with Formoterol and Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Insulin glulisine
Selegiline (Compound) resembles Phentermine (Compound) and Selegiline may lead to a major life threatening interaction when taken with Phentermine and Phentermine may cause a moderate interaction that could exacerbate diseases when taken with Insulin glulisine
Selegiline (Compound) resembles Metamfetamine (Compound) and Metamfetamine may cause a moderate interaction that could exacerbate diseases when taken with Insulin glulisine
Selegiline may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Insulin glulisine
Selegiline may lead to a major life threatening interaction when taken with Phenylephrine and Phenylephrine may cause a moderate interaction that could exacerbate diseases when taken with Insulin glulisine
Selegiline (Compound) resembles Ephedrine (Compound) and Selegiline may lead to a major life threatening interaction when taken with Ephedrine and Ephedrine may cause a moderate interaction that could exacerbate diseases when taken with Insulin glulisine |
DB04953 | DB11113 | 495 | 657 | [
"DDInter708",
"DDInter307"
] | Ezogabine | Castor oil | Ezogabine (D23129) is a close structural analog of the centrally acting analgesic flupitrine. It is a neuronal potassium channel opener being developed as a first-in-class antiepileptic drug (AED) and is currently being studied in Phase 3 trials as an adjunctive treatment for partial-onset seizures in adult patients with refractory epilepsy. FDA approved in June 10, 2011 under the name of ezogabine. | Castor oil is a vegetable oil obtained by pressing the seeds of the castor oil plant (_Ricinus communis_ L.) mainly cultivated in India, South America, Africa, and China. Castor oil is a rich source of , which represents up to 90% of the total castor oil content. It also consists up to 4% linoleic, 3% oleic, 1% stearic, and less than 1% linolenic fatty acids . has a hydroxyl group that provides a functional group location for various chemical reactions, making it a favourable substance in industrial applications . Castor oil does not contain ricin, which is a natural poison found in the castor oil plant; the toxic lectin remains in the bean pulp following oil isolation . Due to its renewability and high versatility in addition to being the only commercial source of a hydroxylated fatty acid , castor oil has been used as a vital raw material for the chemical industry . Castor oil was mainly used in the manufacturing of soaps, lubricants, and coatings . It is an FDA-approved food additive directly added to food products for human consumption. It can also be found in hard candies as a release agent and anti-sticking agent, or supplementary vitamins and mineral oral tablets as an ingredient for protective coatings. Castor oil is found in over-the-counter oral liquids as a stimulant laxative, and is also added in commercial cosmetic, hair, and skincare products. | Moderate | 1 | [
[
[
495,
24,
657
]
],
[
[
495,
24,
927
],
[
927,
63,
657
]
],
[
[
495,
24,
1491
],
[
1491,
24,
657
]
],
[
[
495,
25,
985
],
[
985,
2... | [
[
[
"Ezogabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Castor oil"
]
],
[
[
"Ezogabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
],
[
... | Ezogabine may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib and Encorafenib may cause a moderate interaction that could exacerbate diseases when taken with Castor oil
Ezogabine may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin and Midostaurin may cause a moderate interaction that could exacerbate diseases when taken with Castor oil
Ezogabine may lead to a major life threatening interaction when taken with Osimertinib and Osimertinib may cause a moderate interaction that could exacerbate diseases when taken with Castor oil
Ezogabine may cause a moderate interaction that could exacerbate diseases when taken with Terfenadine and Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Castor oil
Ezogabine may lead to a major life threatening interaction when taken with Halofantrine and Halofantrine may cause a moderate interaction that could exacerbate diseases when taken with Castor oil
Ezogabine may lead to a major life threatening interaction when taken with Ribociclib and Ribociclib may cause a moderate interaction that could exacerbate diseases when taken with Castor oil
Ezogabine may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib and Encorafenib may cause a moderate interaction that could exacerbate diseases when taken with Telavancin and Telavancin may cause a moderate interaction that could exacerbate diseases when taken with Castor oil
Ezogabine may lead to a major life threatening interaction when taken with Osimertinib and Osimertinib may lead to a major life threatening interaction when taken with Telavancin and Telavancin may cause a moderate interaction that could exacerbate diseases when taken with Castor oil
Ezogabine may cause a moderate interaction that could exacerbate diseases when taken with Terfenadine and Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Telavancin and Telavancin may cause a moderate interaction that could exacerbate diseases when taken with Castor oil |
DB01035 | DB01218 | 1,401 | 1,493 | [
"DDInter1524",
"DDInter852"
] | Procainamide | Halofantrine | A derivative of procaine with less CNS action. | Halofantrine is an antimalarial. It belongs to the phenanthrene class of compounds that includes quinine and lumefantrine. It appears to inhibit polymerisation of heme molecules (by the parasite enzyme "heme polymerase"), resulting in the parasite being poisoned by its own waste. Halofantrine has been shown to preferentially block open and inactivated HERG channels leading to some degree of cardiotoxicity. | Major | 2 | [
[
[
1401,
25,
1493
]
],
[
[
1401,
6,
12523
],
[
12523,
45,
1493
]
],
[
[
1401,
21,
28810
],
[
28810,
60,
1493
]
],
[
[
1401,
62,
112
],
[
... | [
[
[
"Procainamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Halofantrine"
]
],
[
[
"Procainamide",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",
"H... | Procainamide (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Halofantrine (Compound)
Procainamide (Compound) causes Gastrointestinal pain (Side Effect) and Gastrointestinal pain (Side Effect) is caused by Halofantrine (Compound)
Procainamide may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Halofantrine
Procainamide may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Halofantrine
Procainamide may cause a moderate interaction that could exacerbate diseases when taken with Salmeterol and Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Halofantrine
Procainamide may cause a moderate interaction that could exacerbate diseases when taken with Castor oil and Castor oil may cause a moderate interaction that could exacerbate diseases when taken with Halofantrine
Procainamide may lead to a major life threatening interaction when taken with Dasatinib and Dasatinib may lead to a major life threatening interaction when taken with Halofantrine
Procainamide may lead to a major life threatening interaction when taken with Sorafenib and Sorafenib may lead to a major life threatening interaction when taken with Halofantrine
Procainamide may lead to a major life threatening interaction when taken with Isoprenaline and Isoprenaline may lead to a major life threatening interaction when taken with Halofantrine |
DB01238 | DB01246 | 673 | 820 | [
"DDInter118",
"DDInter45"
] | Aripiprazole | Alimemazine | Aripiprazole is an atypical antipsychotic orally indicated for the treatment of schizophrenia, bipolar I, major depressive disorder, irritability associated with autism, and Tourette's. It is also indicated as an injection for agitation associated with schizophrenia or bipolar mania. Aripiprazole exerts its effects through agonism of dopaminergic and 5-HT1A receptors and antagonism of alpha-adrenergic and 5-HT2A receptors.[L45859,A4393] Aripiprazole was given FDA approval on November 15, 2002. | A phenothiazine derivative that is used as an antipruritic. | Moderate | 1 | [
[
[
673,
24,
820
]
],
[
[
673,
63,
104
],
[
104,
40,
820
]
],
[
[
673,
63,
401
],
[
401,
24,
820
]
],
[
[
673,
24,
649
],
[
649,
1,
... | [
[
[
"Aripiprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
]
],
[
[
"Aripiprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
],
... | Aripiprazole may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine (Compound) resembles Alimemazine (Compound)
Aripiprazole may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine
Aripiprazole may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol and Clofedanol (Compound) resembles Alimemazine (Compound)
Aripiprazole (Compound) resembles Prochlorperazine (Compound) and Prochlorperazine (Compound) resembles Alimemazine (Compound)
Aripiprazole (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Alimemazine (Compound)
Aripiprazole (Compound) upregulates HMGCS1 (Gene) and HMGCS1 (Gene) is upregulated by Alimemazine (Compound)
Aripiprazole (Compound) causes Tremor (Side Effect) and Tremor (Side Effect) is caused by Alimemazine (Compound)
Aripiprazole may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Alimemazine
Aripiprazole (Compound) resembles Cilostazol (Compound) and Aripiprazole may cause a moderate interaction that could exacerbate diseases when taken with Cilostazol and Cilostazol may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine |
DB00476 | DB08880 | 109 | 1,510 | [
"DDInter608",
"DDInter1771"
] | Duloxetine | Teriflunomide | Duloxetine is a dual serotonin and norepinephrine reuptake inhibitor.[label] It was originally discovered in 1993 and developed by Eli Lilly and Company as LY248686. Duloxetine first received approval from the FDA in August, 2004 as Cymbalta for the treatment of Major Depressive Disorder. It has since received approval for a variety of indications including the treatment of neuropathic pain, Generalized Anxiety disorder, osteoarthritis, and stress incontinence. Duloxetine continues to be investigated for the treatment of pain in cancer, surgery, and more. | Teriflunomide is the active metabolite of leflunomide, and it acts as an immunomodulatory agent by inhibiting pyrimidine synthesis. It is marketed under the name Aubagio® and is indicated for the treatment of multiple sclerosis, specifically relapsing forms. The FDA label states an important warning about the risk of hepatoxicity and teratogenicity for patients using teriflunomide. | Major | 2 | [
[
[
109,
25,
1510
]
],
[
[
109,
24,
741
],
[
741,
63,
1510
]
],
[
[
109,
63,
1061
],
[
1061,
24,
1510
]
],
[
[
109,
24,
752
],
[
752,
... | [
[
[
"Duloxetine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
]
],
[
[
"Duloxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rolapitant"
],
[
"Rolapit... | Duloxetine may cause a moderate interaction that could exacerbate diseases when taken with Rolapitant and Rolapitant may cause a moderate interaction that could exacerbate diseases when taken with Teriflunomide
Duloxetine may cause a moderate interaction that could exacerbate diseases when taken with Treprostinil and Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Teriflunomide
Duloxetine may cause a moderate interaction that could exacerbate diseases when taken with Cimetidine and Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Teriflunomide
Duloxetine may cause a moderate interaction that could exacerbate diseases when taken with Diclofenac and Diclofenac may lead to a major life threatening interaction when taken with Teriflunomide
Duloxetine may cause a moderate interaction that could exacerbate diseases when taken with Osimertinib and Osimertinib may lead to a major life threatening interaction when taken with Teriflunomide
Duloxetine may lead to a major life threatening interaction when taken with Bupropion and Bupropion may lead to a major life threatening interaction when taken with Teriflunomide
Duloxetine may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may lead to a major life threatening interaction when taken with Teriflunomide
Duloxetine (Compound) resembles Atomoxetine (Compound) and Atomoxetine may lead to a major life threatening interaction when taken with Teriflunomide
Duloxetine may cause a moderate interaction that could exacerbate diseases when taken with Rolapitant and Rolapitant may lead to a major life threatening interaction when taken with Enzalutamide and Enzalutamide may cause a moderate interaction that could exacerbate diseases when taken with Teriflunomide |
DB00703 | DB09564 | 997 | 1,296 | [
"DDInter1167",
"DDInter930"
] | Methazolamide | Insulin degludec | A carbonic anhydrase inhibitor that is used as a diuretic and in the treatment of glaucoma. | Insulin degludec is an ultra-long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes.[A18561,A18562,A18563,A18564,A174934] Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas that promotes glucose metabolism.[A18561,A18562,A18563,A18564,A174934] Insulin is released from the pancreas following a meal to promote the uptake of glucose from the blood into internal organs and tissues such as the liver, fat cells, and skeletal muscle.[A18561,A18562,A18563,A18564,A174934] Absorption of glucose into cells allows for its transformation into glycogen or fat for storage.[A18561,A18562,A18563,A18564,A174934] Insulin also inhibits hepatic glucose production, enhances protein synthesis, and inhibits lipolysis and proteolysis among many other functions.[A18561,A18562,A18563,A18564,A174934] Insulin is an essential treatment in the management of Type 1 Diabetes (T1D) which is caused by an autoimmune reaction that destroys the beta cells of the pancreas, resulting in the body not being able to produce or synthesize the insulin needed to manage circulating blood sugar levels.[A18561,A18562,A18563,A18564,A174934] As a result, people with T1D rely primarily on exogenous forms of insulin, such as insulin degludec, to lower glucose levels in the blood.[A18561,A18562,A18563,A18564,A174934] Insulin is also used in the treatment of Type 2 Diabetes (T2D), another form of diabetes mellitus that is a slowly progressing metabolic disorder caused by a combination of genetic and lifestyle factors that promote chronically elevated blood sugar levels.[A18561,A18562,A18563,A18564,A174934] Without treatment or improvement in non-pharmacological measures such as diet and exercise to lower blood glucose, high blood sugar eventually causes cellular resistance to endogenous insulin, and in the long term, damage to pancreatic islet cells.[A18561,A18562,A18563,A18564,A174934] Insulin is typically prescribed later in the course of T2D, after several oral medications such as , , or have been tried, when sufficient damage has been caused to pancreatic cells that the body is no longer able to produce insulin on its own.[A18561,A18562,A18563,A18564,A174934] Marketed as the brand name product Tresiba, insulin degludec has a duration of action up to 42 hours allowing for once-daily dosing, typically at bedtime.[A18561,A18562,A18563,A18564,A174934] Due to its duration of action, Tresiba is considered "basal insulin" as it provides low concentrations of background insulin that can keep blood sugar stable between meals or overnight.[A18561,A18562,A18563,A18564,A174934] Basal insulin is often combined with short-acting "bolus insulin" such as , , or to provide higher doses of insulin required following meals. Use of basal and bolus insulin together is intended to mimic the pancreas' production of endogenous insulin, with the goal of avoiding any periods of hypoglycemia.[A18561,A18562,A18563,A18564,A174934] Compared to endogenous insulin, insulin degludec has an added hexadecanedioic acid on lysine at the B29 position, allowing for the formation of multi-hexamers.[A18561,A18562,A18563,A18564,A174934] When injected subcutaneously, these multi-hexamers form a drug depot store from which monomers are slowly and continuously absorbed into circulation.[A18561,A18562,A18563,A18564,A174934] As a result, Insulin Degludec has a protracted time action profile due to the delayed absorption from subcutaneous tissue depots into the systemic circulation.[A18561,A18562,A18563,A18564,A174934] Compared to available long-acting analogs such as and , which have a duration of action of 20-24 hours, insulin degludec provides a consistent level of basal insulin over 42 hours with a low peak: trough ratio.[A18561,A18562,A18563,A18564,A174934] Limitations of shorter-acting analogs include more frequent dosing and less stable pharmacokinetics, which may negatively impact patient adherence and glucose control, particularly nocturnal control.[A18561,A18562,A18563,A18564,A174934] Without an adequate supply of insulin to promote absorption of glucose from the bloodstream, blood sugar levels can climb to dangerously high levels and can result in symptoms such as fatigue, headache, blurred vision, and increased thirst.[A18561,A18562,A18563,A18564,A174934] If left untreated, the body starts to break down fat, instead of glucose, for energy which results in a build-up of ketone acids in the blood and a syndrome called ketoacidosis, which is a life-threatening medical emergency. In the long term, elevated blood sugar levels increase the risk of heart attack, stroke, and diabetic neuropathy.[A18561,A18562,A18563,A18564,A174934] Insulin Degludec was approved by the FDA in September 2015 as the product Tresiba, for use in providing glycemic control to adults with diabetes mellitus. | Moderate | 1 | [
[
[
997,
24,
1296
]
],
[
[
997,
24,
1411
],
[
1411,
24,
1296
]
],
[
[
997,
64,
1645
],
[
1645,
24,
1296
]
],
[
[
997,
62,
964
],
[
964,
... | [
[
[
"Methazolamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin degludec"
]
],
[
[
"Methazolamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolbutamide"
... | Methazolamide may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec
Methazolamide may lead to a major life threatening interaction when taken with Metformin and Metformin may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec
Methazolamide may cause a minor interaction that can limit clinical effects when taken with Doxycycline and Doxycycline may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec
Methazolamide may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone and Triamcinolone may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec
Methazolamide may lead to a major life threatening interaction when taken with Acetylsalicylic acid and Acetylsalicylic acid may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec
Methazolamide may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide and Semaglutide may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec
Methazolamide may cause a minor interaction that can limit clinical effects when taken with Minocycline and Minocycline may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec
Methazolamide may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide may cause a minor interaction that can limit clinical effects when taken with Amcinonide and Amcinonide may cause a minor interaction that can limit clinical effects when taken with Insulin degludec
Methazolamide may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol and Vilanterol may lead to a major life threatening interaction when taken with Sotalol and Sotalol may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec |
DB00252 | DB00507 | 362 | 316 | [
"DDInter1460",
"DDInter1299"
] | Phenytoin | Nitazoxanide | Phenytoin is classified as a hydantoin derivative and despite its narrow therapeutic index, it is one of the most commonly used anticonvulsants.[A33595,A188832,A189219] Since it's introduction about 80 years ago, phenytoin has not only been established as an effective anti-epileptic, but has also been investigated for several other indications such as bipolar disorder, retina protection, and wound healing.[A188826,A188832] Clinicians are advised to initiate therapeutic drug monitoring in patients who require phenytoin since even small deviations from the recommended therapeutic range can lead to suboptimal treatment, or adverse effects.[A189219,A35884] Both parenteral and oral formulations of phenytoin are available on the market. | Nitazoxanide belongs to the class of drugs known as _thiazolides_. Nitazoxanide (NTZ) is a broad-spectrum anti-infective drug that markedly modulates the survival, growth, and proliferation of a range of extracellular and intracellular protozoa, helminths, anaerobic and microaerophilic bacteria, in addition to viruses. This drug is effective in the treatment of gastrointestinal infections including Cryptosporidium parvum or Giardia lamblia in healthy subjects. It is generally well tolerated. Nitazoxanide is a first-line, standard treatment for illness caused by C. parvum or G. lamblia infection in healthy (not immunosuppressed) adults and children and may also be considered in the treatment of illnesses caused by other protozoa or helminths . Recently, this drug has been studied as a broad-spectrum antiviral agent due to its ability to inhibit the replication of several RNA and DNA viruses . | Moderate | 1 | [
[
[
362,
24,
316
]
],
[
[
362,
23,
1479
],
[
1479,
1,
316
]
],
[
[
362,
18,
17148
],
[
17148,
57,
316
]
],
[
[
362,
21,
28779
],
[
28779,
... | [
[
[
"Phenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nitazoxanide"
]
],
[
[
"Phenytoin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Acetylsalicylic acid"
],
... | Phenytoin may cause a minor interaction that can limit clinical effects when taken with Acetylsalicylic acid and Acetylsalicylic acid (Compound) resembles Nitazoxanide (Compound)
Phenytoin (Compound) downregulates ZDHHC6 (Gene) and ZDHHC6 (Gene) is downregulated by Nitazoxanide (Compound)
Phenytoin (Compound) causes Dry mouth (Side Effect) and Dry mouth (Side Effect) is caused by Nitazoxanide (Compound)
Phenytoin may cause a moderate interaction that could exacerbate diseases when taken with Methotrexate and Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Nitazoxanide
Phenytoin may cause a moderate interaction that could exacerbate diseases when taken with Acetohexamide and Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Nitazoxanide
Phenytoin may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Nitazoxanide
Phenytoin may cause a minor interaction that can limit clinical effects when taken with Lidocaine and Lidocaine may cause a moderate interaction that could exacerbate diseases when taken with Nitazoxanide
Phenytoin may cause a minor interaction that can limit clinical effects when taken with Acetylsalicylic acid and Acetylsalicylic acid (Compound) resembles Salsalate (Compound) and Salsalate (Compound) resembles Nitazoxanide (Compound)
Phenytoin (Compound) downregulates ZDHHC6 (Gene) and ZDHHC6 (Gene) is regulated by MTHFD2 (Gene) and MTHFD2 (Gene) is upregulated by Nitazoxanide (Compound) |
DB11978 | DB11979 | 124 | 1,320 | [
"DDInter822",
"DDInter625"
] | Glasdegib | Elagolix | Glasdegib, also known as PF-04449913, is a small-molecule hedgehog signaling inhibitor selected under the group of benzimidazoles. In early research, benzimidazoles attracted large interest as they represented a class of inhibitors with low molecular weight, potent inhibitory activity, and lacking unstable functionality. The great lipophilicity of this group of compounds brought interest to further modification. This analysis concluded that the presence of p-cyano ureas presented good physicochemical and pharmacokinetic properties from which glasdegib was developed. Glasdegib was developed by Pfizer Inc and approved on November 21, 2018 by the FDA for the treatment of Acute Myeloid Leukemia (AML). Glasdegib targets cancerous cells by inhibiting the sonic hedgehog receptor smoothened (SMO), a transmembrane protein involved in the Hedgehog (Hh) signaling cascade. Aberrant of Hh signaling is one | Elagolix has been used in trials studying the basic science and treatment of Endometriosis, Folliculogenesis, Uterine Fibroids, Heavy Uterine Bleeding, and Heavy Menstrual Bleeding. As of 24 July 2018, however, the U.S. Food and Drug Administration (FDA) approved AbbVie's elagolix under the brand name Orilissa as the first and only oral gonadotropin-releasing hormone (GnRH) antagonist specifically developed for women with moderate to severe endometriosis pain . It has been determined that endometriosis is one of the most common gynecologic disorders in the United States [A35868, A35869, F801]. In particular, estimates suggest that one in ten women of reproductive age is affected by endometriosis and experience debilitating pain symptoms [A35868, A35869, F801]. Moreover, women who are affected by this condition can suffer for up to six to ten years and visit multiple physicians before receiving a proper diagnosis [A35868, A35869, F801]. Subsequently, as Orilissa (elagolix) was approved by the FDA under priority review , this expedited new approval gives healthcare professionals another valuable option for treating the potentially unmet needs of women who are affected by endometriosis, depending on their specific type and severity of endometriosis pain. | Moderate | 1 | [
[
[
124,
24,
1320
]
],
[
[
124,
63,
271
],
[
271,
23,
1320
]
],
[
[
124,
63,
1297
],
[
1297,
24,
1320
]
],
[
[
124,
64,
1249
],
[
1249,
... | [
[
[
"Glasdegib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elagolix"
]
],
[
[
"Glasdegib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mirabegron"
],
[
... | Glasdegib may cause a moderate interaction that could exacerbate diseases when taken with Mirabegron and Mirabegron may cause a minor interaction that can limit clinical effects when taken with Elagolix
Glasdegib may cause a moderate interaction that could exacerbate diseases when taken with Osilodrostat and Osilodrostat may cause a moderate interaction that could exacerbate diseases when taken with Elagolix
Glasdegib may lead to a major life threatening interaction when taken with Nafcillin and Nafcillin may cause a moderate interaction that could exacerbate diseases when taken with Elagolix
Glasdegib may lead to a major life threatening interaction when taken with Macimorelin and Macimorelin may cause a moderate interaction that could exacerbate diseases when taken with Elagolix
Glasdegib may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib and Entrectinib may cause a moderate interaction that could exacerbate diseases when taken with Elagolix
Glasdegib may cause a minor interaction that can limit clinical effects when taken with Darolutamide and Darolutamide may cause a moderate interaction that could exacerbate diseases when taken with Elagolix
Glasdegib may cause a minor interaction that can limit clinical effects when taken with Naloxegol and Naloxegol may cause a moderate interaction that could exacerbate diseases when taken with Elagolix
Glasdegib may lead to a major life threatening interaction when taken with Rifampicin and Rifampicin may lead to a major life threatening interaction when taken with Elagolix
Glasdegib may cause a moderate interaction that could exacerbate diseases when taken with Lomitapide and Lomitapide may lead to a major life threatening interaction when taken with Elagolix |
DB01010 | DB11363 | 61 | 1,276 | [
"DDInter622",
"DDInter39"
] | Edrophonium | Alectinib | A rapid-onset, short-acting cholinesterase inhibitor used in cardiac arrhythmias and in the diagnosis of myasthenia gravis. It has also been used as an antidote to curare principles. | Alectinib is a second generation oral drug that selectively inhibits the activity of anaplastic lymphoma kinase (ALK) tyrosine kinase. It is specifically used in the treatment of non-small cell lung cancer (NSCLC) expressing the ALK-EML4 (echinoderm microtubule-associated protein-like 4) fusion protein that causes proliferation of NSCLC cells. Inhibition of ALK prevents phosphorylation and subsequent downstream activation of STAT3 and AKT resulting in reduced tumour cell viability. Approved under accelerated approval in 2015, alectinib is indicated for use in patients who have progressed on or were not tolerant of crizotinib, which is associated with the development of resistance. | Moderate | 1 | [
[
[
61,
24,
1276
]
],
[
[
61,
63,
190
],
[
190,
24,
1276
]
],
[
[
61,
24,
1011
],
[
1011,
24,
1276
]
],
[
[
61,
24,
1476
],
[
1476,
... | [
[
[
"Edrophonium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alectinib"
]
],
[
[
"Edrophonium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Succinylcholine"
],
... | Edrophonium may cause a moderate interaction that could exacerbate diseases when taken with Succinylcholine and Succinylcholine may cause a moderate interaction that could exacerbate diseases when taken with Alectinib
Edrophonium may cause a moderate interaction that could exacerbate diseases when taken with Fingolimod and Fingolimod may cause a moderate interaction that could exacerbate diseases when taken with Alectinib
Edrophonium may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib and Brigatinib may cause a moderate interaction that could exacerbate diseases when taken with Alectinib
Edrophonium may cause a moderate interaction that could exacerbate diseases when taken with Succinylcholine and Succinylcholine may cause a moderate interaction that could exacerbate diseases when taken with Fingolimod and Fingolimod may cause a moderate interaction that could exacerbate diseases when taken with Alectinib
Edrophonium may cause a moderate interaction that could exacerbate diseases when taken with Fingolimod and Fingolimod may lead to a major life threatening interaction when taken with Acebutolol and Acebutolol may cause a moderate interaction that could exacerbate diseases when taken with Alectinib
Edrophonium may cause a moderate interaction that could exacerbate diseases when taken with Ivabradine and Ivabradine may cause a moderate interaction that could exacerbate diseases when taken with Fingolimod and Fingolimod may cause a moderate interaction that could exacerbate diseases when taken with Alectinib
Edrophonium may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Acebutolol and Acebutolol may cause a moderate interaction that could exacerbate diseases when taken with Alectinib
Edrophonium (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Methoxsalen (Compound) and Methoxsalen may cause a moderate interaction that could exacerbate diseases when taken with Alectinib
Edrophonium may cause a moderate interaction that could exacerbate diseases when taken with Donepezil and Donepezil may cause a minor interaction that can limit clinical effects when taken with Quinine and Quinine may cause a moderate interaction that could exacerbate diseases when taken with Alectinib |
DB00073 | DB14409 | 1,394 | 1,129 | [
"DDInter1608",
"DDInter867"
] | Rituximab | Human adenovirus e serotype 4 strain cl-68578 antigen | Rituximab is a genetically engineered chimeric murine/human monoclonal antibody directed against the CD20 antigen found on the surface of normal and malignant B lymphocytes. The antibody is an IgG1 kappa immunoglobulin containing murine light and heavy-chain variable region sequences and human constant region sequences, [FDA label]. It was originally approved by the U.S. FDA in 1997 as a single agent to treat patients with B-cell Non-Hodgkin's Lymphoma (NHL), however, has now been approved for a variety of conditions [FDA label]. On November 28, 2018, the US FDA approved _Truxima_, the first biosimilar to Rituxan (Rituximab). | Human adenovirus e serotype 4 strain cl-68578 antigen is a vaccine. | Moderate | 1 | [
[
[
1394,
24,
1129
]
],
[
[
1394,
64,
1057
],
[
1057,
24,
1129
]
],
[
[
1394,
24,
1683
],
[
1683,
24,
1129
]
],
[
[
1394,
63,
1184
],
[
11... | [
[
[
"Rituximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Human adenovirus e serotype 4 strain cl-68578 antigen"
]
],
[
[
"Rituximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"E... | Rituximab may lead to a major life threatening interaction when taken with Etanercept and Etanercept may cause a moderate interaction that could exacerbate diseases when taken with Human adenovirus e serotype 4 strain cl-68578 antigen
Rituximab may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab and Ustekinumab may cause a moderate interaction that could exacerbate diseases when taken with Human adenovirus e serotype 4 strain cl-68578 antigen
Rituximab may cause a moderate interaction that could exacerbate diseases when taken with Anakinra and Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Human adenovirus e serotype 4 strain cl-68578 antigen
Rituximab may lead to a major life threatening interaction when taken with Baricitinib and Baricitinib may cause a moderate interaction that could exacerbate diseases when taken with Human adenovirus e serotype 4 strain cl-68578 antigen
Rituximab may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may cause a moderate interaction that could exacerbate diseases when taken with Human adenovirus e serotype 4 strain cl-68578 antigen
Rituximab may lead to a major life threatening interaction when taken with Etanercept and Etanercept may lead to a major life threatening interaction when taken with Ustekinumab and Ustekinumab may cause a moderate interaction that could exacerbate diseases when taken with Human adenovirus e serotype 4 strain cl-68578 antigen
Rituximab may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab and Ustekinumab may lead to a major life threatening interaction when taken with Etanercept and Etanercept may cause a moderate interaction that could exacerbate diseases when taken with Human adenovirus e serotype 4 strain cl-68578 antigen
Rituximab may cause a moderate interaction that could exacerbate diseases when taken with Anakinra and Anakinra may lead to a major life threatening interaction when taken with Etanercept and Etanercept may cause a moderate interaction that could exacerbate diseases when taken with Human adenovirus e serotype 4 strain cl-68578 antigen
Rituximab may lead to a major life threatening interaction when taken with Baricitinib and Baricitinib may lead to a major life threatening interaction when taken with Etanercept and Etanercept may cause a moderate interaction that could exacerbate diseases when taken with Human adenovirus e serotype 4 strain cl-68578 antigen |
DB00491 | DB01285 | 127 | 708 | [
"DDInter1217",
"DDInter445"
] | Miglitol | Corticotropin | Miglitol inhibits the breakdown complex carbohydrates into glucose. It is primarily used in diabetes mellitus type 2 for establishing greater glycemic control by preventing the digestion of carbohydrates (such as disaccharides, oligosaccharides, and polysaccharides) into monosaccharides which can be absorbed by the body. Miglitol should be taken at the start of a meal for maximal effect and the effect will depend on the amount of poly and oligosaccharides in the diet. Miglitol inhibits alpha-glucosidase, making less sugars available for digestion and reducing postprandial hyperglycemia. Unlike other drugs of the same class, miglitol is not metabolized and the unmetabolized drug is excreted by the kidneys. | Corticotropin (ACTH or adrenocorticotropic hormone) is a polypeptide hormone produced and secreted by the pituitary gland. It is an important player in the hypothalamic-pituitary-adrenal axis. | Moderate | 1 | [
[
[
127,
24,
708
]
],
[
[
127,
24,
659
],
[
659,
62,
708
]
],
[
[
127,
24,
1052
],
[
1052,
23,
708
]
],
[
[
127,
63,
245
],
[
245,
2... | [
[
[
"Miglitol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Corticotropin"
]
],
[
[
"Miglitol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
],
[
... | Miglitol may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol and Vilanterol may cause a minor interaction that can limit clinical effects when taken with Corticotropin
Miglitol may cause a moderate interaction that could exacerbate diseases when taken with Ritodrine and Ritodrine may cause a minor interaction that can limit clinical effects when taken with Corticotropin
Miglitol may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Corticotropin
Miglitol may cause a moderate interaction that could exacerbate diseases when taken with Pramlintide and Pramlintide may cause a moderate interaction that could exacerbate diseases when taken with Corticotropin
Miglitol may cause a moderate interaction that could exacerbate diseases when taken with Insulin glulisine and Insulin glulisine may cause a moderate interaction that could exacerbate diseases when taken with Corticotropin
Miglitol may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol and Vilanterol may cause a moderate interaction that could exacerbate diseases when taken with Salmeterol and Salmeterol may cause a minor interaction that can limit clinical effects when taken with Corticotropin
Miglitol may cause a moderate interaction that could exacerbate diseases when taken with Ritodrine and Ritodrine may cause a moderate interaction that could exacerbate diseases when taken with Salmeterol and Salmeterol may cause a minor interaction that can limit clinical effects when taken with Corticotropin
Miglitol may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Salmeterol and Salmeterol may cause a minor interaction that can limit clinical effects when taken with Corticotropin
Miglitol may cause a moderate interaction that could exacerbate diseases when taken with Conjugated estrogens and Conjugated estrogens may cause a minor interaction that can limit clinical effects when taken with Hyaluronidase and Hyaluronidase may cause a minor interaction that can limit clinical effects when taken with Corticotropin |
DB00059 | DB04835 | 1,560 | 1,655 | [
"DDInter1404",
"DDInter1125"
] | Pegaspargase | Maraviroc | Pegaspargase is a conjugate of monomethoxypolyethylene glycol (mPEG) and L-asparaginase (L-asparagine amidohydrolase), an asparagine-specific enzyme that converts L-asparagine into aspartic acid and ammonia. Asparagine is an amino acid that is vital for cell survival. In humans, most normal tissues can produce asparagine through the action of asparagine synthetase. However, leukemia cells have low levels of this enzyme and depend on exogenous sources. Therefore, the use of pegaspargase results in leukemic cell death.[A103,A255912,L44667] Pegaspargase has the same mechanism of action as [L-asparaginase] derived from _Escherichia coli_, a previously developed enzyme used for the treatment of acute lymphoblastic leukemia (ALL). However, using L-asparaginase derived from _Escherich | Maraviroc (brand-named Selzentry, or Celsentri outside the U.S.) is a chemokine receptor antagonist drug developed by the drug company Pfizer that is designed to act against HIV by interfering with the interaction between HIV and CCR5. It was originally labelled as UK-427857 during development but was assigned the Maraviroc name as it entered trials. It was approved for use by the FDA in August, 2007. | Moderate | 1 | [
[
[
1560,
24,
1655
]
],
[
[
1560,
24,
1419
],
[
1419,
24,
1655
]
],
[
[
1560,
24,
1468
],
[
1468,
63,
1655
]
],
[
[
1560,
63,
1648
],
[
16... | [
[
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Maraviroc"
]
],
[
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Imatinib"
],
[
... | Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Maraviroc
Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib and Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Maraviroc
Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Maraviroc
Pegaspargase may lead to a major life threatening interaction when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Maraviroc
Pegaspargase may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may lead to a major life threatening interaction when taken with Maraviroc
Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may lead to a major life threatening interaction when taken with Maraviroc
Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin may lead to a major life threatening interaction when taken with Maraviroc
Pegaspargase may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may lead to a major life threatening interaction when taken with Maraviroc
Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Imatinib (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Maraviroc (Compound) |
DB09104 | DB11189 | 286 | 1,333 | [
"DDInter1118",
"DDInter1117"
] | Magnesium hydroxide | Magnesium glycinate | Magnesium hydroxide is an inorganic compound. It is naturally found as the mineral brucite. Magnesium hydroxide can be used as an antacid or a laxative in either an oral liquid suspension or chewable tablet form. Additionally, magnesium hydroxide has smoke suppressing and flame retardant properties and is thus used commercially as a fire retardant. It can also be used topically as a deodorant or for the relief of canker sores (aphthous ulcers). | Magnesium glycinate is a magnesium salt of glycine that is available as dietary supplements as a source of magnesium. It is used in the treatment of magnesium deficiency. | Moderate | 1 | [
[
[
286,
24,
1333
]
],
[
[
286,
24,
460
],
[
460,
24,
1333
]
],
[
[
286,
63,
1331
],
[
1331,
24,
1333
]
],
[
[
286,
64,
1231
],
[
1231,
... | [
[
[
"Magnesium hydroxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium glycinate"
]
],
[
[
"Magnesium hydroxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"... | Magnesium hydroxide may cause a moderate interaction that could exacerbate diseases when taken with Magnesium carbonate and Magnesium carbonate may cause a moderate interaction that could exacerbate diseases when taken with Magnesium glycinate
Magnesium hydroxide may cause a moderate interaction that could exacerbate diseases when taken with Ergocalciferol and Ergocalciferol may cause a moderate interaction that could exacerbate diseases when taken with Magnesium glycinate
Magnesium hydroxide may lead to a major life threatening interaction when taken with Tolevamer and Tolevamer may cause a moderate interaction that could exacerbate diseases when taken with Magnesium glycinate
Magnesium hydroxide may cause a moderate interaction that could exacerbate diseases when taken with Magnesium carbonate and Magnesium carbonate may cause a moderate interaction that could exacerbate diseases when taken with Ergocalciferol and Ergocalciferol may cause a moderate interaction that could exacerbate diseases when taken with Magnesium glycinate
Magnesium hydroxide may cause a moderate interaction that could exacerbate diseases when taken with Ergocalciferol and Ergocalciferol may cause a moderate interaction that could exacerbate diseases when taken with Magnesium carbonate and Magnesium carbonate may cause a moderate interaction that could exacerbate diseases when taken with Magnesium glycinate
Magnesium hydroxide may lead to a major life threatening interaction when taken with Tolevamer and Tolevamer may lead to a major life threatening interaction when taken with Magnesium carbonate and Magnesium carbonate may cause a moderate interaction that could exacerbate diseases when taken with Magnesium glycinate
Magnesium hydroxide may cause a minor interaction that can limit clinical effects when taken with Perindopril and Perindopril may cause a minor interaction that can limit clinical effects when taken with Magnesium carbonate and Magnesium carbonate may cause a moderate interaction that could exacerbate diseases when taken with Magnesium glycinate
Magnesium hydroxide may cause a moderate interaction that could exacerbate diseases when taken with Ergocalciferol and Ergocalciferol (Compound) resembles Paricalcitol (Compound) and Ergocalciferol may lead to a major life threatening interaction when taken with Paricalcitol and Paricalcitol may cause a moderate interaction that could exacerbate diseases when taken with Magnesium glycinate
Magnesium hydroxide may cause a moderate interaction that could exacerbate diseases when taken with Tetracycline and Tetracycline (Compound) resembles Doxycycline (Compound) and Doxycycline may cause a moderate interaction that could exacerbate diseases when taken with Magnesium glycinate |
DB00321 | DB00836 | 21 | 543 | [
"DDInter78",
"DDInter1088"
] | Amitriptyline | Loperamide | Amitriptyline is a tricyclic antidepressant that has been used to treat depression for decades. ELAVIL, a previously approved branded product of amitriptyline, was first approved by the FDA in 1961. Amitriptyline has been investigated in the treatment of pain-related conditions, attributed to its analgesic properties. | Loperamide is an anti-diarrheal agent that is available as various over-the-counter products for treating diarrhea. The drug was first synthesized in 1969 and used medically in 1976. It is a highly lipophilic synthetic phenylpiperidine opioid that is structurally similar to opiate receptor agonists such as [diphenoxylate] and [haloperidol]. Due to pharmacological properties, loperamide has been misused and abused to self-manage opioid withdrawal symptoms and to induce euphoria.[A251610, A251625] However, loperamide is associated with a risk for experiencing a range of adverse effects, often life-threatening, if taking for non-therapeutic reasons or at doses higher than the recommended dose. | Moderate | 1 | [
[
[
21,
24,
543
]
],
[
[
21,
24,
649
],
[
649,
1,
543
]
],
[
[
21,
24,
262
],
[
262,
24,
543
]
],
[
[
21,
63,
701
],
[
701,
24,
... | [
[
[
"Amitriptyline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Loperamide"
]
],
[
[
"Amitriptyline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofedanol"
],
... | Amitriptyline may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol and Clofedanol (Compound) resembles Loperamide (Compound)
Amitriptyline may cause a moderate interaction that could exacerbate diseases when taken with Clidinium and Clidinium may cause a moderate interaction that could exacerbate diseases when taken with Loperamide
Amitriptyline may cause a moderate interaction that could exacerbate diseases when taken with Clemastine and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Loperamide
Amitriptyline (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Loperamide (Compound)
Amitriptyline (Compound) upregulates INSIG1 (Gene) and INSIG1 (Gene) is upregulated by Loperamide (Compound)
Amitriptyline (Compound) downregulates RPA3 (Gene) and RPA3 (Gene) is downregulated by Loperamide (Compound)
Amitriptyline (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Loperamide (Compound)
Amitriptyline (Compound) resembles Azatadine (Compound) and Amitriptyline may cause a moderate interaction that could exacerbate diseases when taken with Azatadine and Azatadine may cause a moderate interaction that could exacerbate diseases when taken with Loperamide
Amitriptyline may lead to a major life threatening interaction when taken with Ivosidenib and Ivosidenib may cause a moderate interaction that could exacerbate diseases when taken with Loperamide |
DB00002 | DB01101 | 1,284 | 60 | [
"DDInter344",
"DDInter285"
] | Cetuximab | Capecitabine | Cetuximab is a recombinant chimeric human/mouse IgG1 monoclonal antibody that competitively binds to epidermal growth factor receptor (EGFR) and competitively inhibits the binding of epidermal growth factor (EGF). EGFR is a member of the ErbB family of receptor tyrosine kinases found in both normal and tumour cells; it is responsible for regulating epithelial tissue development and homeostasis. EGFR has been implicated in various types of cancer, as it is often overexpressed in malignant cells and EGFR overexpression has been linked to more advanced disease and poor prognosis. EGFR is often mutated in certain types of cancer and serves as a driver of tumorigenesis. _In vitro_, cetuximab was shown to mediate anti-tumour effects in numerous cancer cell lines and human tumour xenografts. Approved by the FDA in February 2004 under the brand name | Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue. | Moderate | 1 | [
[
[
1284,
24,
60
]
],
[
[
1284,
24,
4
],
[
4,
63,
60
]
],
[
[
1284,
24,
1555
],
[
1555,
24,
60
]
],
[
[
1284,
25,
770
],
[
770,
25,
... | [
[
[
"Cetuximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Capecitabine"
]
],
[
[
"Cetuximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Omacetaxine mepesuccinate"
... | Cetuximab may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate and Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Capecitabine
Cetuximab may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin and Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Capecitabine
Cetuximab may lead to a major life threatening interaction when taken with Thalidomide and Thalidomide may lead to a major life threatening interaction when taken with Capecitabine
Cetuximab may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate and Omacetaxine mepesuccinate (Compound) downregulates TYMS (Gene) and TYMS (Gene) is bound by Capecitabine (Compound)
Cetuximab may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin and Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Gemifloxacin and Gemifloxacin may cause a minor interaction that can limit clinical effects when taken with Capecitabine
Cetuximab may cause a moderate interaction that could exacerbate diseases when taken with Cisplatin and Cisplatin (Compound) treats esophageal cancer (Disease) and esophageal cancer (Disease) is treated by Capecitabine (Compound)
Cetuximab may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Moxifloxacin and Moxifloxacin may cause a minor interaction that can limit clinical effects when taken with Capecitabine
Cetuximab may cause a moderate interaction that could exacerbate diseases when taken with Lansoprazole and Lansoprazole (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Capecitabine (Compound)
Cetuximab may lead to a major life threatening interaction when taken with Thalidomide and Thalidomide (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Capecitabine (Compound) |
DB00717 | DB09564 | 1,197 | 1,296 | [
"DDInter1312",
"DDInter930"
] | Norethisterone | Insulin degludec | Norethisterone, also known as norethindrone, is a synthetic progestational hormone belonging to the 19-nortestosterone-derived class of progestins. It is further classified as a second-generation progestin, along with [levonorgestrel] and its derivatives, and is the active form of several other progestins including [norethynodrel] and [lynestrenol]. Norethisterone mimics the actions of endogenous [progesterone], albeit with a greater potency, and is used on its own or in combination with estrogen derivatives in a variety of applications including contraception and hormone replacement therapy.[L9527,L10301,L10304,L10307] First derived in 1951 in Mexico City, norethisterone was originally intended for use as a remedy for irregular menstruation and endometriosis, and was not marketed for use as an oral contraceptive until 1962. | Insulin degludec is an ultra-long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes.[A18561,A18562,A18563,A18564,A174934] Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas that promotes glucose metabolism.[A18561,A18562,A18563,A18564,A174934] Insulin is released from the pancreas following a meal to promote the uptake of glucose from the blood into internal organs and tissues such as the liver, fat cells, and skeletal muscle.[A18561,A18562,A18563,A18564,A174934] Absorption of glucose into cells allows for its transformation into glycogen or fat for storage.[A18561,A18562,A18563,A18564,A174934] Insulin also inhibits hepatic glucose production, enhances protein synthesis, and inhibits lipolysis and proteolysis among many other functions.[A18561,A18562,A18563,A18564,A174934] Insulin is an essential treatment in the management of Type 1 Diabetes (T1D) which is caused by an autoimmune reaction that destroys the beta cells of the pancreas, resulting in the body not being able to produce or synthesize the insulin needed to manage circulating blood sugar levels.[A18561,A18562,A18563,A18564,A174934] As a result, people with T1D rely primarily on exogenous forms of insulin, such as insulin degludec, to lower glucose levels in the blood.[A18561,A18562,A18563,A18564,A174934] Insulin is also used in the treatment of Type 2 Diabetes (T2D), another form of diabetes mellitus that is a slowly progressing metabolic disorder caused by a combination of genetic and lifestyle factors that promote chronically elevated blood sugar levels.[A18561,A18562,A18563,A18564,A174934] Without treatment or improvement in non-pharmacological measures such as diet and exercise to lower blood glucose, high blood sugar eventually causes cellular resistance to endogenous insulin, and in the long term, damage to pancreatic islet cells.[A18561,A18562,A18563,A18564,A174934] Insulin is typically prescribed later in the course of T2D, after several oral medications such as , , or have been tried, when sufficient damage has been caused to pancreatic cells that the body is no longer able to produce insulin on its own.[A18561,A18562,A18563,A18564,A174934] Marketed as the brand name product Tresiba, insulin degludec has a duration of action up to 42 hours allowing for once-daily dosing, typically at bedtime.[A18561,A18562,A18563,A18564,A174934] Due to its duration of action, Tresiba is considered "basal insulin" as it provides low concentrations of background insulin that can keep blood sugar stable between meals or overnight.[A18561,A18562,A18563,A18564,A174934] Basal insulin is often combined with short-acting "bolus insulin" such as , , or to provide higher doses of insulin required following meals. Use of basal and bolus insulin together is intended to mimic the pancreas' production of endogenous insulin, with the goal of avoiding any periods of hypoglycemia.[A18561,A18562,A18563,A18564,A174934] Compared to endogenous insulin, insulin degludec has an added hexadecanedioic acid on lysine at the B29 position, allowing for the formation of multi-hexamers.[A18561,A18562,A18563,A18564,A174934] When injected subcutaneously, these multi-hexamers form a drug depot store from which monomers are slowly and continuously absorbed into circulation.[A18561,A18562,A18563,A18564,A174934] As a result, Insulin Degludec has a protracted time action profile due to the delayed absorption from subcutaneous tissue depots into the systemic circulation.[A18561,A18562,A18563,A18564,A174934] Compared to available long-acting analogs such as and , which have a duration of action of 20-24 hours, insulin degludec provides a consistent level of basal insulin over 42 hours with a low peak: trough ratio.[A18561,A18562,A18563,A18564,A174934] Limitations of shorter-acting analogs include more frequent dosing and less stable pharmacokinetics, which may negatively impact patient adherence and glucose control, particularly nocturnal control.[A18561,A18562,A18563,A18564,A174934] Without an adequate supply of insulin to promote absorption of glucose from the bloodstream, blood sugar levels can climb to dangerously high levels and can result in symptoms such as fatigue, headache, blurred vision, and increased thirst.[A18561,A18562,A18563,A18564,A174934] If left untreated, the body starts to break down fat, instead of glucose, for energy which results in a build-up of ketone acids in the blood and a syndrome called ketoacidosis, which is a life-threatening medical emergency. In the long term, elevated blood sugar levels increase the risk of heart attack, stroke, and diabetic neuropathy.[A18561,A18562,A18563,A18564,A174934] Insulin Degludec was approved by the FDA in September 2015 as the product Tresiba, for use in providing glycemic control to adults with diabetes mellitus. | Moderate | 1 | [
[
[
1197,
24,
1296
]
],
[
[
1197,
24,
1411
],
[
1411,
24,
1296
]
],
[
[
1197,
63,
1645
],
[
1645,
24,
1296
]
],
[
[
1197,
1,
1336
],
[
133... | [
[
[
"Norethisterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin degludec"
]
],
[
[
"Norethisterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolbutamide"
... | Norethisterone may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec
Norethisterone may cause a moderate interaction that could exacerbate diseases when taken with Metformin and Metformin may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec
Norethisterone (Compound) resembles Etonogestrel (Compound) and Etonogestrel may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec
Norethisterone (Compound) resembles Fluoxymesterone (Compound) and Fluoxymesterone may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec
Norethisterone may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide and Semaglutide may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec
Norethisterone may lead to a major life threatening interaction when taken with Dabrafenib and Dabrafenib may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec
Norethisterone may lead to a major life threatening interaction when taken with Brigatinib and Brigatinib may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec
Norethisterone may cause a minor interaction that can limit clinical effects when taken with Pioglitazone and Pioglitazone may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec
Norethisterone may lead to a major life threatening interaction when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec |
DB11967 | DB15233 | 710 | 1,650 | [
"DDInter210",
"DDInter142"
] | Binimetinib | Avapritinib | Binimetinib, also known as _Mektovi_, is a potent and selective oral mitogen-activated protein kinase 1/2 (MEK 1/2) inhibitor which is combined with [Encorafenib].[A34275,L3335] On June 27, 2018, the Food and Drug Administration approved the combination of [Encorafenib] and binimetinib (BRAFTOVI and MEKTOVI, from Array BioPharma Inc.) in combination for patients with unresectable or metastatic melanoma with the BRAF V600E or V600K mutations, as detected by an FDA-approved test. | Avapritinib, or BLU-285, is a selective tyrosine kinase inhibitor of KIT and platelet derived growth factor receptor alpha indicated for the treatment of unresectable, metastatic gastrointestinal stromal tumors and advanced systemic mastocytosis.[A189339,L40363] It is one of the first medications available for the treatment of multidrug resistant cancers. Avapritinib shares a similar mechanism with [ripretinib]. Avapritinib was granted FDA approval on 9 January 2020 and EMA approval on 24 September 2020. | Major | 2 | [
[
[
710,
25,
1650
]
],
[
[
710,
63,
1478
],
[
1478,
24,
1650
]
],
[
[
710,
24,
1320
],
[
1320,
24,
1650
]
],
[
[
710,
63,
1512
],
[
1512,
... | [
[
[
"Binimetinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Avapritinib"
]
],
[
[
"Binimetinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivacaftor"
],
[
"Ivacafto... | Binimetinib may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor and Ivacaftor may cause a moderate interaction that could exacerbate diseases when taken with Avapritinib
Binimetinib may cause a moderate interaction that could exacerbate diseases when taken with Elagolix and Elagolix may cause a moderate interaction that could exacerbate diseases when taken with Avapritinib
Binimetinib may cause a moderate interaction that could exacerbate diseases when taken with Diclofenac and Diclofenac may lead to a major life threatening interaction when taken with Avapritinib
Binimetinib may lead to a major life threatening interaction when taken with Omacetaxine mepesuccinate and Omacetaxine mepesuccinate may lead to a major life threatening interaction when taken with Avapritinib
Binimetinib may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor and Ivacaftor may cause a moderate interaction that could exacerbate diseases when taken with Abiraterone and Abiraterone may cause a moderate interaction that could exacerbate diseases when taken with Avapritinib
Binimetinib may cause a moderate interaction that could exacerbate diseases when taken with Abiraterone and Abiraterone may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor and Ivacaftor may cause a moderate interaction that could exacerbate diseases when taken with Avapritinib
Binimetinib may cause a moderate interaction that could exacerbate diseases when taken with Elagolix and Elagolix may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor and Ivacaftor may cause a moderate interaction that could exacerbate diseases when taken with Avapritinib
Binimetinib may lead to a major life threatening interaction when taken with Omacetaxine mepesuccinate and Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Avapritinib
Binimetinib may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may lead to a major life threatening interaction when taken with Ivacaftor and Ivacaftor may cause a moderate interaction that could exacerbate diseases when taken with Avapritinib |
DB08899 | DB09078 | 129 | 1,228 | [
"DDInter649",
"DDInter1036"
] | Enzalutamide | Lenvatinib | Enzalutamide is an androgen receptor (AR) inhibitor for the treatment of castration-resistant prostate cancer (CRPC), both metastatic and non-metastatic. It is a second-generation antiandrogen agent that the FDA approved on August 31, 2012.[L40639, A252667] Although androgen deprivation therapy (ADT) is the first-line treatment of prostate cancer and remission can be achieved, arising resistance is inevitable, becoming castration-resistant prostate cancer. Until recently, docetaxel is the only treatment available for metastatic CRPC; however, AR inhibitors have been developed for more targeted therapy, although first-generation AR inhibitors like bicalutamide did not substantially increase the survival rate. Second-generation such as enzalutamide is more efficacious due to a higher affinity to AR and no partial agonist activity compared to bicalutamide.[A252667,A252642] Due to a favorable pharmacological profile, | Lenvatinib is a receptor tyrosine kinase (RTK) inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). Lenvatinib also inhibits other RTKs that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progression in addition to their normal cellular functions, including fibroblast growth factor (FGF) receptors FGFR1, 2, 3, and 4; the platelet derived growth factor receptor alpha (PDGFRα), KIT, and RET. These receptor tyrosine kinases (RTKs) located in the cell membrane play a central role in the activation of signal transduction pathways involved in the normal regulation of cellular processes, such as cell proliferation, migration, apoptosis and differentiation, and in pathogenic angiogenesis, lymphogenesis, tumour growth and cancer progression. In particular, VEGF has been identified as a crucial regulator of both physiologic and pathologic angiogenesis and increased expression of VEGF is associated with a poor prognosis in many types of cancers. Lenvatinib is indicated for the treatment of patients with locally recurrent or metastatic, progressive, radioactive iodine (RAI)-refractory differentiated thyroid cancer. Most patients with thyroid cancer have a very good prognosis with treatment (98% 5 year survival rate) involving surgery and hormone therapy. However, for patients with RAI-refractory thyroid cancer, treatment options are limited and the prognosis is poor, leading to a push for the development of more targeted therapies such as lenvatinib. | Moderate | 1 | [
[
[
129,
24,
1228
]
],
[
[
129,
62,
112
],
[
112,
23,
1228
]
],
[
[
129,
63,
463
],
[
463,
23,
1228
]
],
[
[
129,
63,
1100
],
[
1100,
... | [
[
[
"Enzalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lenvatinib"
]
],
[
[
"Enzalutamide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
... | Enzalutamide may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Lenvatinib
Enzalutamide may cause a moderate interaction that could exacerbate diseases when taken with Rifampicin and Rifampicin may cause a minor interaction that can limit clinical effects when taken with Lenvatinib
Enzalutamide may cause a moderate interaction that could exacerbate diseases when taken with Venlafaxine and Venlafaxine may cause a moderate interaction that could exacerbate diseases when taken with Lenvatinib
Enzalutamide may lead to a major life threatening interaction when taken with Pitolisant and Pitolisant may cause a moderate interaction that could exacerbate diseases when taken with Lenvatinib
Enzalutamide may lead to a major life threatening interaction when taken with Sunitinib and Sunitinib may cause a moderate interaction that could exacerbate diseases when taken with Lenvatinib
Enzalutamide may lead to a major life threatening interaction when taken with Idelalisib and Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Lenvatinib
Enzalutamide may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate and Magnesium citrate may cause a moderate interaction that could exacerbate diseases when taken with Lenvatinib
Enzalutamide may cause a moderate interaction that could exacerbate diseases when taken with Bisacodyl and Bisacodyl may cause a moderate interaction that could exacerbate diseases when taken with Lenvatinib
Enzalutamide (Compound) resembles Bicalutamide (Compound) and Bicalutamide may cause a moderate interaction that could exacerbate diseases when taken with Lenvatinib |
DB00776 | DB06691 | 1,335 | 849 | [
"DDInter1360",
"DDInter1155"
] | Oxcarbazepine | Mepyramine | Oxcarbazepine is an anti-epileptic medication used in the treatment of partial onset seizures that was first approved for use in the United States in 2000.[L8627,L8630,L8633] It is a structural derivative of [carbamazepine] and exerts a majority of its activity via a pharmacologically active metabolite, MHD, which exists as a racemate in the blood - a pro-drug of the more active (S)-enantiomer is also marketed as a separate anti-epileptic under the name [eslicarbazepine]. Compared to other anti-epileptic drugs, which are generally metabolized via the cytochrome P450 system, oxcarbazepine has a reduced propensity for involvement in drug-drug interactions owing to its primarily reductive metabolism. | Mepyramine, or pyrilamine, targets the H1 receptor. It is a first generation antihistamine. However, it rapidly permeates the brain and so often causes drowsiness as a side effect. It has been found in over-the-counter combination products for colds and menstrual symptoms, but is considered to be an unapproved prescription medication used for cough, cold, or allergic conditions. | Moderate | 1 | [
[
[
1335,
24,
849
]
],
[
[
1335,
63,
1594
],
[
1594,
24,
849
]
],
[
[
1335,
24,
272
],
[
272,
24,
849
]
],
[
[
1335,
24,
407
],
[
407,
... | [
[
[
"Oxcarbazepine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
]
],
[
[
"Oxcarbazepine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
],
... | Oxcarbazepine may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine
Oxcarbazepine may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine and Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine
Oxcarbazepine may cause a moderate interaction that could exacerbate diseases when taken with Opium and Opium may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine
Oxcarbazepine (Compound) resembles Trimipramine (Compound) and Trimipramine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine
Oxcarbazepine (Compound) resembles Clobazam (Compound) and Clobazam may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine
Oxcarbazepine may lead to a major life threatening interaction when taken with Procarbazine and Procarbazine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine
Oxcarbazepine may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine and Carbinoxamine (Compound) resembles Mepyramine (Compound) and Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine
Oxcarbazepine may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine and Brompheniramine (Compound) resembles Mepyramine (Compound) and Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine
Oxcarbazepine may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine (Compound) resembles Chloropyramine (Compound) and Chloropyramine (Compound) resembles Mepyramine (Compound) |
DB06788 | DB08868 | 1,616 | 1,011 | [
"DDInter864",
"DDInter737"
] | Histrelin | Fingolimod | Histrelin is a gonadotropin-releasing hormone (GnRH) agonist that acts as a potent inhibitor of gonadotropin when administered as an implant delivering continuous therapeutic doses. This drug is a synthetic analog of naturally occurring GnRH with a higher potency. Histrelin implants are non-biodegradable, diffusion-controlled, hydrogel polymer reservoirs containing histrelin acetate that need to be replaced every 52 weeks.[L41700,L41715,L41755] Initially, histrelin implants were developed to reduce testosterone to castration levels in patients with advanced prostate cancer. The Vantas product was approved by the FDA in October 2004 for the palliative treatment of this condition. Vantas was later discontinued by Endo Pharmaceuticals Inc. on September 21, 2021. GnRH agonists are the first line of treatment for children with central precocious puberty (CPP) due to their capacity to reduce LH levels and the concentration of | Multiple sclerosis, or MS, is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Fingolimod is a sphingosine 1-phosphate receptor modulator for the treatment of relapsing-remitting multiple sclerosis. It was developed by Novartis and initially approved by the FDA in 2010. Fingolimod was also studied for the treatment of COVID-19, the disease caused by infection with the SARS-CoV-2 virus.[L12654,L12657] | Major | 2 | [
[
[
1616,
25,
1011
]
],
[
[
1616,
62,
1247
],
[
1247,
23,
1011
]
],
[
[
1616,
24,
144
],
[
144,
63,
1011
]
],
[
[
1616,
63,
867
],
[
867,
... | [
[
[
"Histrelin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fingolimod"
]
],
[
[
"Histrelin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
],
[
"Sulfamet... | Histrelin may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Fingolimod
Histrelin may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol and Olodaterol may cause a moderate interaction that could exacerbate diseases when taken with Fingolimod
Histrelin may cause a moderate interaction that could exacerbate diseases when taken with Olanzapine and Olanzapine may cause a moderate interaction that could exacerbate diseases when taken with Fingolimod
Histrelin may lead to a major life threatening interaction when taken with Ivabradine and Ivabradine may cause a moderate interaction that could exacerbate diseases when taken with Fingolimod
Histrelin may cause a moderate interaction that could exacerbate diseases when taken with Tizanidine and Tizanidine may lead to a major life threatening interaction when taken with Fingolimod
Histrelin may lead to a major life threatening interaction when taken with Pimozide and Pimozide may lead to a major life threatening interaction when taken with Fingolimod
Histrelin may cause a moderate interaction that could exacerbate diseases when taken with Eribulin and Eribulin may lead to a major life threatening interaction when taken with Fingolimod
Histrelin may lead to a major life threatening interaction when taken with Ivosidenib and Ivosidenib may lead to a major life threatening interaction when taken with Fingolimod
Histrelin may cause a moderate interaction that could exacerbate diseases when taken with Rilpivirine and Rilpivirine may lead to a major life threatening interaction when taken with Fingolimod |
DB00242 | DB00851 | 1,064 | 611 | [
"DDInter392",
"DDInter463"
] | Cladribine | Dacarbazine | An antineoplastic agent used in the treatment of lymphoproliferative diseases including hairy-cell leukemia. | An antineoplastic agent. It has significant activity against melanomas. (from Martindale, The Extra Pharmacopoeia, 31st ed, p564). Dacarbazine with Oblimersen is in clinical trials for the treatment of malignant melanoma. | Major | 2 | [
[
[
1064,
25,
611
]
],
[
[
1064,
5,
11555
],
[
11555,
44,
611
]
],
[
[
1064,
7,
7669
],
[
7669,
46,
611
]
],
[
[
1064,
25,
141
],
[
141,
... | [
[
[
"Cladribine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dacarbazine"
]
],
[
[
"Cladribine",
"{u} (Compound) treats {v} (Disease)",
"hematologic cancer"
],
[
"hematologic cancer",
"{u} (Disease) is treated ... | Cladribine (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Dacarbazine (Compound)
Cladribine (Compound) upregulates DDIT4 (Gene) and DDIT4 (Gene) is upregulated by Dacarbazine (Compound)
Cladribine may lead to a major life threatening interaction when taken with Floxuridine and Floxuridine may cause a moderate interaction that could exacerbate diseases when taken with Dacarbazine
Cladribine may lead to a major life threatening interaction when taken with Brentuximab vedotin and Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Dacarbazine
Cladribine may lead to a major life threatening interaction when taken with Efalizumab and Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Dacarbazine
Cladribine may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative and Tuberculin purified protein derivative may cause a moderate interaction that could exacerbate diseases when taken with Dacarbazine
Cladribine may cause a moderate interaction that could exacerbate diseases when taken with Interferon beta-1a and Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Dacarbazine
Cladribine may cause a moderate interaction that could exacerbate diseases when taken with Cytarabine and Cladribine may lead to a major life threatening interaction when taken with Cytarabine and Cytarabine may cause a moderate interaction that could exacerbate diseases when taken with Dacarbazine
Cladribine (Compound) resembles Pentostatin (Compound) and Cladribine may lead to a major life threatening interaction when taken with Pentostatin and Pentostatin may cause a moderate interaction that could exacerbate diseases when taken with Dacarbazine |
DB00884 | DB01082 | 1,008 | 1,448 | [
"DDInter1604",
"DDInter1713"
] | Risedronic acid | Streptomycin | Risedronic acid is a third generation bisphosphonate that is used for the treatment of some forms of osteoperosis and Paget's disease[FDA Label][A959,A203111]. It functions by preventing resorption of bone[FDA Label]. | Streptomycin, an antibiotic derived from _Streptomyces griseus_, was the first aminoglycoside to be discovered and used in practice in the 1940s.[A233325,A233390] Selman Waksman and eventually Albert Schatz were recognized with the Nobel Prize in Medicine for their discovery of streptomycin and its antibacterial activity.[A233325,A232294] Although streptomycin was the first antibiotic determined to be effective against mycobacterium tuberculosis, it has fallen out of favor due to resistance and is now primarily used as adjunctive treatment in cases of multi-drug resistant tuberculosis. | Moderate | 1 | [
[
[
1008,
24,
1448
]
],
[
[
1008,
21,
28882
],
[
28882,
60,
1448
]
],
[
[
1008,
24,
361
],
[
361,
24,
1448
]
],
[
[
1008,
63,
1512
],
[
15... | [
[
[
"Risedronic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Streptomycin"
]
],
[
[
"Risedronic acid",
"{u} (Compound) causes {v} (Side Effect)",
"Body temperature increased"
],
[
"Body temperatur... | Risedronic acid (Compound) causes Body temperature increased (Side Effect) and Body temperature increased (Side Effect) is caused by Streptomycin (Compound)
Risedronic acid may cause a moderate interaction that could exacerbate diseases when taken with Neomycin and Neomycin may cause a moderate interaction that could exacerbate diseases when taken with Streptomycin
Risedronic acid may cause a moderate interaction that could exacerbate diseases when taken with Diclofenac and Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Streptomycin
Risedronic acid (Compound) resembles Zoledronic acid (Compound) and Zoledronic acid may cause a moderate interaction that could exacerbate diseases when taken with Streptomycin
Risedronic acid may cause a moderate interaction that could exacerbate diseases when taken with Magnesium sulfate and Magnesium sulfate may lead to a major life threatening interaction when taken with Streptomycin
Risedronic acid may cause a moderate interaction that could exacerbate diseases when taken with Kanamycin and Kanamycin (Compound) resembles Streptomycin (Compound) and Kanamycin may cause a moderate interaction that could exacerbate diseases when taken with Streptomycin
Risedronic acid (Compound) causes Body temperature increased (Side Effect) and Body temperature increased (Side Effect) is caused by Amikacin (Compound) and Amikacin (Compound) resembles Streptomycin (Compound)
Risedronic acid (Compound) causes Vertigo (Side Effect) and Vertigo (Side Effect) is caused by Flucytosine (Compound) and Flucytosine may cause a moderate interaction that could exacerbate diseases when taken with Streptomycin
Risedronic acid (Compound) causes Angioedema (Side Effect) and Angioedema (Side Effect) is caused by Lidocaine (Compound) and Lidocaine may cause a minor interaction that can limit clinical effects when taken with Streptomycin |
DB00975 | DB01242 | 1,317 | 1,237 | [
"DDInter573",
"DDInter410"
] | Dipyridamole | Clomipramine | A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752) | Clomipramine, the 3-chloro analog of imipramine, is a dibenzazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, clomipramine does not affect mood or arousal, but may cause sedation. In depressed individuals, clomipramine exerts a positive effect on mood. TCAs are potent inhibitors of serotonin and norepinephrine reuptake. Tertiary amine TCAs, such as clomipramine, are more potent inhibitors of serotonin reuptake than secondary amine TCAs, such as nortriptyline and desipramine. TCAs also down-regulate cerebral cortical β-adrenergic receptors and sensitize post-synaptic serotonergic receptors with chronic use. The antidepressant effects of TCAs are thought to be due to an overall increase in serotonergic neurotransmission. TCAs also block histamine-H<sub>1</sub> receptors, α<sub>1</sub>-adrenergic receptors and muscarinic receptors, which accounts for their sedative, hypotensive and anticholinergic effects (e.g. blurred vision, dry mouth, constipation, urinary retention), respectively. See toxicity section below for a complete listing of side effects. Clomipramine may be used to treat obsessive-compulsive disorder and disorders with an obsessive-compulsive component (e.g. depression, schizophrenia, Tourette’s disorder). Unlabeled indications include panic disorder, chronic pain (e.g. central pain, idiopathic pain disorder, tension headache, diabetic peripheral neuropathy, neuropathic pain), cataplexy and associated narcolepsy, autistic disorder, trichotillomania, onchophagia, stuttering, premature ejaculation, and premenstrual syndrome. Clomipramine is rapidly absorbed from the gastrointestinal tract and demethylated in the liver to its primary active metabolite, desmethylclomipramine. | Moderate | 1 | [
[
[
1317,
24,
1237
]
],
[
[
1317,
6,
4973
],
[
4973,
45,
1237
]
],
[
[
1317,
21,
28703
],
[
28703,
60,
1237
]
],
[
[
1317,
64,
1578
],
[
1... | [
[
[
"Dipyridamole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clomipramine"
]
],
[
[
"Dipyridamole",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compoun... | Dipyridamole (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Clomipramine (Compound)
Dipyridamole (Compound) causes Pruritus (Side Effect) and Pruritus (Side Effect) is caused by Clomipramine (Compound)
Dipyridamole may lead to a major life threatening interaction when taken with Lepirudin and Lepirudin may cause a moderate interaction that could exacerbate diseases when taken with Clomipramine
Dipyridamole may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen and Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Clomipramine
Dipyridamole may lead to a major life threatening interaction when taken with Edoxaban and Edoxaban may cause a moderate interaction that could exacerbate diseases when taken with Clomipramine
Dipyridamole may cause a moderate interaction that could exacerbate diseases when taken with Epoprostenol and Epoprostenol may cause a moderate interaction that could exacerbate diseases when taken with Clomipramine
Dipyridamole may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor and Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Clomipramine
Dipyridamole may lead to a major life threatening interaction when taken with Panobinostat and Panobinostat may lead to a major life threatening interaction when taken with Clomipramine
Dipyridamole may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may lead to a major life threatening interaction when taken with Clomipramine |
DB00539 | DB06402 | 11 | 1,079 | [
"DDInter1837",
"DDInter1756"
] | Toremifene | Telavancin | Toremifene is a selective estrogen receptor modulator (SERM) and a nonsteroidal antiestrogen used to treat estrogen receptor positive breast cancer. Like [tamoxifen], toremifene is part of the first-generation triphenylethylene derivative chemical class of SERMs. Toremifene possesses tissue-specific actions: it has estrogenic (agonist) activity on the cardiovascular system and on bone tissue and it has weak estrogenic effects on uterine tissue, however, it also has antiestrogenic (estrogen-antagonist) activity on breast tissue. | Telavancin is a semi-synthetic derivative of vanocymycin that has bactericidal activity against Methicillin-resistant Staphylococcus aureus (MRSA) and other gram-positive bacteria. MRSA is an important pathogen capable of causing hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP), and skin and subcutaneous tissue infections among others. | Major | 2 | [
[
[
11,
25,
1079
]
],
[
[
11,
24,
968
],
[
968,
40,
1079
]
],
[
[
11,
21,
28680
],
[
28680,
60,
1079
]
],
[
[
11,
23,
112
],
[
112,
... | [
[
[
"Toremifene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Telavancin"
]
],
[
[
"Toremifene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oritavancin"
],
[
"Oritavanc... | Toremifene may cause a moderate interaction that could exacerbate diseases when taken with Oritavancin and Oritavancin (Compound) resembles Telavancin (Compound)
Toremifene (Compound) causes Rash (Side Effect) and Rash (Side Effect) is caused by Telavancin (Compound)
Toremifene may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Telavancin
Toremifene may cause a moderate interaction that could exacerbate diseases when taken with Castor oil and Castor oil may cause a moderate interaction that could exacerbate diseases when taken with Telavancin
Toremifene (Compound) resembles Loperamide (Compound) and Toremifene may cause a moderate interaction that could exacerbate diseases when taken with Loperamide and Loperamide may cause a moderate interaction that could exacerbate diseases when taken with Telavancin
Toremifene may lead to a major life threatening interaction when taken with Terfenadine and Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Telavancin
Toremifene may lead to a major life threatening interaction when taken with Glasdegib and Glasdegib may cause a moderate interaction that could exacerbate diseases when taken with Telavancin
Toremifene may lead to a major life threatening interaction when taken with Primaquine and Primaquine may cause a moderate interaction that could exacerbate diseases when taken with Telavancin
Toremifene may cause a moderate interaction that could exacerbate diseases when taken with Salmeterol and Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Telavancin |
DB00401 | DB06674 | 84 | 908 | [
"DDInter1298",
"DDInter837"
] | Nisoldipine | Golimumab | Nisoldipine is a 1,4-dihydropyridine calcium channel blocker. It acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in their inactive conformation. By inhibiting the influx of calcium in smooth muscle cells, nisoldipine prevents calcium-dependent smooth muscle contraction and subsequent vasoconstriction. Nisoldipine may be used in alone or in combination with other agents in the management of hypertension. | Golimumab is a human IgG1қ monoclonal antibody derived from immunizing genetically engineered mice with human TNFα. Golimumab binds and inhibits soluble and transmembrane human TNFα. Increased TNFα is associated with chronic inflammation. Thus golimumab is indicated for use in adults (i) as an adjunct to methotrexate treatment in patients with moderate to severe active rheumatoid arthritis (RA), (ii) alone or as an adjunct to methotrexate treatment in patients with active psoriatic arthritis (PsA), (iii) as a single agent in patients with active ankylosing spondylitis (AS), and (iv) as a single agent in patients with moderate to severe ulcerative colitis (UC) who require chronic steroids or have experienced intolerance or only a partial response to previous medications. In the U.S. and Canada, golimumab is marketed under the brand name Simponi®. The FDA label includes a black box warning of serious infections and malignancy. Additionally in children and adolescents taking golimumab, there have been lymphoma and other malignancies observed. | Moderate | 1 | [
[
[
84,
24,
908
]
],
[
[
84,
1,
336
],
[
336,
24,
908
]
],
[
[
84,
40,
1428
],
[
1428,
24,
908
]
],
[
[
84,
62,
1031
],
[
1031,
24,
... | [
[
[
"Nisoldipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Golimumab"
]
],
[
[
"Nisoldipine",
"{u} (Compound) resembles {v} (Compound)",
"Nifedipine"
],
[
"Nifedipine",
"{u} may cause a modera... | Nisoldipine (Compound) resembles Nifedipine (Compound) and Nifedipine may cause a moderate interaction that could exacerbate diseases when taken with Golimumab
Nisoldipine (Compound) resembles Isradipine (Compound) and Isradipine may cause a moderate interaction that could exacerbate diseases when taken with Golimumab
Nisoldipine may cause a minor interaction that can limit clinical effects when taken with Theophylline and Theophylline may cause a moderate interaction that could exacerbate diseases when taken with Golimumab
Nisoldipine may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Golimumab
Nisoldipine may cause a moderate interaction that could exacerbate diseases when taken with Alefacept and Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Golimumab
Nisoldipine may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone may lead to a major life threatening interaction when taken with Golimumab
Nisoldipine may cause a moderate interaction that could exacerbate diseases when taken with Deflazacort and Deflazacort may lead to a major life threatening interaction when taken with Golimumab
Nisoldipine may cause a moderate interaction that could exacerbate diseases when taken with Infliximab and Infliximab may lead to a major life threatening interaction when taken with Golimumab
Nisoldipine (Compound) resembles Nifedipine (Compound) and Nifedipine may cause a moderate interaction that could exacerbate diseases when taken with Simvastatin and Simvastatin may cause a moderate interaction that could exacerbate diseases when taken with Golimumab |
DB00261 | DB05316 | 702 | 749 | [
"DDInter93",
"DDInter1467"
] | Anagrelide | Pimavanserin | Anagrelide is a platelet-reducing agent used to lower dangerously elevated platelet levels (i.e. to treat thrombocythemia) in patients with myeloproliferative neoplasms. It is an oral imidazoquinazoline that was first approved for use in the US in 1997. It appears to carry a better response rate than other thrombocythemia treatments (e.g. [busulfan], [hydroxyurea]) and may be better tolerated. | Pimavanserin is an atypical antipsychotic indicated for the treatment of psychiatric disorders. Although the exact mechanism of action is unknown, it is thought that pimavanserin interacts with the serotonin receptors, particularly the 5-HT<sub>2A</sub> and HT<sub>2C</sub> receptors. Unlike other atypical antipsychotics, pimavanserin lacks inherent dopaminergic activity. In fact, pimavanserin is the first antipsychotic drug without D<sub>2</sub> blocking activity. Therefore, pimavanserin can be used to treat psychotic symptoms without causing extrapyramidal or worsening motor symptoms.[A232613,A232573] Pimavanserin is marketed under the trade name NUPLAZID and developed by Acadia Pharmaceuticals. It was approved by the FDA in April 2016 for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis thanks to favorable results from a pivotal six-week, randomized, placebo-controlled, parallel-group study.[L48241,A232573] Pimavanserin was also under review as a potential treatment for dementia-related psychosis; however, as of April 2021, FDA approval has not been granted for this indication despite previous breakthrough designation. | Major | 2 | [
[
[
702,
25,
749
]
],
[
[
702,
23,
112
],
[
112,
23,
749
]
],
[
[
702,
25,
1264
],
[
1264,
24,
749
]
],
[
[
702,
64,
521
],
[
521,
2... | [
[
[
"Anagrelide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pimavanserin"
]
],
[
[
"Anagrelide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metroni... | Anagrelide may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Pimavanserin
Anagrelide may lead to a major life threatening interaction when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Pimavanserin
Anagrelide may lead to a major life threatening interaction when taken with Goserelin and Goserelin may cause a moderate interaction that could exacerbate diseases when taken with Pimavanserin
Anagrelide may lead to a major life threatening interaction when taken with Bosutinib and Bosutinib may cause a moderate interaction that could exacerbate diseases when taken with Pimavanserin
Anagrelide may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor and Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Pimavanserin
Anagrelide may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol and Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Pimavanserin
Anagrelide may lead to a major life threatening interaction when taken with Toremifene and Toremifene may lead to a major life threatening interaction when taken with Pimavanserin
Anagrelide may lead to a major life threatening interaction when taken with Vemurafenib and Vemurafenib may lead to a major life threatening interaction when taken with Pimavanserin
Anagrelide may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a moderate interaction that could exacerbate diseases when taken with Zafirlukast and Zafirlukast may cause a moderate interaction that could exacerbate diseases when taken with Pimavanserin |
DB00586 | DB01174 | 1,512 | 697 | [
"DDInter537",
"DDInter1442"
] | Diclofenac | Phenobarbital | Diclofenac is a phenylacetic acid derivative and non-steroidal anti-inflammatory drug (NSAID).[label] NSAIDs inhibit cyclooxygenase (COX)-1 and-2 which are the enzyme responsible for producing prostaglandins (PGs). PGs contribute to inflammation and pain signalling. Diclofenac, like other NSAIDs, is often used as first line therapy for acute and chronic pain and inflammation from a variety of causes. Diclofenac was the product of rational drug design based on the structures of [phenylbutazone], [mefenamic acid], and [indomethacin]. The addition of two chlorine groups in the ortho position of the phenyl ring locks the ring in maximal torsion which appears to be related to increased potency. It is often used in combination with [misoprostol] to prevent NSAID-induced gastric ulcers. Diclofenac was first approved by the | A barbituric acid derivative that acts as a nonselective central nervous system depressant. It promotes binding to inhibitory gamma-aminobutyric acid subtype receptors, and modulates chloride currents through receptor channels. It also inhibits glutamate induced depolarizations. | Minor | 0 | [
[
[
1512,
23,
697
]
],
[
[
1512,
6,
7950
],
[
7950,
45,
697
]
],
[
[
1512,
21,
28860
],
[
28860,
60,
697
]
],
[
[
1512,
63,
1018
],
[
1018... | [
[
[
"Diclofenac",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Phenobarbital"
]
],
[
[
"Diclofenac",
"{u} (Compound) binds {v} (Gene)",
"CYP1A2"
],
[
"CYP1A2",
"{u} (Gene) is bound by {v} (Compound)"... | Diclofenac (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Phenobarbital (Compound)
Diclofenac (Compound) causes Mental disability (Side Effect) and Mental disability (Side Effect) is caused by Phenobarbital (Compound)
Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Ticlopidine and Ticlopidine may cause a minor interaction that can limit clinical effects when taken with Phenobarbital
Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Sulfasalazine and Sulfasalazine may cause a minor interaction that can limit clinical effects when taken with Phenobarbital
Diclofenac may cause a minor interaction that can limit clinical effects when taken with Cimetidine and Cimetidine may cause a minor interaction that can limit clinical effects when taken with Phenobarbital
Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Phenobarbital
Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Anagrelide and Anagrelide may cause a moderate interaction that could exacerbate diseases when taken with Phenobarbital
Diclofenac may lead to a major life threatening interaction when taken with Regorafenib and Regorafenib may cause a moderate interaction that could exacerbate diseases when taken with Phenobarbital
Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide may cause a moderate interaction that could exacerbate diseases when taken with Phenobarbital |
DB00420 | DB01276 | 508 | 123 | [
"DDInter1532",
"DDInter706"
] | Promazine | Exenatide | A phenothiazine with actions similar to chlorpromazine but with less antipsychotic activity. It is primarily used in short-term treatment of disturbed behavior and as an antiemetic. It is currently not approved for use in the United States. | Exenatide is a glucagon-like peptide-1 (GLP-1) analog. It activates the GLP-1 receptor and increases insulin secretion, decreases glucagon secretion, and slows gastric emptying to improve glycemic control. Exenatide was given FDA approval on April 28, 2005. It is available as immediate- and extended-release formulations.[L42685,L42690] Bydureon, the brand name product of extended-release exenatide in an injectable suspension, was discontinued in 2021. Bydureon BCise, an auto-injector extended-release formulation, remains available. | Moderate | 1 | [
[
[
508,
24,
123
]
],
[
[
508,
1,
820
],
[
820,
24,
123
]
],
[
[
508,
40,
1630
],
[
1630,
24,
123
]
],
[
[
508,
24,
222
],
[
222,
24... | [
[
[
"Promazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Exenatide"
]
],
[
[
"Promazine",
"{u} (Compound) resembles {v} (Compound)",
"Alimemazine"
],
[
"Alimemazine",
"{u} may cause a moderate... | Promazine (Compound) resembles Alimemazine (Compound) and Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Exenatide
Promazine (Compound) resembles Perphenazine (Compound) and Perphenazine may cause a moderate interaction that could exacerbate diseases when taken with Exenatide
Promazine may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Exenatide
Promazine may cause a moderate interaction that could exacerbate diseases when taken with Tetracosactide and Tetracosactide may cause a moderate interaction that could exacerbate diseases when taken with Exenatide
Promazine may lead to a major life threatening interaction when taken with Pasireotide and Pasireotide may cause a moderate interaction that could exacerbate diseases when taken with Exenatide
Promazine may cause a moderate interaction that could exacerbate diseases when taken with Goserelin and Goserelin may cause a moderate interaction that could exacerbate diseases when taken with Exenatide
Promazine (Compound) resembles Promethazine (Compound) and Promazine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Exenatide
Promazine may cause a minor interaction that can limit clinical effects when taken with Sucralfate and Sucralfate may cause a moderate interaction that could exacerbate diseases when taken with Exenatide
Promazine (Compound) resembles Methotrimeprazine (Compound) and Methotrimeprazine may cause a moderate interaction that could exacerbate diseases when taken with Exenatide |
DB00581 | DB06663 | 355 | 1,154 | [
"DDInter1018",
"DDInter1398"
] | Lactulose | Pasireotide | Lactulose is a synthetic disaccharide derivative of lactose that is most commonly used as a laxative agent despite also being formally indicated to serve as an adjunct therapy in treating portal-systemic encephalopathy (PSE).[FDA Label,L6199,L6202] Despite being first synthesized in 1929, investigations regarding its possible use as a laxative for the treatment of chronic constipation did not occur until the 1960s and its first clinical use for treating PSE was not until 1966. Nevertheless, although lactulose received formal FDA approval in 1977 and has since become a readily available generic and brand-name non-prescription medication listed on the World Health Organization's List of Essential Medicines as one of the most effective and safe medicines employed in a health system, data regarding its optimal place in therapy is often ambiguous. Especially considering the use of lactulose as a laxative is typically only considered after lifestyle and dietary modifications fail and the | Pasireotide is a synthetic long-acting cyclic hexapeptide with somatostatin-like activity. It is marketed as a diaspartate salt called Signifor, which is used in the treatment of Cushing's disease. | Moderate | 1 | [
[
[
355,
24,
1154
]
],
[
[
355,
21,
28810
],
[
28810,
60,
1154
]
],
[
[
355,
40,
1647
],
[
1647,
24,
1154
]
],
[
[
355,
24,
1662
],
[
1662... | [
[
[
"Lactulose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pasireotide"
]
],
[
[
"Lactulose",
"{u} (Compound) causes {v} (Side Effect)",
"Gastrointestinal pain"
],
[
"Gastrointestinal pain",
"{u... | Lactulose (Compound) causes Gastrointestinal pain (Side Effect) and Gastrointestinal pain (Side Effect) is caused by Pasireotide (Compound)
Lactulose (Compound) resembles Acarbose (Compound) and Acarbose may cause a moderate interaction that could exacerbate diseases when taken with Pasireotide
Lactulose may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid and Picosulfuric acid may cause a moderate interaction that could exacerbate diseases when taken with Pasireotide
Lactulose may cause a minor interaction that can limit clinical effects when taken with Magnesium hydroxide and Magnesium hydroxide may cause a moderate interaction that could exacerbate diseases when taken with Pasireotide
Lactulose may cause a moderate interaction that could exacerbate diseases when taken with Propofol and Propofol may cause a moderate interaction that could exacerbate diseases when taken with Pasireotide
Lactulose may cause a moderate interaction that could exacerbate diseases when taken with Anagrelide and Anagrelide may lead to a major life threatening interaction when taken with Pasireotide
Lactulose may cause a moderate interaction that could exacerbate diseases when taken with Sevoflurane and Sevoflurane may lead to a major life threatening interaction when taken with Pasireotide
Lactulose may cause a moderate interaction that could exacerbate diseases when taken with Glasdegib and Glasdegib may lead to a major life threatening interaction when taken with Pasireotide
Lactulose (Compound) causes Gastrointestinal pain (Side Effect) and Gastrointestinal pain (Side Effect) is caused by Desmopressin (Compound) and Desmopressin (Compound) resembles Pasireotide (Compound) |
DB00087 | DB06603 | 599 | 39 | [
"DDInter41",
"DDInter1387"
] | Alemtuzumab | Panobinostat | Alemtuzumab is a humanized monoclonal antibody specific to lymphocyte antigens. It is a recombinant DNA-derived humanized monoclonal antibody (Campath-1H) that is directed against the 21-28 kD cell surface glycoprotein, CD52. The Campath-1H antibody is an IgG1 kappa with the human variable framework and constant regions, and complementarity-determining regions from a murine (rat) monoclonal antibody (Campath-1G). Alemtuzumab is produced in mammalian cell (Chinese hamster ovary) suspension culture in a medium containing neomycin. Alemtuzumab was approved by the FDA in 2001. It is marketed as LEMTRADA for multiple sclerosis (MS) treatment and CAMPTAH for B-cell chronic lymphocytic leukemia (B-CLL). The dose of alemtuzumab used for B-CLL is | Panobinostat is an oral deacetylace (DAC) inhibitor approved on February 23, 2015 by the FDA for the treatment of multiple myeloma. The approval was accelerated based on progression-free survival, therefore confirmatory trials by the sponsor to demonstrate clinical efficacy in multiple myeloma treatment are in progress of being conducted. Panobinostat is marketed by Novartis under the brand name Farydak. Panobinostat acts as a non-selective histone deacetylase inhibitor (pan-HDAC inhibitor) and it is the most potent DAC inhibiting agent available on the market. | Moderate | 1 | [
[
[
599,
24,
39
]
],
[
[
599,
63,
1257
],
[
1257,
24,
39
]
],
[
[
599,
24,
221
],
[
221,
63,
39
]
],
[
[
599,
24,
58
],
[
58,
24,
... | [
[
[
"Alemtuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Panobinostat"
]
],
[
[
"Alemtuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pegfilgrastim"
],
... | Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Pegfilgrastim and Pegfilgrastim may cause a moderate interaction that could exacerbate diseases when taken with Panobinostat
Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Poliovirus type 1 antigen (formaldehyde inactivated) and Poliovirus type 1 antigen (formaldehyde inactivated) may cause a moderate interaction that could exacerbate diseases when taken with Panobinostat
Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Alefacept and Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Panobinostat
Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Bosutinib and Bosutinib may lead to a major life threatening interaction when taken with Panobinostat
Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Pentamidine and Pentamidine may lead to a major life threatening interaction when taken with Panobinostat
Alemtuzumab may lead to a major life threatening interaction when taken with Tofacitinib and Tofacitinib may lead to a major life threatening interaction when taken with Panobinostat
Alemtuzumab may lead to a major life threatening interaction when taken with Samarium (153Sm) lexidronam and Samarium (153Sm) lexidronam may lead to a major life threatening interaction when taken with Panobinostat
Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Etanercept and Etanercept may lead to a major life threatening interaction when taken with Panobinostat
Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Pegfilgrastim and Pegfilgrastim may cause a moderate interaction that could exacerbate diseases when taken with Topotecan and Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Panobinostat |
DB08873 | DB09074 | 74 | 1,362 | [
"DDInter221",
"DDInter1327"
] | Boceprevir | Olaparib | Boceprevir is a direct acting antiviral medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in the United States, and affecting 72% of all chronic HCV patients. Treatment options for chronic Hepatitis C have advanced significantly since 2011, with the development of Direct Acting Antivirals (DAAs) such as Boceprevir. Boceprevir is an inhibitor of NS3/4A, a serine protease enzyme, encoded by HCV genotypes 1 and 4 [synthesis]. These enzymes are essential for viral replication and serve to cleave the virally encoded polyprotein into mature proteins like NS4A, NS4B, NS5A and NS5B [FDA Label]. The barrier | Olaparib is a selective and potent inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, PARP1 and PARP2.[L41100, L40908, L43792] PARP inhibitors represent a novel class of anti-cancer therapy and they work by taking advantage of a defect in DNA repair in cancer cells with BRCA mutations and inducing cell death. Olaparib is used to treat a number of BRCA-associated tumours, including ovarian cancer, breast cancer, pancreatic cancer, and prostate cancer.[L41100, L40908, L43792] It was first approved by the FDA and EU in December 2014, and by Health Canada in April 2016. | Major | 2 | [
[
[
74,
25,
1362
]
],
[
[
74,
63,
896
],
[
896,
24,
1362
]
],
[
[
74,
64,
1478
],
[
1478,
24,
1362
]
],
[
[
74,
24,
1619
],
[
1619,
... | [
[
[
"Boceprevir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Olaparib"
]
],
[
[
"Boceprevir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etoposide"
],
[
"Etoposide",
... | Boceprevir may cause a moderate interaction that could exacerbate diseases when taken with Etoposide and Etoposide may cause a moderate interaction that could exacerbate diseases when taken with Olaparib
Boceprevir may lead to a major life threatening interaction when taken with Ivacaftor and Ivacaftor may cause a moderate interaction that could exacerbate diseases when taken with Olaparib
Boceprevir may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Olaparib
Boceprevir may lead to a major life threatening interaction when taken with Fostamatinib and Fostamatinib may cause a moderate interaction that could exacerbate diseases when taken with Olaparib
Boceprevir may lead to a major life threatening interaction when taken with Ponatinib and Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Olaparib
Boceprevir may cause a moderate interaction that could exacerbate diseases when taken with Vemurafenib and Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Olaparib
Boceprevir may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may lead to a major life threatening interaction when taken with Olaparib
Boceprevir may lead to a major life threatening interaction when taken with Enzalutamide and Enzalutamide may lead to a major life threatening interaction when taken with Olaparib
Boceprevir may lead to a major life threatening interaction when taken with Crizotinib and Crizotinib may lead to a major life threatening interaction when taken with Olaparib |
DB00278 | DB06081 | 291 | 1,046 | [
"DDInter117",
"DDInter286"
] | Argatroban | Caplacizumab | Argatroban is a direct, selective thrombin inhibitor. The American College of Cardiologists (ACC) recommend using bivalirudin or argatroban in patients who have had, or at risk for, heparin induced thrombocytopenia (HIT) and are undergoing percutaneous coronary intervention. Argatroban is a non-heparin anticoagulant shown to both normalize platelet count in patients with HIT and prevent the formation of thrombi. Parental anticoagulants must be stopped and a baseline activated partial thromboplastin time must be obtained prior to administering argatroban. | Caplacizumab, firstly called ALX-0081, is a humanized single-variable-domain immunoglobulin consisting of two identical humanized building blocks genetically linked by a three-alanine linker. Caplacizumab was developed by Ablynx, a Sanofi company and FDA approved on February 6, 2019, and approved previously by the EU in October 2018 as a combination therapy with plasma exchange and immunosuppression. | Major | 2 | [
[
[
291,
25,
1046
]
],
[
[
291,
23,
1631
],
[
1631,
62,
1046
]
],
[
[
291,
24,
1039
],
[
1039,
24,
1046
]
],
[
[
291,
24,
1427
],
[
1427,
... | [
[
[
"Argatroban",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Caplacizumab"
]
],
[
[
"Argatroban",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Turmeric"
],
[
"Turmeric",
... | Argatroban may cause a minor interaction that can limit clinical effects when taken with Turmeric and Turmeric may cause a minor interaction that can limit clinical effects when taken with Caplacizumab
Argatroban may cause a moderate interaction that could exacerbate diseases when taken with Dexfenfluramine and Dexfenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Caplacizumab
Argatroban may cause a moderate interaction that could exacerbate diseases when taken with Vortioxetine and Vortioxetine may cause a moderate interaction that could exacerbate diseases when taken with Caplacizumab
Argatroban may cause a moderate interaction that could exacerbate diseases when taken with Fluvoxamine and Fluvoxamine may cause a moderate interaction that could exacerbate diseases when taken with Caplacizumab
Argatroban may lead to a major life threatening interaction when taken with Cilostazol and Cilostazol may cause a moderate interaction that could exacerbate diseases when taken with Caplacizumab
Argatroban may cause a moderate interaction that could exacerbate diseases when taken with Acetylsalicylic acid and Acetylsalicylic acid may lead to a major life threatening interaction when taken with Caplacizumab
Argatroban may lead to a major life threatening interaction when taken with Prasugrel and Prasugrel may lead to a major life threatening interaction when taken with Caplacizumab
Argatroban may lead to a major life threatening interaction when taken with Omacetaxine mepesuccinate and Omacetaxine mepesuccinate may lead to a major life threatening interaction when taken with Caplacizumab
Argatroban may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor and Ticagrelor may lead to a major life threatening interaction when taken with Caplacizumab |
DB01166 | DB06779 | 477 | 365 | [
"DDInter379",
"DDInter470"
] | Cilostazol | Dalteparin | Cilostazol is a quinolinone derivative and antiplatelet agent with vasodilating properties that has been used in the symptomatic treatment of intermittent claudication in patients with peripheral ischaemia. It is marketed under the brand name Pletal by Otsuka Pharmaceutical Co.. Cilostazol works by inhibiting both primary and secondary aggregation and reducing calcium-induced contractions. | Dalteparin, a low molecular weight heparin (LMWH) prepared by nitrous acid degradation of unfractionated heparin of porcine intestinal mucosa origin, is an anticoagulant. It is composed of strongly acidic sulphated polysaccharide chains with an average molecular weight of 5000 and about 90% of the material within the range of 2000-9000. LMWHs have a more predictable response, a greater bioavailability, and a longer anti-Xa half life than unfractionated heparin. Dalteparin can also be safely used in most pregnant women. Low molecular weight heparins are less effective at inactivating factor IIa due to their shorter length compared to unfractionated heparin. | Major | 2 | [
[
[
477,
25,
365
]
],
[
[
477,
23,
539
],
[
539,
62,
365
]
],
[
[
477,
63,
305
],
[
305,
24,
365
]
],
[
[
477,
24,
1496
],
[
1496,
6... | [
[
[
"Cilostazol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dalteparin"
]
],
[
[
"Cilostazol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Capsicum"
],
[
"Capsicum",
... | Cilostazol may cause a minor interaction that can limit clinical effects when taken with Capsicum and Capsicum may cause a minor interaction that can limit clinical effects when taken with Dalteparin
Cilostazol may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Escherichia coli and Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Dalteparin
Cilostazol may cause a moderate interaction that could exacerbate diseases when taken with Nintedanib and Nintedanib may cause a moderate interaction that could exacerbate diseases when taken with Dalteparin
Cilostazol may cause a moderate interaction that could exacerbate diseases when taken with Dexfenfluramine and Dexfenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Dalteparin
Cilostazol may lead to a major life threatening interaction when taken with Fluvoxamine and Fluvoxamine may cause a moderate interaction that could exacerbate diseases when taken with Dalteparin
Cilostazol may lead to a major life threatening interaction when taken with Ticlopidine and Ticlopidine may lead to a major life threatening interaction when taken with Dalteparin
Cilostazol may cause a moderate interaction that could exacerbate diseases when taken with Ketoprofen and Ketoprofen may lead to a major life threatening interaction when taken with Dalteparin
Cilostazol may cause a moderate interaction that could exacerbate diseases when taken with Prasugrel and Prasugrel may lead to a major life threatening interaction when taken with Dalteparin
Cilostazol may lead to a major life threatening interaction when taken with Ponatinib and Ponatinib may lead to a major life threatening interaction when taken with Dalteparin |
DB08816 | DB09083 | 578 | 880 | [
"DDInter1802",
"DDInter996"
] | Ticagrelor | Ivabradine | Ticagrelor, or AZD6140, was first described in the literature in 2003.[A204170,A2903] Ticagrelor is an ADP derivative developed for its P2Y<sub>12</sub> receptor antagonism. Unlike [clopidogrel], ticagrelor is not a prodrug. It is marketed by Astra Zeneca as Brilinta in the US and Brilique or Possia in the EU,. Ticagrelor was granted EMA approval on 3 December 2010. Ticagrelor was granted FDA approval on 20 July 2011. | Ivabradine is a novel heart rate lowering medicine for the symptomatic management of stable angina pectoralis and symptomatic chronic heart failure. Ivabradine, brand name Corlanor, was approved by the FDA in April 2015 for the treatment of chronic heart failure in patients with an ejection fraction of ≤35%, in sinus rhythm with resting heart rate ≥70 beats per minute, who are not on beta-blockers due to contraindications or already receiving maximum beta-blocker dose. Recently a new indication was added to treat symptomatic heart failure from dilated cardiomyopathy for patients 6 months or more in age[Label]. Ivabradine acts by selectively inhibiting the "funny" channel pacemaker current (If) in the sinoatrial node in a dose-dependent fashion, resulting in a lower heart rate and thus more blood to flow to the myocardium. Although non-dihydropyridine calcium channel blockers and beta blockers also effectively lower heart rate, they exhibit adverse events due to their negative ionotropic effects. Therefore, as ivabradine is designed as a "pure" heart rate-lowering drug by selectively acting on the If channels, it may offer a more favorable side effect profile due to its lower likelihood of causing serious adverse effects. | Moderate | 1 | [
[
[
578,
24,
880
]
],
[
[
578,
24,
1478
],
[
1478,
24,
880
]
],
[
[
578,
24,
159
],
[
159,
63,
880
]
],
[
[
578,
63,
1051
],
[
1051,
... | [
[
[
"Ticagrelor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivabradine"
]
],
[
[
"Ticagrelor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivacaftor"
],
[
... | Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor and Ivacaftor may cause a moderate interaction that could exacerbate diseases when taken with Ivabradine
Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Ivabradine
Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Aminoglutethimide and Aminoglutethimide may cause a moderate interaction that could exacerbate diseases when taken with Ivabradine
Ticagrelor may cause a minor interaction that can limit clinical effects when taken with Fingolimod and Fingolimod may cause a moderate interaction that could exacerbate diseases when taken with Ivabradine
Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Panobinostat and Panobinostat may lead to a major life threatening interaction when taken with Ivabradine
Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib and Ribociclib may lead to a major life threatening interaction when taken with Ivabradine
Ticagrelor may lead to a major life threatening interaction when taken with Idelalisib and Idelalisib may lead to a major life threatening interaction when taken with Ivabradine
Ticagrelor may lead to a major life threatening interaction when taken with Lumacaftor and Lumacaftor may lead to a major life threatening interaction when taken with Ivabradine
Ticagrelor may lead to a major life threatening interaction when taken with Dasatinib and Dasatinib may lead to a major life threatening interaction when taken with Ivabradine |
DB00254 | DB00774 | 964 | 1,577 | [
"DDInter598",
"DDInter889"
] | Doxycycline | Hydroflumethiazide | Doxycycline is a broad-spectrum antibiotic synthetically derived from [oxytetracycline]. It is a second-generation tetracycline that was first discovered in 1967. Second-generation tetracyclines exhibit lesser toxicity than first-generation tetracyclines. Doxycycline is used to treat a wide variety of gram-positive and gram-negative bacterial infections. It is also used to treat acne and malaria. | A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p822) | Minor | 0 | [
[
[
964,
23,
1577
]
],
[
[
964,
23,
359
],
[
359,
40,
1577
]
],
[
[
964,
23,
504
],
[
504,
1,
1577
]
],
[
[
964,
40,
1620
],
[
1620,
... | [
[
[
"Doxycycline",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Hydroflumethiazide"
]
],
[
[
"Doxycycline",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Chlorothiazide"
]... | Doxycycline may cause a minor interaction that can limit clinical effects when taken with Chlorothiazide and Chlorothiazide (Compound) resembles Hydroflumethiazide (Compound)
Doxycycline may cause a minor interaction that can limit clinical effects when taken with Hydrochlorothiazide and Hydrochlorothiazide (Compound) resembles Hydroflumethiazide (Compound)
Doxycycline (Compound) resembles Tetracycline (Compound) and Tetracycline may cause a minor interaction that can limit clinical effects when taken with Hydroflumethiazide
Doxycycline (Compound) resembles Oxytetracycline (Compound) and Oxytetracycline may cause a minor interaction that can limit clinical effects when taken with Hydroflumethiazide
Doxycycline may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin may cause a minor interaction that can limit clinical effects when taken with Hydroflumethiazide
Doxycycline (Compound) resembles Minocycline (Compound) and Minocycline may cause a minor interaction that can limit clinical effects when taken with Hydroflumethiazide
Doxycycline may cause a moderate interaction that could exacerbate diseases when taken with Methoxsalen and Methoxsalen may cause a moderate interaction that could exacerbate diseases when taken with Hydroflumethiazide
Doxycycline may cause a moderate interaction that could exacerbate diseases when taken with Insulin glulisine and Insulin glulisine may cause a moderate interaction that could exacerbate diseases when taken with Hydroflumethiazide
Doxycycline may cause a moderate interaction that could exacerbate diseases when taken with Insulin lispro and Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Hydroflumethiazide |
DB00480 | DB00631 | 1,668 | 372 | [
"DDInter1035",
"DDInter405"
] | Lenalidomide | Clofarabine | Lenalidomide (previously referred to as CC-5013) is an immunomodulatory drug with potent antineoplastic, anti-angiogenic, and anti-inflammatory properties. It is a 4-amino-glutamyl analogue of [thalidomide] and like thalidomide, lenalidomide exists as a racemic mixture of the active S(-) and R(+) forms. However, lenalidomide is much safer and potent than thalidomide, with fewer adverse effects and toxicities.[A714, A228543] Thalidomide and its analogues, including lenalidomide, are referred to as immunomodulatory imide drugs (also known as cereblon modulators), which are a class of immunomodulatory drugs that contain an imide group. Lenalidomide works through various mechanisms of actions that promote malignant cell death and enhance host immunity | Clofarabine is a purine nucleoside antimetabolite that is being studied in the treatment of cancer. It is marketed as Clolar in the U.S. and Canada, or Evoltra in Europe, Australia, and New Zealand. Clofarabine is used in paediatrics to treat a type of leukaemia called relapsed or refractory acute lymphoblastic leukaemia (ALL), only after at least two other types of treatment have failed. It is not known if the drug extends life expectancy. Its potential use in acute myeloid leukaemia (AML) and juvenile myelomonocytic leukaemia (JMML) has been investigated. | Moderate | 1 | [
[
[
1668,
24,
372
]
],
[
[
1668,
64,
1064
],
[
1064,
25,
372
]
],
[
[
1668,
5,
11555
],
[
11555,
44,
372
]
],
[
[
1668,
6,
7720
],
[
7720,... | [
[
[
"Lenalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofarabine"
]
],
[
[
"Lenalidomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cladribine"
],
[
"Cladr... | Lenalidomide may lead to a major life threatening interaction when taken with Cladribine and Cladribine may lead to a major life threatening interaction when taken with Clofarabine
Lenalidomide (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Clofarabine (Compound)
Lenalidomide (Compound) binds PTGS2 (Gene) and PTGS2 (Gene) is upregulated by Clofarabine (Compound)
Lenalidomide (Compound) downregulates IER3 (Gene) and IER3 (Gene) is upregulated by Clofarabine (Compound)
Lenalidomide (Compound) upregulates RRP8 (Gene) and RRP8 (Gene) is upregulated by Clofarabine (Compound)
Lenalidomide (Compound) causes Dry skin (Side Effect) and Dry skin (Side Effect) is caused by Clofarabine (Compound)
Lenalidomide may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib and Encorafenib may cause a moderate interaction that could exacerbate diseases when taken with Clofarabine
Lenalidomide may cause a moderate interaction that could exacerbate diseases when taken with Pegaspargase and Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Clofarabine
Lenalidomide may lead to a major life threatening interaction when taken with Tamoxifen and Tamoxifen may cause a moderate interaction that could exacerbate diseases when taken with Clofarabine |
DB00283 | DB01209 | 701 | 1,359 | [
"DDInter395",
"DDInter531"
] | Clemastine | Dezocine | An ethanolamine-derivative, first generation histamine H1 antagonist used in hay fever, rhinitis, allergic skin conditions, and pruritus. It causes drowsiness. | Dezocine is a partial opiate drug and is used for pain management. Dezocine is a very effective alternative to fentanyl when administered during outpatient laparoscopy, although is associated with an increased incidence of postoperative nausea. | Moderate | 1 | [
[
[
701,
24,
1359
]
],
[
[
701,
24,
234
],
[
234,
1,
1359
]
],
[
[
701,
24,
717
],
[
717,
24,
1359
]
],
[
[
701,
35,
1594
],
[
1594,
... | [
[
[
"Clemastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dezocine"
]
],
[
[
"Clemastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentazocine"
],
[
... | Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Pentazocine and Pentazocine (Compound) resembles Dezocine (Compound)
Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Trimethobenzamide and Trimethobenzamide may cause a moderate interaction that could exacerbate diseases when taken with Dezocine
Clemastine (Compound) resembles Doxylamine (Compound) and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Dezocine
Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Levocetirizine and Levocetirizine may cause a moderate interaction that could exacerbate diseases when taken with Dezocine
Clemastine (Compound) resembles Mepenzolate (Compound) and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Mepenzolate and Mepenzolate may cause a moderate interaction that could exacerbate diseases when taken with Dezocine
Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Trospium and Trospium may cause a moderate interaction that could exacerbate diseases when taken with Dezocine
Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Opium and Opium may lead to a major life threatening interaction when taken with Dezocine
Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Morphine and Morphine may lead to a major life threatening interaction when taken with Dezocine
Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Dextromethorphan and Dextromethorphan (Compound) resembles Dezocine (Compound) and Dextromethorphan may cause a moderate interaction that could exacerbate diseases when taken with Dezocine |
DB00358 | DB00373 | 1,010 | 461 | [
"DDInter1140",
"DDInter1809"
] | Mefloquine | Timolol | Malaria is a protozoan disease that places an enormous burden on human health in endemic areas around the world. The 2020 World Health Organization malaria report indicates a 60% decrease in the global malaria fatality rate between 2000 to 2019. Despite this, malaria remains a significant cause of morbidity and mortality; 90% of deaths from malaria occur in Africa. Individuals at the highest risk for malaria are those in disease naïve populations, children under age 5, refugees in Central and Eastern Africa, nonimmune civilian and military travelers, pregnant women, and immigrants traveling to their place of origin. Mefloquine, commonly known as Lariam, is an antimalarial drug used for the prevention and treatment of malaria caused by infection with Plasmodium vivax and Plasmodium falciparum. The drug was initially discovered by the Walter Reed Army Institute of Research (WRAIR) during a malaria drug discovery program between 196 | Timolol is a nonselective beta-adrenergic antagonist given in an eye drop solution to reduce intraocular pressure, or pressure in the eyes. It is also used in tablet form as a drug to treat hypertension. Timolol was first approved by the FDA in 1978. This drug is marketed by several manufacturers and is an effective agent for the management of conditions such as open-angle glaucoma and hypertension. | Moderate | 1 | [
[
[
1010,
24,
461
]
],
[
[
1010,
24,
729
],
[
729,
40,
461
]
],
[
[
1010,
6,
4973
],
[
4973,
45,
461
]
],
[
[
1010,
21,
28814
],
[
28814,
... | [
[
[
"Mefloquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Timolol"
]
],
[
[
"Mefloquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Penbutolol"
],
[
... | Mefloquine may cause a moderate interaction that could exacerbate diseases when taken with Penbutolol and Penbutolol (Compound) resembles Timolol (Compound)
Mefloquine (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Timolol (Compound)
Mefloquine (Compound) causes Affect lability (Side Effect) and Affect lability (Side Effect) is caused by Timolol (Compound)
Mefloquine may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide and Magnesium hydroxide may cause a minor interaction that can limit clinical effects when taken with Timolol
Mefloquine may lead to a major life threatening interaction when taken with Crizotinib and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Timolol
Mefloquine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Timolol
Mefloquine may cause a moderate interaction that could exacerbate diseases when taken with Lidocaine and Lidocaine may cause a moderate interaction that could exacerbate diseases when taken with Timolol
Mefloquine may cause a moderate interaction that could exacerbate diseases when taken with Orciprenaline and Orciprenaline may lead to a major life threatening interaction when taken with Timolol
Mefloquine may lead to a major life threatening interaction when taken with Dolasetron and Dolasetron may lead to a major life threatening interaction when taken with Timolol |
DB00980 | DB09280 | 969 | 1,604 | [
"DDInter1564",
"DDInter1101"
] | Ramelteon | Lumacaftor | Ramelteon is the first in a new class of sleep agents that selectively binds to the melatonin receptors in the suprachiasmatic nucleus (SCN). It is used for insomnia, particularly delayed sleep onset. Ramelteon has not been shown to produce dependence and has shown no potential for abuse. | Lumacaftor is a drug used in combination with as the fixed dose combination product Orkambi for the management of Cystic Fibrosis (CF) in patients aged 6 years and older. Cystic Fibrosis is an autosomal recessive disorder caused by one of several different mutations in the gene for the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) protein, a transmembrane ion channel involved in the transport of chloride and sodium ions across cell membranes of the lungs, pancreas, and other organs. Mutations in the CFTR gene result in altered production, misfolding, or function of the CFTR protein and consequently abnormal fluid and ion transport across cell membranes.[A20298, A20299] As a result, CF patients produce thick, sticky mucus that clogs the ducts of organs where it is produced making patients more susceptible to infections, lung damage, pancreatic insufficiency, and malnutrition. Lumacaftor improves CF symptoms and underlying disease pathology by aiding the conformational stability of F508del-mutated CFTR proteins, preventing misfolding and resulting in increased processing and trafficking of mature protein to the cell surface. Results from clinical trials indicated that treatment with Orkambi (lumacaftor/ivacaftor) results in improved lung function, reduced chance of experiencing a pulmonary exacerbation, increased weight gain, and improvements in CF symptoms.[FDA Label] This data has been heavily scrutinized, however, with clinical trials showing only modest improvements despite a hefty yearly cost of $259,000 for Orkambi. Improvements in lung function (ppFEV1) were found to be statistically significant, but minimal, with only a 2.6-3.0% change from baseline with more than 70% of patients failing to achieve an absolute improvement of at least 5%.[A20343, L936] A wide variety of CFTR mutations correlate to the Cystic Fibrosis phenotype and are associated with differing levels of disease severity. The most common mutation, affecting approximately 70% of patients with CF worldwide, is known as F508del-CFTR, or delta-F508 (ΔF508), in which a deletion in the amino acid phenylalanine at position 508 results in impaired production of the CFTR protein, thereby causing a significant reduction in the amount of ion transporter present on cell membranes. When used in combination with as the fixed dose combination product Orkambi, lumacaftor is specific for the management of CF in patients with delta-F508 mutations as it acts as a protein-folding chaperone, aiding the conformational stability of the mutated CFTR protein. Consequently, lumacaftor increases successful production of CFTR ion channels and the total number of receptors available for use at the cell membrane for fluid and ion transport. The next most common mutation, G551D, affecting 4-5% of CF patients worldwide, is characterized as a missense mutation, whereby there is sufficient amount of protein at the cell surface, but opening and closing mechanisms of the channel are altered. Treatment of patients with G551D and other rarer missense mutations is usually managed with (Kalydeco), as it aids with altered gating mechanisms by potentiating channel opening probability of CFTR protein. Prior to the development of lumacaftor and (Kalydeco), management of CF primarily involved therapies for the control of infections, nutritional support, clearance of mucus, and management of symptoms rather than improvements in the underlying disease process. Approved for use by the Food and Drug Administration in July 2015 and by Health Canada in January 2016, Orkambi was the first combination product approved for the management of Cystic Fibrosis with delta-F508 mutations. Ivacaftor is manufactured and distributed by Vertex Pharmaceuticals. | Moderate | 1 | [
[
[
969,
24,
1604
]
],
[
[
969,
63,
254
],
[
254,
24,
1604
]
],
[
[
969,
24,
985
],
[
985,
64,
1604
]
],
[
[
969,
24,
868
],
[
868,
... | [
[
[
"Ramelteon",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lumacaftor"
]
],
[
[
"Ramelteon",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nitisinone"
],
[
... | Ramelteon may cause a moderate interaction that could exacerbate diseases when taken with Nitisinone and Nitisinone may cause a moderate interaction that could exacerbate diseases when taken with Lumacaftor
Ramelteon may cause a moderate interaction that could exacerbate diseases when taken with Osimertinib and Osimertinib may lead to a major life threatening interaction when taken with Lumacaftor
Ramelteon may cause a moderate interaction that could exacerbate diseases when taken with Vemurafenib and Vemurafenib may lead to a major life threatening interaction when taken with Lumacaftor
Ramelteon may cause a moderate interaction that could exacerbate diseases when taken with Nitisinone and Nitisinone may cause a moderate interaction that could exacerbate diseases when taken with Meloxicam and Meloxicam may cause a moderate interaction that could exacerbate diseases when taken with Lumacaftor
Ramelteon may cause a moderate interaction that could exacerbate diseases when taken with Osimertinib and Osimertinib may cause a moderate interaction that could exacerbate diseases when taken with Ergometrine and Ergometrine may cause a moderate interaction that could exacerbate diseases when taken with Lumacaftor
Ramelteon (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Nifedipine (Compound) and Nifedipine may lead to a major life threatening interaction when taken with Lumacaftor
Ramelteon may cause a moderate interaction that could exacerbate diseases when taken with Olaparib and Olaparib may cause a moderate interaction that could exacerbate diseases when taken with Enfortumab vedotin and Enfortumab vedotin may cause a minor interaction that can limit clinical effects when taken with Lumacaftor
Ramelteon (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Betamethasone (Compound) and Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Lumacaftor
Ramelteon may cause a moderate interaction that could exacerbate diseases when taken with Osimertinib and Osimertinib may lead to a major life threatening interaction when taken with Mirtazapine and Mirtazapine may cause a moderate interaction that could exacerbate diseases when taken with Lumacaftor |
DB00719 | DB11915 | 1,219 | 1,293 | [
"DDInter149",
"DDInter1909"
] | Azatadine | Valbenazine | Antihistamines such as azatadine appear to compete with histamine for histamine H1- receptor sites on effector cells. The antihistamines antagonize those pharmacological effects of histamine which are mediated through activation of H1- receptor sites and thereby reduce the intensity of allergic reactions and tissue injury response involving histamine release. | Valbenazine is a modified metabolite of [tetrabenazine], and it is currently being approved for the treatment of various movement disorders, particularly tardive dyskinesia and chorea associated with Huntington's disease.[L47885,A261135] Tardive dyskinesia has long been regarded as a consequence of anti-dopamine receptor therapy, and until 2008 with the advent of [tetrabenazine], most treatments were ineffective. However, challenges in using [tetrabenazine] as a treatment of tardive dyskinesia included frequent dosing and safety and tolerability concerns. On April 2017, valbenazine was approved by the FDA under the brand name INGREZZA as the first and only approved treatment for adults with Tardive Dyskinesia (TD). On August 2023, valbenazine was again approved by the FDA for the treatment of chorea associated with Huntington's disease respectively. This approval was supported by positive results in multiple trials, including the KINECT-HD Phase 3 study and the ongoing KINECT-HD2 open-label extension trial. The reduction in chorea severity was observed as early as 2 weeks after starting treatment with an initial dose of 40 mg. | Moderate | 1 | [
[
[
1219,
24,
1293
]
],
[
[
1219,
24,
516
],
[
516,
24,
1293
]
],
[
[
1219,
63,
1242
],
[
1242,
24,
1293
]
],
[
[
1219,
40,
830
],
[
830,
... | [
[
[
"Azatadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Valbenazine"
]
],
[
[
"Azatadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levocetirizine"
],
[... | Azatadine may cause a moderate interaction that could exacerbate diseases when taken with Levocetirizine and Levocetirizine may cause a moderate interaction that could exacerbate diseases when taken with Valbenazine
Azatadine may cause a moderate interaction that could exacerbate diseases when taken with Cetirizine and Cetirizine may cause a moderate interaction that could exacerbate diseases when taken with Valbenazine
Azatadine (Compound) resembles Phenindamine (Compound) and Phenindamine may cause a moderate interaction that could exacerbate diseases when taken with Valbenazine
Azatadine may cause a moderate interaction that could exacerbate diseases when taken with Procarbazine and Procarbazine may lead to a major life threatening interaction when taken with Valbenazine
Azatadine may cause a moderate interaction that could exacerbate diseases when taken with Levocetirizine and Levocetirizine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Valbenazine
Azatadine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Valbenazine
Azatadine may cause a moderate interaction that could exacerbate diseases when taken with Metoclopramide and Metoclopramide may cause a moderate interaction that could exacerbate diseases when taken with Levocetirizine and Levocetirizine may cause a moderate interaction that could exacerbate diseases when taken with Valbenazine
Azatadine may cause a moderate interaction that could exacerbate diseases when taken with Cetirizine and Cetirizine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Valbenazine
Azatadine may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Valbenazine |
DB00570 | DB10795 | 147 | 221 | [
"DDInter1936",
"DDInter1486"
] | Vinblastine | Poliovirus type 1 antigen (formaldehyde inactivated) | Antitumor alkaloid isolated from Vinca rosea. (Merck, 11th ed.) | Poliovirus type 1 antigen is a suspension of poliovirus Type 1 (Mahoney) used in the active immunization of infants (as young as 6 weeks of age), children, and adults for the prevention of poliomyelitis caused by poliovirus Type 1. The vaccine contains purified and inactivated poliovirus type 1 that were grown from a continuous line of monkey kidney cells. | Moderate | 1 | [
[
[
147,
24,
221
]
],
[
[
147,
24,
36
],
[
36,
24,
221
]
],
[
[
147,
64,
581
],
[
581,
24,
221
]
],
[
[
147,
63,
599
],
[
599,
24,
... | [
[
[
"Vinblastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Poliovirus type 1 antigen (formaldehyde inactivated)"
]
],
[
[
"Vinblastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken w... | Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Eribulin and Eribulin may cause a moderate interaction that could exacerbate diseases when taken with Poliovirus type 1 antigen (formaldehyde inactivated)
Vinblastine may lead to a major life threatening interaction when taken with Infliximab and Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Poliovirus type 1 antigen (formaldehyde inactivated)
Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Alemtuzumab and Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Poliovirus type 1 antigen (formaldehyde inactivated)
Vinblastine may lead to a major life threatening interaction when taken with Idelalisib and Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Poliovirus type 1 antigen (formaldehyde inactivated)
Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib and Ribociclib may cause a moderate interaction that could exacerbate diseases when taken with Poliovirus type 1 antigen (formaldehyde inactivated)
Vinblastine may cause a minor interaction that can limit clinical effects when taken with Teniposide and Teniposide may cause a moderate interaction that could exacerbate diseases when taken with Poliovirus type 1 antigen (formaldehyde inactivated)
Vinblastine may cause a minor interaction that can limit clinical effects when taken with Lomustine and Lomustine may cause a moderate interaction that could exacerbate diseases when taken with Poliovirus type 1 antigen (formaldehyde inactivated)
Vinblastine may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may cause a moderate interaction that could exacerbate diseases when taken with Poliovirus type 1 antigen (formaldehyde inactivated)
Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Eribulin and Eribulin may lead to a major life threatening interaction when taken with Infliximab and Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Poliovirus type 1 antigen (formaldehyde inactivated) |
DB08875 | DB11967 | 1,618 | 710 | [
"DDInter262",
"DDInter210"
] | Cabozantinib | Binimetinib | Cabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer. In 2016, a capsule formulation (Cabometyx) was approved for the treatment of advanced renal cell carcinoma, and this same formulation gained additional approval in both the US and Canada in 2019 for the treatment of hepatocellular carcinoma in previously treated patients.[L15128,L15133] | Binimetinib, also known as _Mektovi_, is a potent and selective oral mitogen-activated protein kinase 1/2 (MEK 1/2) inhibitor which is combined with [Encorafenib].[A34275,L3335] On June 27, 2018, the Food and Drug Administration approved the combination of [Encorafenib] and binimetinib (BRAFTOVI and MEKTOVI, from Array BioPharma Inc.) in combination for patients with unresectable or metastatic melanoma with the BRAF V600E or V600K mutations, as detected by an FDA-approved test. | Major | 2 | [
[
[
1618,
25,
710
]
],
[
[
1618,
64,
441
],
[
441,
24,
710
]
],
[
[
1618,
25,
1293
],
[
1293,
24,
710
]
],
[
[
1618,
25,
68
],
[
68,
... | [
[
[
"Cabozantinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Binimetinib"
]
],
[
[
"Cabozantinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Delavirdine"
],
[
"Delavirdine",
... | Cabozantinib may lead to a major life threatening interaction when taken with Delavirdine and Delavirdine may cause a moderate interaction that could exacerbate diseases when taken with Binimetinib
Cabozantinib may lead to a major life threatening interaction when taken with Valbenazine and Valbenazine may cause a moderate interaction that could exacerbate diseases when taken with Binimetinib
Cabozantinib may lead to a major life threatening interaction when taken with Troleandomycin and Troleandomycin may cause a moderate interaction that could exacerbate diseases when taken with Binimetinib
Cabozantinib may cause a moderate interaction that could exacerbate diseases when taken with Eslicarbazepine and Eslicarbazepine may cause a moderate interaction that could exacerbate diseases when taken with Binimetinib
Cabozantinib may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Binimetinib
Cabozantinib may cause a moderate interaction that could exacerbate diseases when taken with Afatinib and Afatinib may cause a moderate interaction that could exacerbate diseases when taken with Binimetinib
Cabozantinib may lead to a major life threatening interaction when taken with Ramucirumab and Ramucirumab may lead to a major life threatening interaction when taken with Binimetinib
Cabozantinib may lead to a major life threatening interaction when taken with Acalabrutinib and Acalabrutinib may lead to a major life threatening interaction when taken with Binimetinib
Cabozantinib may lead to a major life threatening interaction when taken with Zanubrutinib and Zanubrutinib may lead to a major life threatening interaction when taken with Binimetinib |
DB01118 | DB09036 | 33 | 812 | [
"DDInter76",
"DDInter1668"
] | Amiodarone | Siltuximab | Amiodarone is a benzofuran derivative, anti-arrhythmic drug used commonly in a variety of settings. Most known for its approved indication in life-threatening ventricular arrhythmias, it is also used off-label in the outpatient and inpatient setting for atrial fibrillation. Because of its ability to cause serious toxicity and possibly death, amiodarone use should be reserved for its approved indications, according to prescribing information.[L3561,L11265,L11286] | Siltuximab is a chimeric (human-mouse) monoclonal immunoglobulin G1-kappa antibody produced in a Chinese hamster ovary (CHO) cell line by recombinant DNA technology. Siltuximab prevents the binding of IL-6 to soluble and membrane-bound IL-6 receptors by forming high affinity complexes with human interleukin-6 (IL-6). Its use is indicated for the treatment of adult patients with multicentric Castleman's disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative. MCD is a rare blood disorder caused by dysregulated IL-6 production, proliferation of lymphocytes, and subsequent enlargement of the lymph nodes. It is administered as a 1 hour intravenous infusion every 3 weeks. | Moderate | 1 | [
[
[
33,
24,
812
]
],
[
[
33,
24,
792
],
[
792,
24,
812
]
],
[
[
33,
63,
1031
],
[
1031,
24,
812
]
],
[
[
33,
64,
126
],
[
126,
24,
... | [
[
[
"Amiodarone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Siltuximab"
]
],
[
[
"Amiodarone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rivaroxaban"
],
[
... | Amiodarone may cause a moderate interaction that could exacerbate diseases when taken with Rivaroxaban and Rivaroxaban may cause a moderate interaction that could exacerbate diseases when taken with Siltuximab
Amiodarone may cause a moderate interaction that could exacerbate diseases when taken with Theophylline and Theophylline may cause a moderate interaction that could exacerbate diseases when taken with Siltuximab
Amiodarone may lead to a major life threatening interaction when taken with Warfarin and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Siltuximab
Amiodarone may lead to a major life threatening interaction when taken with Venetoclax and Venetoclax may cause a moderate interaction that could exacerbate diseases when taken with Siltuximab
Amiodarone may cause a moderate interaction that could exacerbate diseases when taken with Etanercept and Etanercept may lead to a major life threatening interaction when taken with Siltuximab
Amiodarone may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may lead to a major life threatening interaction when taken with Siltuximab
Amiodarone may cause a moderate interaction that could exacerbate diseases when taken with Golimumab and Golimumab may lead to a major life threatening interaction when taken with Siltuximab
Amiodarone may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may lead to a major life threatening interaction when taken with Siltuximab
Amiodarone may cause a moderate interaction that could exacerbate diseases when taken with Rivaroxaban and Rivaroxaban may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Siltuximab |
DB01009 | DB09135 | 935 | 1,211 | [
"DDInter1009",
"DDInter967"
] | Ketoprofen | Ioxilan | Ketoprofen, a propionic acid derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with analgesic and antipyretic properties. | Ioxilan is a tri-iodinated diagnostic contrast agent. Intravascular injection results in opacification of vessels in the path of flow of the contrast medium, permitting radiographic visualization of the internal structures of the human body until significant hemodilution occurs. | Major | 2 | [
[
[
935,
25,
1211
]
],
[
[
935,
1,
1523
],
[
1523,
24,
1211
]
],
[
[
935,
24,
712
],
[
712,
25,
1211
]
],
[
[
935,
63,
372
],
[
372,
... | [
[
[
"Ketoprofen",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ioxilan"
]
],
[
[
"Ketoprofen",
"{u} (Compound) resembles {v} (Compound)",
"Labetalol"
],
[
"Labetalol",
"{u} may cause a moderate interaction that c... | Ketoprofen (Compound) resembles Labetalol (Compound) and Labetalol may cause a moderate interaction that could exacerbate diseases when taken with Ioxilan
Ketoprofen may cause a moderate interaction that could exacerbate diseases when taken with Olsalazine and Olsalazine may lead to a major life threatening interaction when taken with Ioxilan
Ketoprofen may cause a moderate interaction that could exacerbate diseases when taken with Clofarabine and Clofarabine may lead to a major life threatening interaction when taken with Ioxilan
Ketoprofen may lead to a major life threatening interaction when taken with Sirolimus and Sirolimus may lead to a major life threatening interaction when taken with Ioxilan
Ketoprofen (Compound) resembles Ketorolac (Compound) and Ketorolac may lead to a major life threatening interaction when taken with Ioxilan
Ketoprofen (Compound) resembles Labetalol (Compound) and Labetalol may cause a moderate interaction that could exacerbate diseases when taken with Tyropanoic acid and Tyropanoic acid may cause a moderate interaction that could exacerbate diseases when taken with Ioxilan
Ketoprofen may cause a moderate interaction that could exacerbate diseases when taken with Olsalazine and Olsalazine may cause a moderate interaction that could exacerbate diseases when taken with Remdesivir and Remdesivir may cause a moderate interaction that could exacerbate diseases when taken with Ioxilan
Ketoprofen may cause a moderate interaction that could exacerbate diseases when taken with Clofarabine and Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Ioxilan
Ketoprofen may cause a moderate interaction that could exacerbate diseases when taken with Vancomycin and Vancomycin may cause a moderate interaction that could exacerbate diseases when taken with Etacrynic acid and Etacrynic acid may cause a moderate interaction that could exacerbate diseases when taken with Ioxilan |
DB00544 | DB14443 | 970 | 987 | [
"DDInter757",
"DDInter1931"
] | Fluorouracil | Vibrio cholerae CVD 103-HgR strain live antigen | A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid. | _Vibrio cholerae_ CVD 103-HgR strain live antigen is a component of Vaxchora, an oral vaccine for immunization against _Vibrio cholerae_ serogroup O1. Cholera is an acute bacterial disease of the small intestine caused by _Vibrio cholerae_, which is gram-negative bacteria. Two serogroups of _V. cholerae_, O1 and O139, are causative agents of epidemic cholera. Serogroup O1 is responsible for the majority of cholera outbreaks. Cholera outbreaks remain a major global public health problem that mainly affects countries with limited access to clean water, poor hygiene, and proper sanitation; thus, effective vaccines to protect individuals against cholera disease are critical. The FDA approved the cholera vaccine containing _Vibrio cholerae_ CVD 103-HgR strain live antigen under the brand name Vaxchora in June 2016, making it the first vaccine indicated for cholera prevention to become available in the U.S. Vaxchora was later approved by the European Commission in April 2020. It is indicated for individuals aged two years and older. | Moderate | 1 | [
[
[
970,
24,
987
]
],
[
[
970,
63,
141
],
[
141,
24,
987
]
],
[
[
970,
24,
1488
],
[
1488,
24,
987
]
],
[
[
970,
64,
377
],
[
377,
2... | [
[
[
"Fluorouracil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vibrio cholerae CVD 103-HgR strain live antigen"
]
],
[
[
"Fluorouracil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with... | Fluorouracil may cause a moderate interaction that could exacerbate diseases when taken with Floxuridine and Floxuridine may cause a moderate interaction that could exacerbate diseases when taken with Vibrio cholerae CVD 103-HgR strain live antigen
Fluorouracil may cause a moderate interaction that could exacerbate diseases when taken with Fludarabine and Fludarabine may cause a moderate interaction that could exacerbate diseases when taken with Vibrio cholerae CVD 103-HgR strain live antigen
Fluorouracil may lead to a major life threatening interaction when taken with Mitomycin and Mitomycin may cause a moderate interaction that could exacerbate diseases when taken with Vibrio cholerae CVD 103-HgR strain live antigen
Fluorouracil may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may cause a moderate interaction that could exacerbate diseases when taken with Vibrio cholerae CVD 103-HgR strain live antigen
Fluorouracil may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may cause a moderate interaction that could exacerbate diseases when taken with Vibrio cholerae CVD 103-HgR strain live antigen
Fluorouracil may cause a minor interaction that can limit clinical effects when taken with Vinblastine and Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Vibrio cholerae CVD 103-HgR strain live antigen
Fluorouracil may cause a moderate interaction that could exacerbate diseases when taken with Floxuridine and Floxuridine may cause a moderate interaction that could exacerbate diseases when taken with Fludarabine and Fludarabine may cause a moderate interaction that could exacerbate diseases when taken with Vibrio cholerae CVD 103-HgR strain live antigen
Fluorouracil may cause a moderate interaction that could exacerbate diseases when taken with Fludarabine and Fludarabine may cause a moderate interaction that could exacerbate diseases when taken with Ixazomib and Ixazomib may cause a moderate interaction that could exacerbate diseases when taken with Vibrio cholerae CVD 103-HgR strain live antigen
Fluorouracil may cause a moderate interaction that could exacerbate diseases when taken with Temozolomide and Temozolomide may cause a moderate interaction that could exacerbate diseases when taken with Floxuridine and Floxuridine may cause a moderate interaction that could exacerbate diseases when taken with Vibrio cholerae CVD 103-HgR strain live antigen |
DB00544 | DB06372 | 970 | 259 | [
"DDInter757",
"DDInter1594"
] | Fluorouracil | Rilonacept | A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid. | Rilonacept is a dimeric fusion protein consisting of portions of IL-1R and the IL-1R accessory protein linked to the Fc portion of immunoglobulin G1. Rilonacept functions as an interleukin 1 inhibitor and is used in the treatment of CAPS, also known as cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome (FCAS) and Muckle-Wells Syndrome (MWS), in adults and children greater than 12 years old. | Moderate | 1 | [
[
[
970,
24,
259
]
],
[
[
970,
63,
1461
],
[
1461,
23,
259
]
],
[
[
970,
24,
0
],
[
0,
24,
259
]
],
[
[
970,
40,
132
],
[
132,
24,
... | [
[
[
"Fluorouracil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rilonacept"
]
],
[
[
"Fluorouracil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vitamin E"
],
[... | Fluorouracil may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Rilonacept
Fluorouracil may cause a moderate interaction that could exacerbate diseases when taken with Dactinomycin and Dactinomycin may cause a moderate interaction that could exacerbate diseases when taken with Rilonacept
Fluorouracil (Compound) resembles Uracil mustard (Compound) and Uracil mustard may cause a moderate interaction that could exacerbate diseases when taken with Rilonacept
Fluorouracil may cause a moderate interaction that could exacerbate diseases when taken with Naxitamab and Naxitamab may cause a moderate interaction that could exacerbate diseases when taken with Rilonacept
Fluorouracil may cause a moderate interaction that could exacerbate diseases when taken with Tioguanine and Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Rilonacept
Fluorouracil may lead to a major life threatening interaction when taken with Mitomycin and Mitomycin may cause a moderate interaction that could exacerbate diseases when taken with Rilonacept
Fluorouracil may cause a minor interaction that can limit clinical effects when taken with Vinblastine and Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Rilonacept
Fluorouracil may lead to a major life threatening interaction when taken with Warfarin and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Rilonacept
Fluorouracil may lead to a major life threatening interaction when taken with Fingolimod and Fingolimod may lead to a major life threatening interaction when taken with Rilonacept |
DB00818 | DB11730 | 898 | 351 | [
"DDInter1538",
"DDInter1588"
] | Propofol | Ribociclib | Propofol is an intravenous anaesthetic agent used for induction and maintenance of general anaesthesia. IV administration of propfol is used to induce unconsciousness after which anaesthesia may be maintained using a combination of medications. Recovery from propofol-induced anaesthesia is generally rapid and associated with less frequent side effects (e.g. drowsiness, nausea, vomiting) than with thiopental, methohexital, and etomidate. Propofol may be used prior to diagnostic procedures requiring anaesthesia, in the management of refractory status epilepticus, and for induction and/or maintenance of anaesthesia prior to and during surgeries. | Ribociclib is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Targeting CDK4/6 with enhanced precision may play a role in ensuring that cancer cells do not continue to replicate uncontrollably. Ribociclib was approved by the U.S. FDA in March, 2017 as Kisqali. | Moderate | 1 | [
[
[
898,
24,
351
]
],
[
[
898,
23,
112
],
[
112,
23,
351
]
],
[
[
898,
63,
355
],
[
355,
24,
351
]
],
[
[
898,
24,
1491
],
[
1491,
2... | [
[
[
"Propofol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ribociclib"
]
],
[
[
"Propofol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
... | Propofol may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Ribociclib
Propofol may cause a moderate interaction that could exacerbate diseases when taken with Lactulose and Lactulose may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib
Propofol may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin and Midostaurin may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib
Propofol may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib and Alpelisib may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib
Propofol may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide may lead to a major life threatening interaction when taken with Ribociclib
Propofol may cause a moderate interaction that could exacerbate diseases when taken with Osilodrostat and Osilodrostat may lead to a major life threatening interaction when taken with Ribociclib
Propofol may cause a moderate interaction that could exacerbate diseases when taken with Quinine and Quinine may lead to a major life threatening interaction when taken with Ribociclib
Propofol may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Ribociclib
Propofol may cause a moderate interaction that could exacerbate diseases when taken with Lactulose and Lactulose may cause a moderate interaction that could exacerbate diseases when taken with Methylprednisolone and Methylprednisolone may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib |
DB00026 | DB01168 | 1,184 | 1,053 | [
"DDInter94",
"DDInter1526"
] | Anakinra | Procarbazine | Anakinra is a recombinant human interleukin-1 (IL-1) receptor antagonist (IL-1Ra) composed of 153 amino acid residues. Unlike native human IL-1Ra, anakinra has an additional methionine residue at the amino terminus. This drug binds to the IL-1 receptor, competing with and inhibiting the activity of IL-1 alpha and beta. Anakinra is indicated for the management of rheumatoid arthritis (RA) in patients 18 years of age or older who have failed one or more disease-modifying antirheumatic drugs (DMARDs), as well as the treatment of neonatal-onset multisystem inflammatory disease (NOMID) and deficiency of interleukin-1 receptor antagonist (DIRA). Since IL-1 has an important role in inflammation and immunological responses, anakinra is also used for the off-label treatment of inflammatory diseases. Anakinra is produced using the _ | An antineoplastic agent used primarily in combination with mechlorethamine, vincristine, and prednisone (the MOPP protocol) in the treatment of Hodgkin's disease. | Moderate | 1 | [
[
[
1184,
24,
1053
]
],
[
[
1184,
24,
126
],
[
126,
23,
1053
]
],
[
[
1184,
24,
496
],
[
496,
63,
1053
]
],
[
[
1184,
24,
1648
],
[
1648,
... | [
[
[
"Anakinra",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Procarbazine"
]
],
[
[
"Anakinra",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Warfarin"
],
[
... | Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin may cause a minor interaction that can limit clinical effects when taken with Procarbazine
Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis A Vaccine and Hepatitis A Vaccine may cause a moderate interaction that could exacerbate diseases when taken with Procarbazine
Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Procarbazine
Anakinra may cause a minor interaction that can limit clinical effects when taken with Vitamin E and Vitamin E may cause a moderate interaction that could exacerbate diseases when taken with Procarbazine
Anakinra may lead to a major life threatening interaction when taken with Baricitinib and Baricitinib may lead to a major life threatening interaction when taken with Procarbazine
Anakinra may lead to a major life threatening interaction when taken with Cladribine and Cladribine may lead to a major life threatening interaction when taken with Procarbazine
Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Carbamazepine and Carbamazepine may lead to a major life threatening interaction when taken with Procarbazine
Anakinra may lead to a major life threatening interaction when taken with Etanercept and Etanercept may lead to a major life threatening interaction when taken with Procarbazine
Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Oliceridine and Oliceridine may lead to a major life threatening interaction when taken with Procarbazine |
DB01105 | DB11632 | 222 | 580 | [
"DDInter1665",
"DDInter1343"
] | Sibutramine | Opicapone | Sibutramine (trade name Meridia in the USA, Reductil in Europe and other countries), usually as sibutramide hydrochloride monohydrate, is an orally administered agent for the treatment of obesity. It is a centrally acting stimulant chemically related to amphetamines thus it is classified as a Schedule IV controlled substance in the United States. In October 2010, Sibutramine was withdrawn from Canadian and U.S. markets due to concerns that the drug increases the risk of heart attack and stroke in patients with a history of heart disease. | Opicapone is a potent, reversible, and peripherally-acting third-generation inhibitor of catechol-o-methyltransferase (COMT), an enzyme involved in the breakdown of various catecholamines including dopamine.[A36938, A203048] Many patients with Parkinson’s disease treated with levodopa plus a dopa decarboxylase (DDC) inhibitor (eg carbidopa) experience motor complications over time, which calls for the management of these symptoms through the use of a dopamine agonist, a monoamine oxidase B inhibitor (selegiline, rasagiline), a _catechol-O-methyl transferase (COMT)_ inhibitor, or amantadine, or using a modified-release formulation of levodopa. Opicapone is used for adjunct therapy to levodopa and carbidopa in adult patients with Parkinson's disease and end-of-dose motor fluctuations. Opicapone was approved for use by the European Commission in June 2016 and the FDA in April 2020. It is marketed under the brand name Ongentys as once-daily oral capsules. Exhibiting a long duration of action that exceeds 24 hours, opicapone can be administered once-daily and demonstrates the lowest risk for cytotoxicity compared to other catechol-O-methyltransferase inhibitors. | Moderate | 1 | [
[
[
222,
24,
580
]
],
[
[
222,
24,
649
],
[
649,
24,
580
]
],
[
[
222,
63,
401
],
[
401,
24,
580
]
],
[
[
222,
64,
506
],
[
506,
24,... | [
[
[
"Sibutramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opicapone"
]
],
[
[
"Sibutramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofedanol"
],
[
... | Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol and Clofedanol may cause a moderate interaction that could exacerbate diseases when taken with Opicapone
Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Opicapone
Sibutramine may lead to a major life threatening interaction when taken with Dextromethorphan and Dextromethorphan may cause a moderate interaction that could exacerbate diseases when taken with Opicapone
Sibutramine may lead to a major life threatening interaction when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Opicapone
Sibutramine may lead to a major life threatening interaction when taken with Procarbazine and Procarbazine may lead to a major life threatening interaction when taken with Opicapone
Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol and Clofedanol may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Opicapone
Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Cyclizine and Cyclizine (Compound) resembles Methdilazine (Compound) and Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Opicapone
Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Opicapone
Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Triprolidine and Triprolidine may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Opicapone |
DB01082 | DB01181 | 1,448 | 1,532 | [
"DDInter1713",
"DDInter906"
] | Streptomycin | Ifosfamide | Streptomycin, an antibiotic derived from _Streptomyces griseus_, was the first aminoglycoside to be discovered and used in practice in the 1940s.[A233325,A233390] Selman Waksman and eventually Albert Schatz were recognized with the Nobel Prize in Medicine for their discovery of streptomycin and its antibacterial activity.[A233325,A232294] Although streptomycin was the first antibiotic determined to be effective against mycobacterium tuberculosis, it has fallen out of favor due to resistance and is now primarily used as adjunctive treatment in cases of multi-drug resistant tuberculosis. | Ifosfamide is a chemotherapeutic agent chemically related to the nitrogen mustards and a synthetic analog of cyclophosphamide. It is active as an alkylating agent and an immunosuppressive agent. | Moderate | 1 | [
[
[
1448,
24,
1532
]
],
[
[
1448,
21,
28725
],
[
28725,
60,
1532
]
],
[
[
1448,
63,
1132
],
[
1132,
24,
1532
]
],
[
[
1448,
24,
445
],
[
4... | [
[
[
"Streptomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ifosfamide"
]
],
[
[
"Streptomycin",
"{u} (Compound) causes {v} (Side Effect)",
"Pancytopenia"
],
[
"Pancytopenia",
"{u} (Side Effec... | Streptomycin (Compound) causes Pancytopenia (Side Effect) and Pancytopenia (Side Effect) is caused by Ifosfamide (Compound)
Streptomycin may cause a moderate interaction that could exacerbate diseases when taken with Gentamicin and Gentamicin may cause a moderate interaction that could exacerbate diseases when taken with Ifosfamide
Streptomycin may cause a moderate interaction that could exacerbate diseases when taken with Givosiran and Givosiran may cause a moderate interaction that could exacerbate diseases when taken with Ifosfamide
Streptomycin (Compound) resembles Kanamycin (Compound) and Streptomycin may cause a moderate interaction that could exacerbate diseases when taken with Kanamycin and Kanamycin may cause a moderate interaction that could exacerbate diseases when taken with Ifosfamide
Streptomycin may lead to a major life threatening interaction when taken with Sirolimus and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Ifosfamide
Streptomycin may lead to a major life threatening interaction when taken with Iodixanol and Iodixanol may lead to a major life threatening interaction when taken with Ifosfamide
Streptomycin (Compound) causes Pancytopenia (Side Effect) and Pancytopenia (Side Effect) is caused by Trovafloxacin (Compound) and Trovafloxacin may cause a minor interaction that can limit clinical effects when taken with Ifosfamide
Streptomycin (Compound) causes Nephrotoxicity (Side Effect) and Nephrotoxicity (Side Effect) is caused by Gentamicin (Compound) and Gentamicin may cause a moderate interaction that could exacerbate diseases when taken with Ifosfamide
Streptomycin may cause a moderate interaction that could exacerbate diseases when taken with Gentamicin and Gentamicin (Compound) downregulates UBQLN2 (Gene) and UBQLN2 (Gene) is upregulated by Ifosfamide (Compound) |
DB01229 | DB08860 | 973 | 788 | [
"DDInter1378",
"DDInter1479"
] | Paclitaxel (protein-bound) | Pitavastatin | Paclitaxel can cause developmental toxicity, female reproductive toxicity and male reproductive toxicity according to state or federal government labeling requirements. | Pitavastatin, also known as the brand name product Livalo, is a lipid-lowering drug belonging to the statin class of medications. By inhibiting the endogenous production of cholesterol within the liver, statins lower abnormal cholesterol and lipid levels and ultimately reduce the risk of cardiovascular disease. More specifically, statin medications competitively inhibit the enzyme hydroxymethylglutaryl-coenzyme A (HMG-CoA) Reductase, which catalyzes the conversion of HMG-CoA to mevalonic acid. This is the third step in a sequence of metabolic reactions involved in the production of several compounds involved in lipid metabolism and transport including cholesterol, low-density lipoprotein (LDL) (sometimes referred to as "bad cholesterol"), and very low-density lipoprotein (VLDL). Prescribing of statin medications is considered standard practice following any cardiovascular events and for people with a moderate to high risk of development of CVD, such as those with Type 2 Diabetes. The clear evidence of the benefit of statin use coupled with very minimal side effects or long term effects has resulted in this class becoming one of the most widely prescribed medications in North America.[A181087, A181406] Pitavastatin and other drugs from the statin class of medications including [atorvastatin], [pravastatin], [rosuvastatin], [fluvastatin], and [lovastatin] are considered first-line options for the treatment of dyslipidemia.[A181087, A181406] Increasing use of the statin class of drugs is largely due to the fact that cardiovascular disease (CVD), which includes heart attack, atherosclerosis, angina, peripheral artery disease, and stroke, has become a leading cause of death in high-income countries and a major cause of morbidity around the world. Elevated cholesterol levels, and in particular, elevated low-density lipoprotein (LDL) levels, are an important risk factor for the development of CVD.[A181087,A181553] Use of statins to target and reduce LDL levels has been shown in a number of landmark studies to significantly reduce the risk of development of CVD and all-cause mortality.[A181090,A181093,A181096,A181427,A181475,A181538] Statins are considered a cost-effective treatment option for CVD due to their evidence of reducing all-cause mortality including fatal and non-fatal CVD as well as the need for surgical revascularization or angioplasty following a heart attack.[A181087, A181406] Evidence has shown that even for low-risk individuals (with <10% risk of a major vascular event occurring within 5 years) statins cause a 20%-22% relative reduction in major cardiovascular events (heart attack, stroke, coronary revascularization, and coronary death) for every 1 mmol/L reduction in LDL without any significant side effects or risks.[A181397, A181403] While all statin medications are considered equally effective from a clinical standpoint, [rosuvastatin] is considered the most potent; doses of 10 to 40mg [rosuvastatin] per day were found in clinical studies to result in a 45.8% to 54.6% decrease in LDL cholesterol levels.[A181409,A181535,A181538,A1793] Study data has confirmed that pitavastatin's potency in lowering LDL-C is comparable to that of other statins but also has increased efficacy in increasing HDL-C (also known as "good cholesterol").[A182000,A182003,A182006] Despite these differences in potency, several trials have demonstrated only minimal differences in terms of clinical outcomes between statins.[A181538, A181427] | Moderate | 1 | [
[
[
973,
24,
788
]
],
[
[
973,
63,
671
],
[
671,
1,
788
]
],
[
[
973,
63,
700
],
[
700,
40,
788
]
],
[
[
973,
6,
17404
],
[
17404,
4... | [
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pitavastatin"
]
],
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluvastatin"
],
[... | Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Pitavastatin
Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Fluvastatin and Fluvastatin (Compound) resembles Pitavastatin (Compound)
Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Atorvastatin and Atorvastatin (Compound) resembles Pitavastatin (Compound)
Paclitaxel (Compound) binds ABCG2 (Gene) and ABCG2 (Gene) is bound by Pitavastatin (Compound)
Paclitaxel (Compound) upregulates PPP1R13B (Gene) and PPP1R13B (Gene) is upregulated by Pitavastatin (Compound)
Paclitaxel (Compound) downregulates ABCB6 (Gene) and ABCB6 (Gene) is upregulated by Pitavastatin (Compound)
Paclitaxel (Compound) downregulates RPS4Y1 (Gene) and RPS4Y1 (Gene) is downregulated by Pitavastatin (Compound)
Paclitaxel (Compound) upregulates PLK1 (Gene) and PLK1 (Gene) is downregulated by Pitavastatin (Compound)
Paclitaxel (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Pitavastatin (Compound)
Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin and Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Pitavastatin |
DB00549 | DB11837 | 522 | 1,297 | [
"DDInter1955",
"DDInter1351"
] | Zafirlukast | Osilodrostat | Zafirlukast is an oral leukotriene receptor antagonist (LTRA) for the maintenance treatment of asthma, often used in conjunction with an inhaled steroid and/or long-acting bronchodilator. It is available as a tablet and is usually dosed twice daily. Another leukotriene receptor antagonist is montelukast (Singulair), which is usually taken just once daily. Zafirlukast blocks the action of the cysteinyl leukotrienes on the CysLT1 receptors, thus reducing constriction of the airways, build-up of mucus in the lungs and inflammation of the breathing passages. | Osilodrostat is an inhibitor of 11β-hydroxylase (also referred to as CYP11B1), the enzyme that catalyzes the final step in the biosynthesis of endogenous cortisol. It is used to lower circulating cortisol levels in the treatment of Cushing's disease, a disorder in which cortisol levels are chronically and supraphysiologically elevated. Cushing's disease is often the result of ACTH hypersecretion secondary to a pituitary tumor, and surgical resection of the tumour is generally the treatment of choice. As an orally bioavailable drug therapy, osilodrostat provides a novel treatment option for patients in whom removal of the causative tumor is not an option or for whom previous pituitary surgery has not been curative. Osilodrostat is manufactured by Novartis under the brand name Isturisa. It has undergone phase II clinical trials for the treatment of solid tumours, hypertension, and heart failure, but development for these indications was discontinued by Novartis in January 2013. Osilodrostat was approved for use in the EU in January 2020 for the treatment of endogenous Cushing's syndrome (i.e. Cushing's disease), and was granted FDA approval and Orphan Drug designation in the US in March 2020 for the same indication. | Moderate | 1 | [
[
[
522,
24,
1297
]
],
[
[
522,
24,
112
],
[
112,
23,
1297
]
],
[
[
522,
23,
222
],
[
222,
23,
1297
]
],
[
[
522,
23,
907
],
[
907,
... | [
[
[
"Zafirlukast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osilodrostat"
]
],
[
[
"Zafirlukast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
... | Zafirlukast may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Osilodrostat
Zafirlukast may cause a minor interaction that can limit clinical effects when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Osilodrostat
Zafirlukast may cause a minor interaction that can limit clinical effects when taken with Doravirine and Doravirine may cause a minor interaction that can limit clinical effects when taken with Osilodrostat
Zafirlukast may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin and Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Osilodrostat
Zafirlukast may cause a minor interaction that can limit clinical effects when taken with Modafinil and Modafinil may cause a moderate interaction that could exacerbate diseases when taken with Osilodrostat
Zafirlukast may cause a moderate interaction that could exacerbate diseases when taken with Pimavanserin and Pimavanserin may cause a moderate interaction that could exacerbate diseases when taken with Osilodrostat
Zafirlukast may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib and Gilteritinib may cause a moderate interaction that could exacerbate diseases when taken with Osilodrostat
Zafirlukast may lead to a major life threatening interaction when taken with Lomitapide and Lomitapide may cause a moderate interaction that could exacerbate diseases when taken with Osilodrostat
Zafirlukast may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib and Ribociclib may lead to a major life threatening interaction when taken with Osilodrostat |
DB00308 | DB11978 | 347 | 124 | [
"DDInter901",
"DDInter822"
] | Ibutilide | Glasdegib | Ibutilide is a Class III antiarrhythmic agent available in intravenous formulations. It is indicated for the conversion of acute atrial flutter and recent onset atrial fibrillation to normal sinus rhythm (NSR). | Glasdegib, also known as PF-04449913, is a small-molecule hedgehog signaling inhibitor selected under the group of benzimidazoles. In early research, benzimidazoles attracted large interest as they represented a class of inhibitors with low molecular weight, potent inhibitory activity, and lacking unstable functionality. The great lipophilicity of this group of compounds brought interest to further modification. This analysis concluded that the presence of p-cyano ureas presented good physicochemical and pharmacokinetic properties from which glasdegib was developed. Glasdegib was developed by Pfizer Inc and approved on November 21, 2018 by the FDA for the treatment of Acute Myeloid Leukemia (AML). Glasdegib targets cancerous cells by inhibiting the sonic hedgehog receptor smoothened (SMO), a transmembrane protein involved in the Hedgehog (Hh) signaling cascade. Aberrant of Hh signaling is one of the main pathophysiologies of AML, with observed overexpression or constitutive activation of SMO.[A258498,A258503] Although the efficacy of glasdegib monotherapy is limited, the landmark Phase 2 Bright AML 1003 trial showed a superior overall survival and complete response when glasdegib is combined with low dose cytarabine. Currently, the current gold standard of AML in older patients is still venetoclax with hypomethylation agents, new clinical combinations of glasdegib are being tested in hope of replacing venetoclax due to glasdegib's more favorable side effects profile. | Major | 2 | [
[
[
347,
25,
124
]
],
[
[
347,
23,
112
],
[
112,
23,
124
]
],
[
[
347,
25,
79
],
[
79,
24,
124
]
],
[
[
347,
24,
688
],
[
688,
24,
... | [
[
[
"Ibutilide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Glasdegib"
]
],
[
[
"Ibutilide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazol... | Ibutilide may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Glasdegib
Ibutilide may lead to a major life threatening interaction when taken with Sorafenib and Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Glasdegib
Ibutilide may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol and Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Glasdegib
Ibutilide may lead to a major life threatening interaction when taken with Goserelin and Goserelin may cause a moderate interaction that could exacerbate diseases when taken with Glasdegib
Ibutilide may lead to a major life threatening interaction when taken with Triclabendazole and Triclabendazole may cause a moderate interaction that could exacerbate diseases when taken with Glasdegib
Ibutilide may lead to a major life threatening interaction when taken with Anagrelide and Anagrelide may lead to a major life threatening interaction when taken with Glasdegib
Ibutilide may lead to a major life threatening interaction when taken with Ivosidenib and Ivosidenib may lead to a major life threatening interaction when taken with Glasdegib
Ibutilide may lead to a major life threatening interaction when taken with Pasireotide and Pasireotide may lead to a major life threatening interaction when taken with Glasdegib
Ibutilide (Compound) resembles Dronedarone (Compound) and Dronedarone may lead to a major life threatening interaction when taken with Glasdegib |
DB00222 | DB01267 | 245 | 519 | [
"DDInter825",
"DDInter1381"
] | Glimepiride | Paliperidone | First introduced in 1995, glimepiride is a member of the second-generation sulfonylurea (SU) drug class used for the management of type 2 diabetes mellitus (T2DM) to improve glycemic control. Type 2 diabetes is a metabolic disorder with increasing prevalences worldwide; it is characterized by insulin resistance in accordance with progressive β cell failure and long-term microvascular and macrovascular complications that lead to co-morbidities and mortalities. Sulfonylureas are one of the insulin secretagogues widely used for the management of type 2 diabetes to lower blood glucose levels. The main effect of SUs is thought to be effective when residual pancreatic β-cells are present, as they work by stimulating the release of insulin from the pancreatic beta cells and they are also thought to exert extra-pancreatic effects, such as increasing the insulin-mediated peripheral glucose uptake. Glimepiride works by stimulating the secretion of insulin granules from | Paliperidone is the primary active metabolite of risperidone. The mechanism of action is unknown but it is likely to act via a similar pathway to risperidone. It has been proposed that the drug's therapeutic activity in schizophrenia is mediated through a combination of central dopamine Type 2 (D2) and serotonin Type 2 (5HT2A) receptor antagonism. Paliperidone is also active as an antagonist at alpha 1 and alpha 2 adrenergic receptors and H1 histaminergic receptors, which may explain some of the other effects of the drug. Paliperidone was approved by the FDA for treatment of schizophrenia on December 20, 2006. It is available as an extended-release tablet, a once-monthly intramuscular injection, an every-three-month intramuscular injection, and a twice-yearly gluteal injection.[L16168,L37744,L4137,L37749] | Moderate | 1 | [
[
[
245,
24,
519
]
],
[
[
245,
24,
1664
],
[
1664,
1,
519
]
],
[
[
245,
21,
28826
],
[
28826,
60,
519
]
],
[
[
245,
40,
959
],
[
959,
... | [
[
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paliperidone"
]
],
[
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Risperidone"
],
... | Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Risperidone and Risperidone (Compound) resembles Paliperidone (Compound)
Glimepiride (Compound) causes Jaundice (Side Effect) and Jaundice (Side Effect) is caused by Paliperidone (Compound)
Glimepiride (Compound) resembles Glipizide (Compound) and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Paliperidone
Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Albiglutide and Albiglutide may cause a moderate interaction that could exacerbate diseases when taken with Paliperidone
Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline and Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Paliperidone
Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Insulin human and Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Paliperidone
Glimepiride may lead to a major life threatening interaction when taken with Fluconazole and Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Paliperidone
Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Hydroxychloroquine and Hydroxychloroquine may lead to a major life threatening interaction when taken with Paliperidone
Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Risperidone and Risperidone (Compound) resembles Iloperidone (Compound) and Iloperidone (Compound) resembles Paliperidone (Compound) |
DB06410 | DB12130 | 1,196 | 1,017 | [
"DDInter595",
"DDInter1094"
] | Doxercalciferol | Lorlatinib | Doxercalciferol is a synthetic vitamin D2 analog that undergoes metabolic activation in vivo to form 1α,25-dihydroxyvitamin D2 (1α,25-(OH)2D2), a naturally occurring, biologically active form of vitamin D2. Doxercalciferol is indicated for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease on dialysis, as well as for the treatment of secondary hyperparathyroidism in patients with Stage 3 or Stage 4 chronic kidney disease. Doxercalciferol is marketed under the brand name Hectoral by Genzyme Corporation, and is manufactured by Catalent Pharma Solutions, Inc. | Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer which was first approved by the US FDA in November of 2018. It was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-positive non-small cell lung cancer, followed by an expanded approval in 2022 to include lorlatinib as a first-line treatment option in advanced ALK-positive NSCLC. | Moderate | 1 | [
[
[
1196,
24,
1017
]
],
[
[
1196,
64,
1041
],
[
1041,
24,
1017
]
],
[
[
1196,
24,
214
],
[
214,
24,
1017
]
],
[
[
1196,
24,
1654
],
[
1654... | [
[
[
"Doxercalciferol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
]
],
[
[
"Doxercalciferol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Paricalcitol"
],
[
... | Doxercalciferol may lead to a major life threatening interaction when taken with Paricalcitol and Paricalcitol may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Doxercalciferol may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib and Fostamatinib may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Doxercalciferol may cause a moderate interaction that could exacerbate diseases when taken with Somapacitan and Somapacitan may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Doxercalciferol may cause a moderate interaction that could exacerbate diseases when taken with Isoniazid and Isoniazid may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Doxercalciferol may lead to a major life threatening interaction when taken with Erdafitinib and Erdafitinib may lead to a major life threatening interaction when taken with Lorlatinib
Doxercalciferol may cause a moderate interaction that could exacerbate diseases when taken with Lefamulin and Lefamulin may lead to a major life threatening interaction when taken with Lorlatinib
Doxercalciferol may cause a moderate interaction that could exacerbate diseases when taken with Rifampicin and Rifampicin may lead to a major life threatening interaction when taken with Lorlatinib
Doxercalciferol may lead to a major life threatening interaction when taken with Paricalcitol and Paricalcitol may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib and Fostamatinib may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Doxercalciferol may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib and Fostamatinib may cause a moderate interaction that could exacerbate diseases when taken with Lidocaine and Lidocaine may cause a minor interaction that can limit clinical effects when taken with Lorlatinib |
DB06717 | DB12130 | 875 | 1,017 | [
"DDInter778",
"DDInter1094"
] | Fosaprepitant | Lorlatinib | Fosaprepitant is an intravenously administered antiemetic drug. It is a prodrug of Aprepitant. It aids in the prevention of acute and delayed nausea and vomiting associated with chemotherapy treatment. | Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer which was first approved by the US FDA in November of 2018. It was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-positive non-small cell lung cancer, followed by an expanded approval in 2022 to include lorlatinib as a first-line treatment option in advanced ALK-positive NSCLC. | Moderate | 1 | [
[
[
875,
24,
1017
]
],
[
[
875,
63,
608
],
[
608,
23,
1017
]
],
[
[
875,
62,
1101
],
[
1101,
23,
1017
]
],
[
[
875,
63,
175
],
[
175,
... | [
[
[
"Fosaprepitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
]
],
[
[
"Fosaprepitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lidocaine"
],
... | Fosaprepitant may cause a moderate interaction that could exacerbate diseases when taken with Lidocaine and Lidocaine may cause a minor interaction that can limit clinical effects when taken with Lorlatinib
Fosaprepitant may cause a minor interaction that can limit clinical effects when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Lorlatinib
Fosaprepitant may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone and Triamcinolone may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Fosaprepitant may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib and Tofacitinib may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Fosaprepitant may lead to a major life threatening interaction when taken with Halofantrine and Halofantrine may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Fosaprepitant may lead to a major life threatening interaction when taken with Naloxegol and Naloxegol may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Fosaprepitant may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib and Gilteritinib may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Fosaprepitant may cause a minor interaction that can limit clinical effects when taken with Sibutramine and Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Fosaprepitant (Compound) resembles Aprepitant (Compound) and Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib |
DB00559 | DB01105 | 152 | 222 | [
"DDInter223",
"DDInter1665"
] | Bosentan | Sibutramine | Bosentan is a dual endothelin receptor antagonist marketed under the trade name Tracleer by Actelion Pharmaceuticals. Bosentan is used to treat pulmonary hypertension by blocking the action of endothelin molecules that would otherwise promote narrowing of the blood vessels and lead to high blood pressure. | Sibutramine (trade name Meridia in the USA, Reductil in Europe and other countries), usually as sibutramide hydrochloride monohydrate, is an orally administered agent for the treatment of obesity. It is a centrally acting stimulant chemically related to amphetamines thus it is classified as a Schedule IV controlled substance in the United States. In October 2010, Sibutramine was withdrawn from Canadian and U.S. markets due to concerns that the drug increases the risk of heart attack and stroke in patients with a history of heart disease. | Moderate | 1 | [
[
[
152,
24,
222
]
],
[
[
152,
6,
8374
],
[
8374,
45,
222
]
],
[
[
152,
21,
29215
],
[
29215,
60,
222
]
],
[
[
152,
24,
384
],
[
384,
... | [
[
[
"Bosentan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
]
],
[
[
"Bosentan",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Bosentan (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Sibutramine (Compound)
Bosentan (Compound) causes Ecchymosis (Side Effect) and Ecchymosis (Side Effect) is caused by Sibutramine (Compound)
Bosentan may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may cause a minor interaction that can limit clinical effects when taken with Sibutramine
Bosentan may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fluconazole may cause a minor interaction that can limit clinical effects when taken with Sibutramine
Bosentan may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant may cause a minor interaction that can limit clinical effects when taken with Sibutramine
Bosentan may lead to a major life threatening interaction when taken with Entrectinib and Entrectinib may cause a minor interaction that can limit clinical effects when taken with Sibutramine
Bosentan may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine
Bosentan may cause a moderate interaction that could exacerbate diseases when taken with Dapagliflozin and Dapagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine
Bosentan may lead to a major life threatening interaction when taken with Lorlatinib and Lorlatinib may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine |
DB00065 | DB00252 | 581 | 362 | [
"DDInter923",
"DDInter1460"
] | Infliximab | Phenytoin | Infliximab is a tumor necrosis factor (TNF-alpha or TNF-α) blocker and a chimeric monoclonal IgG1 antibody composed of human constant (75%) and murine variable (25%) regions. Infliximab is produced by a recombinant cell line cultured by continuous perfusion. Tumor necrosis factor-alpha (TNF-α) is a key proinflammatory cytokine involved in chronic inflammatory diseases. Its hyperactivity and enhanced signalling pathways can be observed in inflammatory diseases where it activates further pro-inflammatory cascades. By binding to both the soluble subunit and the membrane-bound precursor of TNF-α, infliximab disrupts the interaction of TNF-α with its receptors and may also cause lysis of cells that produce TNF-α. Infliximab was first approved by the FDA in 1998 under the market name Remicade as an intravenous injection. It is indicated for the treatment | Phenytoin is classified as a hydantoin derivative and despite its narrow therapeutic index, it is one of the most commonly used anticonvulsants.[A33595,A188832,A189219] Since it's introduction about 80 years ago, phenytoin has not only been established as an effective anti-epileptic, but has also been investigated for several other indications such as bipolar disorder, retina protection, and wound healing.[A188826,A188832] Clinicians are advised to initiate therapeutic drug monitoring in patients who require phenytoin since even small deviations from the recommended therapeutic range can lead to suboptimal treatment, or adverse effects.[A189219,A35884] Both parenteral and oral formulations of phenytoin are available on the market. | Moderate | 1 | [
[
[
581,
24,
362
]
],
[
[
581,
24,
759
],
[
759,
40,
362
]
],
[
[
581,
24,
126
],
[
126,
63,
362
]
],
[
[
581,
25,
1101
],
[
1101,
6... | [
[
[
"Infliximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenytoin"
]
],
[
[
"Infliximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Primidone"
],
[
... | Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Primidone and Primidone (Compound) resembles Phenytoin (Compound)
Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Phenytoin
Infliximab may lead to a major life threatening interaction when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Phenytoin
Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Lidocaine and Lidocaine may cause a minor interaction that can limit clinical effects when taken with Phenytoin
Infliximab may lead to a major life threatening interaction when taken with Hydrocortisone and Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Phenytoin
Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Alefacept and Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Phenytoin
Infliximab may lead to a major life threatening interaction when taken with Asparaginase Escherichia coli and Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Phenytoin
Infliximab may lead to a major life threatening interaction when taken with Cladribine and Cladribine may cause a moderate interaction that could exacerbate diseases when taken with Phenytoin
Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Interferon beta-1a and Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Phenytoin |
DB00574 | DB09030 | 121 | 840 | [
"DDInter717",
"DDInter1945"
] | Fenfluramine | Vorapaxar | Dravet syndrome is a pediatric encephalopathy that typically manifests within the first year of life following exposure to elevated temperatures. It is characterized by recurrent pharmacoresistant seizures, which increase in frequency and severity with disease progression. Concomitantly with these seizures, patients typically display delayed development and neurocognitive impairment.[A214694, A214709, A214712, A214715] Fenfluramine is a serotonergic phenethylamine originally used as an appetite suppressant until concerns regarding cardiotoxicity in obese patients lead to its withdrawal from the market in 1997.[A214694, A214718, A11906] Through its ability to modulate neurotransmission, fenfluramine has reemerged as an effective therapy against pharmacoresistant seizures, such as those involved in Dravet syndrome.[A214688, A214691, A214700] Fenfluramine was granted initial FDA approval in 1973 prior to its withdrawal | Vorapaxar is a tricyclic himbacine-derived selective inhibitor of protease activated receptor (PAR-1) indicated for reducing the incidence of thrombotic cardiovascular events in patients with a history of myocardial infarction (MI) or with peripheral arterial disease (PAD). By inhibiting PAR-1, a thrombin receptor expressed on platelets, vorapaxar prevents thrombin-related platelet aggregation. | Moderate | 1 | [
[
[
121,
24,
840
]
],
[
[
121,
64,
529
],
[
529,
24,
840
]
],
[
[
121,
24,
885
],
[
885,
24,
840
]
],
[
[
121,
25,
1039
],
[
1039,
2... | [
[
[
"Fenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vorapaxar"
]
],
[
[
"Fenfluramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fluvoxamine"
],
[
"Fluvox... | Fenfluramine may lead to a major life threatening interaction when taken with Fluvoxamine and Fluvoxamine may cause a moderate interaction that could exacerbate diseases when taken with Vorapaxar
Fenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Epoprostenol and Epoprostenol may cause a moderate interaction that could exacerbate diseases when taken with Vorapaxar
Fenfluramine may lead to a major life threatening interaction when taken with Dexfenfluramine and Dex
Fenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Treprostinil and Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Vorapaxar
Fenfluramine may lead to a major life threatening interaction when taken with Vortioxetine and Vortioxetine may cause a moderate interaction that could exacerbate diseases when taken with Vorapaxar
Fenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Anagrelide and Anagrelide may lead to a major life threatening interaction when taken with Vorapaxar
Fenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Enoxaparin and Enoxaparin may lead to a major life threatening interaction when taken with Vorapaxar
Fenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Tazemetostat and Tazemetostat may lead to a major life threatening interaction when taken with Vorapaxar
Fenfluramine may lead to a major life threatening interaction when taken with Panobinostat and Panobinostat may lead to a major life threatening interaction when taken with Vorapaxar |
DB10316 | DB14762 | 334 | 994 | [
"DDInter1248",
"DDInter1602"
] | Mumps virus strain B level jeryl lynn live antigen | Risankizumab | Mumps virus strain B level jeryl lynn live antigen is a live attenuated virus vaccine for subcutenous injection. It is an active immunization against mumps, which is a common childhood disease. | Risankizumab is a fully humanized IgG1 monoclonal antibody (mAb) directed against interleukin 23 (IL-23). It gained its first global approval in Japan in March 2019, followed by approval in Canada, the US, and Europe in April 2019. Risankizumab is used to treat plaque psoriasis, psoriatic arthritis, and Crohn's disease.[L39885,L44191,L44231] Risankizumab is being investigated for atopic dermatitis. | Major | 2 | [
[
[
334,
25,
994
]
],
[
[
334,
64,
4
],
[
4,
24,
994
]
],
[
[
334,
25,
270
],
[
270,
24,
994
]
],
[
[
334,
25,
676
],
[
676,
64,
... | [
[
[
"Mumps virus strain B level jeryl lynn live antigen",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Risankizumab"
]
],
[
[
"Mumps virus strain B level jeryl lynn live antigen",
"{u} may lead to a major life threatening interaction when... | Mumps virus strain B level jeryl lynn live antigen may lead to a major life threatening interaction when taken with Omacetaxine mepesuccinate and Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Risankizumab
Mumps virus strain B level jeryl lynn live antigen may lead to a major life threatening interaction when taken with Ocrelizumab and Ocrelizumab may cause a moderate interaction that could exacerbate diseases when taken with Risankizumab
Mumps virus strain B level jeryl lynn live antigen may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may lead to a major life threatening interaction when taken with Risankizumab
Mumps virus strain B level jeryl lynn live antigen may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may lead to a major life threatening interaction when taken with Risankizumab
Mumps virus strain B level jeryl lynn live antigen may lead to a major life threatening interaction when taken with Baricitinib and Baricitinib may lead to a major life threatening interaction when taken with Risankizumab
Mumps virus strain B level jeryl lynn live antigen may lead to a major life threatening interaction when taken with Omacetaxine mepesuccinate and Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Alefacept and Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Risankizumab
Mumps virus strain B level jeryl lynn live antigen may lead to a major life threatening interaction when taken with Alefacept and Alefacept may cause a minor interaction that can limit clinical effects when taken with Zinc sulfate and Zinc sulfate may cause a minor interaction that can limit clinical effects when taken with Risankizumab
Mumps virus strain B level jeryl lynn live antigen may lead to a major life threatening interaction when taken with Ocrelizumab and Ocrelizumab may cause a minor interaction that can limit clinical effects when taken with Zinc sulfate and Zinc sulfate may cause a minor interaction that can limit clinical effects when taken with Risankizumab
Mumps virus strain B level jeryl lynn live antigen may lead to a major life threatening interaction when taken with Vinblastine and Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Risankizumab |
DB00572 | DB00808 | 85 | 1,605 | [
"DDInter136",
"DDInter916"
] | Atropine | Indapamide | Atropine is an alkaloid originally synthesized from Atropa belladonna. It is a racemic mixture of d-and l-hyoscyamine, of which only l-hyoscyamine is pharmacologically active.[A251670,L42835] Atropine is generally available as a sulfate salt and can be administered by intravenous, subcutaneous, intramuscular, intraosseous, endotracheal and ophthalmic methods. Oral atropine is only available in combination products.[A251660,L42840] Atropine is a competitive, reversible antagonist of muscarinic receptors that blocks the effects of acetylcholine and other choline esters.[A251660,L42815,L42825,L42835] It has a variety of therapeutic applications, including pupil dilation and the treatment of anticholinergic poisoning and symptomatic bradycardia in the absence of reversible causes. Atropine is a relatively inexpensive drug and | The most significant modifiable risk factor for cardiovascular disease and the most prominent contributor to all-cause mortality is hypertension. Characterized by an office blood pressure of ≥140/90, hypertension is pervasive and impacts an estimated 25% of adults globally. Treatment for hypertension should include a number of lifestyle changes (ie. reduced sodium intake) along with pharmacotherapy - it should be noted that treatment with several antihypertensive agents may be required in order to achieve blood pressure targets. Thiazide-like diuretics such as indapamide are a valuable tool for the treatment of hypertension and continue to grow in popularity, falling behind only ACE inhibitors in terms of prescription frequency. When compared to [hydrochlorothiazide] (another commonly prescribed diuretic), indapamide has been shown to be superior at lowering systolic blood pressure, reducing left ventricular mass index, lowering oxidative stress, inhibiting platelet aggregation, and reducing microalbuminuria associated with diabetes. Interestingly, unlike thiazide diuretics, several sources suggest that indapamide is not associated with glucose or lipid disturbances.[A204134,A204161] Indapamide is characterized by both a methylindoline and a sulfamoyl chlorobenzamide functional group, with the former being largely responsible for the molecule’s lipid solubility. | Minor | 0 | [
[
[
85,
23,
1605
]
],
[
[
85,
62,
811
],
[
811,
1,
1605
]
],
[
[
85,
21,
28640
],
[
28640,
60,
1605
]
],
[
[
85,
24,
1511
],
[
1511,
... | [
[
[
"Atropine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Indapamide"
]
],
[
[
"Atropine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metolazone"
],
[
"Met... | Atropine may cause a minor interaction that can limit clinical effects when taken with Metolazone and Metolazone (Compound) resembles Indapamide (Compound)
Atropine (Compound) causes Depression (Side Effect) and Depression (Side Effect) is caused by Indapamide (Compound)
Atropine may cause a moderate interaction that could exacerbate diseases when taken with Mepenzolate and Mepenzolate may cause a minor interaction that can limit clinical effects when taken with Indapamide
Atropine may cause a moderate interaction that could exacerbate diseases when taken with Dicyclomine and Dicyclomine may cause a minor interaction that can limit clinical effects when taken with Indapamide
Atropine may cause a moderate interaction that could exacerbate diseases when taken with Trospium and Trospium may cause a minor interaction that can limit clinical effects when taken with Indapamide
Atropine (Compound) resembles Scopolamine (Compound) and Atropine may cause a moderate interaction that could exacerbate diseases when taken with Scopolamine and Scopolamine may cause a minor interaction that can limit clinical effects when taken with Indapamide
Atropine may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Indapamide
Atropine may cause a moderate interaction that could exacerbate diseases when taken with Morphine and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Indapamide
Atropine (Compound) resembles Dolasetron (Compound) and Dolasetron may lead to a major life threatening interaction when taken with Indapamide |
DB08816 | DB09098 | 578 | 98 | [
"DDInter1802",
"DDInter1700"
] | Ticagrelor | Somatrem | Ticagrelor, or AZD6140, was first described in the literature in 2003.[A204170,A2903] Ticagrelor is an ADP derivative developed for its P2Y<sub>12</sub> receptor antagonism. Unlike [clopidogrel], ticagrelor is not a prodrug. It is marketed by Astra Zeneca as Brilinta in the US and Brilique or Possia in the EU,. Ticagrelor was granted EMA approval on 3 December 2010. Ticagrelor was granted FDA approval on 20 July 2011. | Despite the ability of almost all contemporary recombinant growth hormones to cause definite and demonstrable increases in growth rate in patients who are administered the drug, the use of these agents continues to be mired in persistent bioethical debate . Such discussion revolves around whether patients' natural disposition of short stature should be considered a medical condition justifying medical treatment with such hormone therapy - especially when these hormone agents have been proven effective at increasing the height of children with or without growth hormone deficiency . | Moderate | 1 | [
[
[
578,
24,
98
]
],
[
[
578,
23,
1459
],
[
1459,
23,
98
]
],
[
[
578,
62,
336
],
[
336,
24,
98
]
],
[
[
578,
63,
1671
],
[
1671,
24... | [
[
[
"Ticagrelor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
]
],
[
[
"Ticagrelor",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Dolutegravir"
],
[
... | Ticagrelor may cause a minor interaction that can limit clinical effects when taken with Dolutegravir and Dolutegravir may cause a minor interaction that can limit clinical effects when taken with Somatrem
Ticagrelor may cause a minor interaction that can limit clinical effects when taken with Nifedipine and Nifedipine may cause a moderate interaction that could exacerbate diseases when taken with Somatrem
Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Flibanserin and Flibanserin may cause a moderate interaction that could exacerbate diseases when taken with Somatrem
Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Somatrem
Ticagrelor may lead to a major life threatening interaction when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Somatrem
Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Vemurafenib and Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Somatrem
Ticagrelor may lead to a major life threatening interaction when taken with Zanubrutinib and Zanubrutinib may cause a moderate interaction that could exacerbate diseases when taken with Somatrem
Ticagrelor may cause a minor interaction that can limit clinical effects when taken with Doravirine and Doravirine may cause a moderate interaction that could exacerbate diseases when taken with Somatrem
Ticagrelor may lead to a major life threatening interaction when taken with Idelalisib and Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Somatrem |
DB00662 | DB01114 | 717 | 272 | [
"DDInter1873",
"DDInter362"
] | Trimethobenzamide | Chlorpheniramine | Trimethobenzamide is a novel antiemetic which prevents nausea and vomiting in humans. Its actions are unclear but most likely involves the chemoreceptor trigger zone (CTZ). In dogs pretreated with trimethobenzamide HCl, the emetic response to apomorphine is inhibited, while little or no protection is afforded against emesis induced by intragastric copper sulfate. | A histamine H1 antagonist used in allergic reactions, hay fever, rhinitis, urticaria, and asthma. It has also been used in veterinary applications. One of the most widely used of the classical antihistaminics, it generally causes less drowsiness and sedation than promethazine. | Moderate | 1 | [
[
[
717,
24,
272
]
],
[
[
717,
24,
358
],
[
358,
63,
272
]
],
[
[
717,
63,
128
],
[
128,
24,
272
]
],
[
[
717,
21,
28705
],
[
28705,
... | [
[
[
"Trimethobenzamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorpheniramine"
]
],
[
[
"Trimethobenzamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Orphena... | Trimethobenzamide may cause a moderate interaction that could exacerbate diseases when taken with Orphenadrine and Orphenadrine may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine
Trimethobenzamide may cause a moderate interaction that could exacerbate diseases when taken with Dexbrompheniramine and Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine
Trimethobenzamide (Compound) causes Drowsiness (Side Effect) and Drowsiness (Side Effect) is caused by Chlorpheniramine (Compound)
Trimethobenzamide may cause a moderate interaction that could exacerbate diseases when taken with Clonazepam and Clonazepam may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine
Trimethobenzamide may lead to a major life threatening interaction when taken with Dextropropoxyphene and Dextropropoxyphene may lead to a major life threatening interaction when taken with Chlorpheniramine
Trimethobenzamide may cause a moderate interaction that could exacerbate diseases when taken with Zonisamide and Zonisamide may lead to a major life threatening interaction when taken with Chlorpheniramine
Trimethobenzamide may cause a moderate interaction that could exacerbate diseases when taken with Promazine and Promazine (Compound) resembles Chlorpheniramine (Compound) and Promazine may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine
Trimethobenzamide may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine and Diphenhydramine (Compound) resembles Chlorpheniramine (Compound) and Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine
Trimethobenzamide may cause a moderate interaction that could exacerbate diseases when taken with Orphenadrine and Orphenadrine (Compound) resembles Pheniramine (Compound) and Pheniramine (Compound) resembles Chlorpheniramine (Compound) |
DB01218 | DB09020 | 1,493 | 28 | [
"DDInter852",
"DDInter212"
] | Halofantrine | Bisacodyl | Halofantrine is an antimalarial. It belongs to the phenanthrene class of compounds that includes quinine and lumefantrine. It appears to inhibit polymerisation of heme molecules (by the parasite enzyme "heme polymerase"), resulting in the parasite being poisoned by its own waste. Halofantrine has been shown to preferentially block open and inactivated HERG channels leading to some degree of cardiotoxicity. | Bisacodyl, a diphenylmethane derivative, is a commonly used over the counter stimulant laxative for occasional constipation.[A233300,L13362] Both bisacodyl and [picosulfate] are metabolized to the same active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM).[A233290,A233300,A207700] Bisacodyl was patented on 25 September 1956 but has been used as a laxative since 1952. | Moderate | 1 | [
[
[
1493,
24,
28
]
],
[
[
1493,
7,
5998
],
[
5998,
46,
28
]
],
[
[
1493,
18,
3023
],
[
3023,
57,
28
]
],
[
[
1493,
21,
28809
],
[
28809,
... | [
[
[
"Halofantrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bisacodyl"
]
],
[
[
"Halofantrine",
"{u} (Compound) upregulates {v} (Gene)",
"HMOX1"
],
[
"HMOX1",
"{u} (Gene) is upregulated by {v}... | Halofantrine (Compound) upregulates HMOX1 (Gene) and HMOX1 (Gene) is upregulated by Bisacodyl (Compound)
Halofantrine (Compound) downregulates RUVBL1 (Gene) and RUVBL1 (Gene) is downregulated by Bisacodyl (Compound)
Halofantrine (Compound) causes Diarrhoea (Side Effect) and Diarrhoea (Side Effect) is caused by Bisacodyl (Compound)
Halofantrine may lead to a major life threatening interaction when taken with Dronedarone and Dronedarone may cause a moderate interaction that could exacerbate diseases when taken with Bisacodyl
Halofantrine may lead to a major life threatening interaction when taken with Pitolisant and Pitolisant may cause a moderate interaction that could exacerbate diseases when taken with Bisacodyl
Halofantrine may lead to a major life threatening interaction when taken with Tramadol and Tramadol may cause a moderate interaction that could exacerbate diseases when taken with Bisacodyl
Halofantrine may cause a moderate interaction that could exacerbate diseases when taken with Lactulose and Lactulose may cause a moderate interaction that could exacerbate diseases when taken with Bisacodyl
Halofantrine may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide and Magnesium hydroxide may cause a moderate interaction that could exacerbate diseases when taken with Bisacodyl
Halofantrine (Compound) upregulates HMOX1 (Gene) and HMOX1 (Gene) is regulated by RYBP (Gene) and RYBP (Gene) is upregulated by Bisacodyl (Compound) |
DB00472 | DB01166 | 758 | 477 | [
"DDInter758",
"DDInter379"
] | Fluoxetine | Cilostazol | Fluoxetine is a 2nd generation antidepressant categorized as a selective serotonin reuptake inhibitor (SSRI). It gained FDA approval in 1987 and although it was initially intended for the treatment of depression, today it is commonly prescribed to manage depression in addition to various other pathologies. | Cilostazol is a quinolinone derivative and antiplatelet agent with vasodilating properties that has been used in the symptomatic treatment of intermittent claudication in patients with peripheral ischaemia. It is marketed under the brand name Pletal by Otsuka Pharmaceutical Co.. Cilostazol works by inhibiting both primary and secondary aggregation and reducing calcium-induced contractions. | Moderate | 1 | [
[
[
758,
24,
477
]
],
[
[
758,
6,
8374
],
[
8374,
45,
477
]
],
[
[
758,
7,
3727
],
[
3727,
46,
477
]
],
[
[
758,
21,
28919
],
[
28919,
... | [
[
[
"Fluoxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cilostazol"
]
],
[
[
"Fluoxetine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",... | Fluoxetine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Cilostazol (Compound)
Fluoxetine (Compound) upregulates MAL (Gene) and MAL (Gene) is upregulated by Cilostazol (Compound)
Fluoxetine (Compound) causes Arthritis (Side Effect) and Arthritis (Side Effect) is caused by Cilostazol (Compound)
Fluoxetine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Cilostazol
Fluoxetine may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin may cause a minor interaction that can limit clinical effects when taken with Cilostazol
Fluoxetine may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Cilostazol
Fluoxetine may lead to a major life threatening interaction when taken with Tamoxifen and Tamoxifen may cause a moderate interaction that could exacerbate diseases when taken with Cilostazol
Fluoxetine (Compound) resembles Duloxetine (Compound) and Duloxetine may cause a moderate interaction that could exacerbate diseases when taken with Cilostazol
Fluoxetine may cause a moderate interaction that could exacerbate diseases when taken with Daunorubicin and Daunorubicin may cause a moderate interaction that could exacerbate diseases when taken with Cilostazol |
DB01045 | DB09330 | 463 | 985 | [
"DDInter1590",
"DDInter1352"
] | Rifampicin | Osimertinib | A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160) | Osimertinib is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug developed by AstraZeneca Pharmaceuticals.[A7926,L43453] Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in cases where tumour EGFR expression is positive for the T790M mutation as detected by FDA-approved testing and which has progressed following therapy with a first-generation EGFR tyrosine kinase inhibitor. Approximately 10% of patients with NSCLC have a rapid and clinically effective response to EGFR-TKIs due to the presence of specific activating EGFR mutations within the tumour cells. More specifically, deletions around the LREA motif in exon 19 and exon 21 L858R point mutations are correlated with response to therapy. Development of third-generation EGFR-TKIs, such as osimertinib, has been in response to altered tumour resistance patterns following treatment and toxic side effects that impact patient quality of life. Treatment with first-generation EGFR-TKIs (gefitinib and erlotinib) has been associated with the development of resistance through activating mutations in the EGFR gene. Second-generation EGFR-TKIs (afatinib and dacomitinib) were then developed to be more potent inhibitors, although their use is associated with increased toxicity through nonspecific targeting of wild-type EGFR. In contrast, third-generation inhibitors are specific for the gate-keeper T790M mutations which increases ATP binding activity to EGFR and result in poor prognosis for late-stage disease. Furthermore, osimertinib has been shown to spare wild-type EGFR during therapy, thereby reducing non-specific binding and limiting toxicity.[A7926,A7927,A7931] | Major | 2 | [
[
[
463,
25,
985
]
],
[
[
463,
64,
168
],
[
168,
23,
985
]
],
[
[
463,
63,
112
],
[
112,
23,
985
]
],
[
[
463,
62,
608
],
[
608,
23,... | [
[
[
"Rifampicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Osimertinib"
]
],
[
[
"Rifampicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bortezomib"
],
[
"Bortezomib",
"{u} ... | Rifampicin may lead to a major life threatening interaction when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Osimertinib
Rifampicin may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Osimertinib
Rifampicin may cause a minor interaction that can limit clinical effects when taken with Lidocaine and Lidocaine may cause a minor interaction that can limit clinical effects when taken with Osimertinib
Rifampicin may lead to a major life threatening interaction when taken with Ivacaftor and Ivacaftor may cause a moderate interaction that could exacerbate diseases when taken with Osimertinib
Rifampicin may cause a moderate interaction that could exacerbate diseases when taken with Vinorelbine and Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Osimertinib
Rifampicin may cause a moderate interaction that could exacerbate diseases when taken with Dabrafenib and Dabrafenib may cause a moderate interaction that could exacerbate diseases when taken with Osimertinib
Rifampicin may lead to a major life threatening interaction when taken with Alpelisib and Alpelisib may cause a moderate interaction that could exacerbate diseases when taken with Osimertinib
Rifampicin may cause a moderate interaction that could exacerbate diseases when taken with Enasidenib and Enasidenib may cause a moderate interaction that could exacerbate diseases when taken with Osimertinib
Rifampicin may lead to a major life threatening interaction when taken with Imatinib and Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Osimertinib |
DB00372 | DB00387 | 999 | 1,386 | [
"DDInter1793",
"DDInter1528"
] | Thiethylperazine | Procyclidine | A dopamine antagonist that is particularly useful in treating the nausea and vomiting associated with anesthesia, mildly emetic cancer chemotherapy agents, radiation therapy, and toxins. This piperazine phenothiazine does not prevent vertigo or motion sickness. (From AMA Drug Evaluations Annual, 1994, p457) | A muscarinic antagonist that crosses the blood-brain barrier and is used in the treatment of drug-induced extrapyramidal disorders and in parkinsonism. | Moderate | 1 | [
[
[
999,
24,
1386
]
],
[
[
999,
24,
1105
],
[
1105,
1,
1386
]
],
[
[
999,
24,
1376
],
[
1376,
63,
1386
]
],
[
[
999,
63,
352
],
[
352,
... | [
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Procyclidine"
]
],
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trihexyphenid... | Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Trihexyphenidyl and Trihexyphenidyl (Compound) resembles Procyclidine (Compound)
Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine and Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Procyclidine
Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Trospium and Trospium may cause a moderate interaction that could exacerbate diseases when taken with Procyclidine
Thiethylperazine may lead to a major life threatening interaction when taken with Metoclopramide and Metoclopramide may cause a moderate interaction that could exacerbate diseases when taken with Procyclidine
Thiethylperazine may lead to a major life threatening interaction when taken with Potassium chloride and Potassium chloride may lead to a major life threatening interaction when taken with Procyclidine
Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Glycopyrronium and Glycopyrronium (Compound) resembles Procyclidine (Compound) and Glycopyrronium may cause a moderate interaction that could exacerbate diseases when taken with Procyclidine
Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Trihexyphenidyl and Trihexyphenidyl (Compound) resembles Oxyphencyclimine (Compound) and Oxyphencyclimine (Compound) resembles Procyclidine (Compound)
Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Trospium and Trospium (Compound) resembles Diphenidol (Compound) and Diphenidol (Compound) resembles Procyclidine (Compound)
Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Aclidinium and Aclidinium may cause a moderate interaction that could exacerbate diseases when taken with Trihexyphenidyl and Trihexyphenidyl (Compound) resembles Procyclidine (Compound) |
DB01259 | DB15982 | 392 | 1,339 | [
"DDInter1024",
"DDInter193"
] | Lapatinib | Berotralstat | Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer. It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug capecitabine. Lapatinib is a human epidermal growth factor receptor type 2 (HER2/ERBB2) and epidermal growth factor receptor (HER1/EGFR/ERBB1) tyrosine kinases inhibitor. It binds to the intracellular phosphorylation domain to prevent receptor autophosphorylation upon ligand binding. | Berotralstat is a selective inhibitor of plasma kallikrein used in the prophylaxis of attacks of hereditary angioedema (HAE). It works by blocking the enzymatic activity of plasma kallikrein in releasing bradykinin, the major biologic peptide that promotes swelling and pain associated with attacks of HAE. Berotralstat is strictly used to prevent, but not treat, these attacks. Developed by BioCryst Pharmaceuticals, berotralstat is marketed under the name Orladeyo as oral capsules. Berotralstat was first approved by the FDA on December 3, 2020, as the first once-daily oral therapy to prevent angioedema attacks of HAE in adults and pediatric patients 12 years and older. Berotralstat was approved by the European Commission on April 30, 2021 and by Health Canada on June 06, 2022. | Major | 2 | [
[
[
392,
25,
1339
]
],
[
[
392,
63,
1101
],
[
1101,
23,
1339
]
],
[
[
392,
24,
283
],
[
283,
23,
1339
]
],
[
[
392,
24,
761
],
[
761,
... | [
[
[
"Lapatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Berotralstat"
]
],
[
[
"Lapatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
"Bexarotene... | Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Berotralstat
Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib and Fedratinib may cause a minor interaction that can limit clinical effects when taken with Berotralstat
Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Saxagliptin and Saxagliptin may cause a moderate interaction that could exacerbate diseases when taken with Berotralstat
Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Berotralstat
Lapatinib may lead to a major life threatening interaction when taken with Ribociclib and Ribociclib may cause a moderate interaction that could exacerbate diseases when taken with Berotralstat
Lapatinib may lead to a major life threatening interaction when taken with Toremifene and Toremifene may cause a moderate interaction that could exacerbate diseases when taken with Berotralstat
Lapatinib (Compound) resembles Gefitinib (Compound) and Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Gefitinib and Gefitinib may cause a moderate interaction that could exacerbate diseases when taken with Berotralstat
Lapatinib may lead to a major life threatening interaction when taken with Cobicistat and Cobicistat may lead to a major life threatening interaction when taken with Berotralstat
Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may lead to a major life threatening interaction when taken with Berotralstat |
DB00242 | DB01229 | 1,064 | 973 | [
"DDInter392",
"DDInter1378"
] | Cladribine | Paclitaxel (protein-bound) | An antineoplastic agent used in the treatment of lymphoproliferative diseases including hairy-cell leukemia. | Paclitaxel can cause developmental toxicity, female reproductive toxicity and male reproductive toxicity according to state or federal government labeling requirements. | Major | 2 | [
[
[
1064,
25,
973
]
],
[
[
1064,
25,
310
],
[
310,
63,
973
]
],
[
[
1064,
6,
17404
],
[
17404,
45,
973
]
],
[
[
1064,
18,
7824
],
[
7824,
... | [
[
[
"Cladribine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Paclitaxel"
]
],
[
[
"Cladribine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cabazitaxel"
],
[
"Cabazitaxel",
"{u}... | Cladribine may lead to a major life threatening interaction when taken with Paclitaxel
Cladribine may lead to a major life threatening interaction when taken with Cabazitaxel and Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel
Cladribine (Compound) binds ABCG2 (Gene) and ABCG2 (Gene) is bound by Paclitaxel (Compound)
Cladribine (Compound) downregulates CDCA8 (Gene) and CDCA8 (Gene) is upregulated by Paclitaxel (Compound)
Cladribine (Compound) upregulates RELB (Gene) and RELB (Gene) is upregulated by Paclitaxel (Compound)
Cladribine (Compound) upregulates LIG1 (Gene) and LIG1 (Gene) is downregulated by Paclitaxel (Compound)
Cladribine (Compound) binds PNP (Gene) and PNP (Gene) is downregulated by Paclitaxel (Compound)
Cladribine (Compound) downregulates TOP2A (Gene) and TOP2A (Gene) is downregulated by Paclitaxel (Compound)
Cladribine (Compound) causes Infection (Side Effect) and Infection (Side Effect) is caused by Paclitaxel (Compound)
Cladribine may lead to a major life threatening interaction when taken with Vinorelbine and Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel |
DB00916 | DB01224 | 112 | 623 | [
"DDInter1202",
"DDInter1553"
] | Metronidazole | Quetiapine | Metronidazole is a commonly used antibiotic, belonging to the nitroimidazole class of antibiotics. It is frequently used to treat gastrointestinal infections as well as trichomoniasis and giardiasis, and amebiasis which are parasitic infections.[A181036,A181039] Metronidazole has been used as an antibiotic for several decades, with added antiparasitic properties that set it apart from many other antibacterial drugs, allowing it to treat a wide variety of infections. It is available in capsule form, tablet form, and topical form, and suppository preparations for the treatment of various infections. | Initially approved by the FDA in 1997, quetiapine is a second-generation atypical antipsychotic used in schizophrenia, major depression, and bipolar disorder. Quetiapine demonstrates a high level of therapeutic efficacy and low risk of adverse effects during long-term treatment. It is well-tolerated and a suitable option for some patients with high sensitivity to other drugs, such as [clozapine] and [olanzapine]. | Minor | 0 | [
[
[
112,
23,
623
]
],
[
[
112,
62,
827
],
[
827,
1,
623
]
],
[
[
112,
6,
8374
],
[
8374,
45,
623
]
],
[
[
112,
21,
29039
],
[
29039,
... | [
[
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Quetiapine"
]
],
[
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Trazodone"
],
[
... | Metronidazole may cause a minor interaction that can limit clinical effects when taken with Trazodone and Trazodone (Compound) resembles Quetiapine (Compound)
Metronidazole (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Quetiapine (Compound)
Metronidazole (Compound) causes Cystitis noninfective (Side Effect) and Cystitis noninfective (Side Effect) is caused by Quetiapine (Compound)
Metronidazole may cause a minor interaction that can limit clinical effects when taken with Cimetidine and Cimetidine may cause a minor interaction that can limit clinical effects when taken with Quetiapine
Metronidazole may cause a minor interaction that can limit clinical effects when taken with Osilodrostat and Osilodrostat may cause a moderate interaction that could exacerbate diseases when taken with Quetiapine
Metronidazole may cause a minor interaction that can limit clinical effects when taken with Tamoxifen and Tamoxifen may cause a moderate interaction that could exacerbate diseases when taken with Quetiapine
Metronidazole may cause a minor interaction that can limit clinical effects when taken with Cilostazol and Cilostazol may cause a moderate interaction that could exacerbate diseases when taken with Quetiapine
Metronidazole may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide and Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Quetiapine
Metronidazole may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Quetiapine |
DB01268 | DB13139 | 1,151 | 1,032 | [
"DDInter1731",
"DDInter1063"
] | Sunitinib | Levosalbutamol | Sunitinib is a small-molecule multi-targeted receptor tyrosine kinase (RTK) inhibitor. On January 26, 2006, the agent was formally approved by the US FDA for the indications of treating renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). For these purposes, sunitinib is generally available as an orally administered formulation. Sunitinib inhibits cellular signaling by targeting multiple RTKs. These include all platelet-derived growth factor receptors (PDGF-R) and vascular endothelial growth factor receptors (VEGF-R). Sunitinib also inhibits KIT (CD117), the RTK that drives the majority of GISTs. In addition, sunitinib inhibits other RTKs including RET, CSF-1R, and flt3. | Levosalbutamol, or levalbuterol, is a short-acting β2 adrenergic receptor agonist used in the treatment of asthma and chronic obstructive pulmonary disease (COPD). [Salbutamol] has been marketed as a racemic mixture, although beta2-agonist activity resides almost exclusively in the (R)-enantiomer. The enantioselective disposition of salbutamol and the possibility that (S)-salbutamol has adverse effects have led to the development of an enantiomerically pure (R)-salbutamol formulation known as levosalbutamol (levalbuterol). | Moderate | 1 | [
[
[
1151,
24,
1032
]
],
[
[
1151,
63,
1220
],
[
1220,
23,
1032
]
],
[
[
1151,
25,
1618
],
[
1618,
24,
1032
]
],
[
[
1151,
24,
124
],
[
124... | [
[
[
"Sunitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levosalbutamol"
]
],
[
[
"Sunitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
],
... | Sunitinib may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone may cause a minor interaction that can limit clinical effects when taken with Levosalbutamol
Sunitinib may lead to a major life threatening interaction when taken with Cabozantinib and Cabozantinib may cause a moderate interaction that could exacerbate diseases when taken with Levosalbutamol
Sunitinib may cause a moderate interaction that could exacerbate diseases when taken with Glasdegib and Glasdegib may cause a moderate interaction that could exacerbate diseases when taken with Levosalbutamol
Sunitinib may lead to a major life threatening interaction when taken with Ivosidenib and Ivosidenib may cause a moderate interaction that could exacerbate diseases when taken with Levosalbutamol
Sunitinib may cause a moderate interaction that could exacerbate diseases when taken with Granisetron and Granisetron may cause a moderate interaction that could exacerbate diseases when taken with Levosalbutamol
Sunitinib may lead to a major life threatening interaction when taken with Halofantrine and Halofantrine may cause a moderate interaction that could exacerbate diseases when taken with Levosalbutamol
Sunitinib may lead to a major life threatening interaction when taken with Ribociclib and Ribociclib may lead to a major life threatening interaction when taken with Levosalbutamol
Sunitinib may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone (Compound) resembles Beclomethasone dipropionate (Compound) and Beclomethasone dipropionate may cause a minor interaction that can limit clinical effects when taken with Levosalbutamol
Sunitinib may lead to a major life threatening interaction when taken with Cabozantinib and Cabozantinib may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone may cause a minor interaction that can limit clinical effects when taken with Levosalbutamol |
DB00694 | DB11979 | 51 | 1,320 | [
"DDInter485",
"DDInter625"
] | Daunorubicin | Elagolix | A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of leukemia and other neoplasms. | Elagolix has been used in trials studying the basic science and treatment of Endometriosis, Folliculogenesis, Uterine Fibroids, Heavy Uterine Bleeding, and Heavy Menstrual Bleeding. As of 24 July 2018, however, the U.S. Food and Drug Administration (FDA) approved AbbVie's elagolix under the brand name Orilissa as the first and only oral gonadotropin-releasing hormone (GnRH) antagonist specifically developed for women with moderate to severe endometriosis pain . It has been determined that endometriosis is one of the most common gynecologic disorders in the United States [A35868, A35869, F801]. In particular, estimates suggest that one in ten women of reproductive age is affected by endometriosis and experience debilitating pain symptoms [A35868, A35869, F801]. Moreover, women who are affected by this condition can suffer for up to six to ten years and visit multiple physicians before receiving a proper diagnosis [A35868, A35869, F801]. Subsequently, as Orilissa (elagolix) was approved by the FDA under priority review , this expedited new approval gives healthcare professionals another valuable option for treating the potentially unmet needs of women who are affected by endometriosis, depending on their specific type and severity of endometriosis pain. | Moderate | 1 | [
[
[
51,
24,
1320
]
],
[
[
51,
24,
1612
],
[
1612,
23,
1320
]
],
[
[
51,
24,
1297
],
[
1297,
24,
1320
]
],
[
[
51,
63,
79
],
[
79,
24... | [
[
[
"Daunorubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elagolix"
]
],
[
[
"Daunorubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostemsavir"
],
[... | Daunorubicin may cause a moderate interaction that could exacerbate diseases when taken with Fostemsavir and Fostemsavir may cause a minor interaction that can limit clinical effects when taken with Elagolix
Daunorubicin may cause a moderate interaction that could exacerbate diseases when taken with Osilodrostat and Osilodrostat may cause a moderate interaction that could exacerbate diseases when taken with Elagolix
Daunorubicin may cause a moderate interaction that could exacerbate diseases when taken with Sorafenib and Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Elagolix
Daunorubicin may lead to a major life threatening interaction when taken with Macimorelin and Macimorelin may cause a moderate interaction that could exacerbate diseases when taken with Elagolix
Daunorubicin may cause a minor interaction that can limit clinical effects when taken with Delafloxacin and Delafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Elagolix
Daunorubicin may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib and Entrectinib may cause a moderate interaction that could exacerbate diseases when taken with Elagolix
Daunorubicin may lead to a major life threatening interaction when taken with Cabozantinib and Cabozantinib may cause a moderate interaction that could exacerbate diseases when taken with Elagolix
Daunorubicin (Compound) resembles Idarubicin (Compound) and Daunorubicin may cause a moderate interaction that could exacerbate diseases when taken with Idarubicin and Idarubicin may cause a moderate interaction that could exacerbate diseases when taken with Elagolix
Daunorubicin (Compound) resembles Epirubicin (Compound) and Daunorubicin may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Elagolix |
DB06643 | DB09036 | 1,136 | 812 | [
"DDInter500",
"DDInter1668"
] | Denosumab | Siltuximab | Denosumab is a novel, fully human IgG2 monoclonal antibody specific to receptor activator of nuclear factor kappa-B ligand (RANKL), suppresses bone resorption via inhibiting RANK-mediated activation of osteoclasts. It is the first and currently the only RANKL inhibitor approved to prevent osteoclast-mediated bone loss. Chemically, it consists of 2 heavy and 2 light chains, with each light chain consisting of 215 amino acids and each heavy chain consisting of 448 amino acids with 4 intramolecular disulfides. Denosumab was approved by the FDA approved on June 2010 for the treatment of osteoporosis in postmenopausal women. It further received additional indication approval to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for non-metastatic prostate cancer and women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer in September | Siltuximab is a chimeric (human-mouse) monoclonal immunoglobulin G1-kappa antibody produced in a Chinese hamster ovary (CHO) cell line by recombinant DNA technology. Siltuximab prevents the binding of IL-6 to soluble and membrane-bound IL-6 receptors by forming high affinity complexes with human interleukin-6 (IL-6). Its use is indicated for the treatment of adult patients with multicentric Castleman's disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative. MCD is a rare blood disorder caused by dysregulated IL-6 production, proliferation of lymphocytes, and subsequent enlargement of the lymph nodes. It is administered as a 1 hour intravenous infusion every 3 weeks. | Moderate | 1 | [
[
[
1136,
24,
812
]
],
[
[
1136,
63,
147
],
[
147,
24,
812
]
],
[
[
1136,
24,
1456
],
[
1456,
63,
812
]
],
[
[
1136,
24,
713
],
[
713,
... | [
[
[
"Denosumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Siltuximab"
]
],
[
[
"Denosumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vinblastine"
],
[
... | Denosumab may cause a moderate interaction that could exacerbate diseases when taken with Vinblastine and Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Siltuximab
Denosumab may cause a moderate interaction that could exacerbate diseases when taken with Venetoclax and Venetoclax may cause a moderate interaction that could exacerbate diseases when taken with Siltuximab
Denosumab may cause a moderate interaction that could exacerbate diseases when taken with Dimethyl fumarate and Dimethyl fumarate may cause a moderate interaction that could exacerbate diseases when taken with Siltuximab
Denosumab may cause a moderate interaction that could exacerbate diseases when taken with Etanercept and Etanercept may lead to a major life threatening interaction when taken with Siltuximab
Denosumab may cause a moderate interaction that could exacerbate diseases when taken with Teriflunomide and Teriflunomide may lead to a major life threatening interaction when taken with Siltuximab
Denosumab may cause a moderate interaction that could exacerbate diseases when taken with Upadacitinib and Upadacitinib may lead to a major life threatening interaction when taken with Siltuximab
Denosumab may lead to a major life threatening interaction when taken with Cladribine and Cladribine may lead to a major life threatening interaction when taken with Siltuximab
Denosumab may cause a moderate interaction that could exacerbate diseases when taken with Vinblastine and Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Siltuximab
Denosumab may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate and Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate and Diroximel fumarate may cause a moderate interaction that could exacerbate diseases when taken with Siltuximab |
DB00059 | DB00549 | 1,560 | 522 | [
"DDInter1404",
"DDInter1955"
] | Pegaspargase | Zafirlukast | Pegaspargase is a conjugate of monomethoxypolyethylene glycol (mPEG) and L-asparaginase (L-asparagine amidohydrolase), an asparagine-specific enzyme that converts L-asparagine into aspartic acid and ammonia. Asparagine is an amino acid that is vital for cell survival. In humans, most normal tissues can produce asparagine through the action of asparagine synthetase. However, leukemia cells have low levels of this enzyme and depend on exogenous sources. Therefore, the use of pegaspargase results in leukemic cell death.[A103,A255912,L44667] Pegaspargase has the same mechanism of action as [L-asparaginase] derived from _Escherichia coli_, a previously developed enzyme used for the treatment of acute lymphoblastic leukemia (ALL). However, using L-asparaginase derived from _Escherich | Zafirlukast is an oral leukotriene receptor antagonist (LTRA) for the maintenance treatment of asthma, often used in conjunction with an inhaled steroid and/or long-acting bronchodilator. It is available as a tablet and is usually dosed twice daily. Another leukotriene receptor antagonist is montelukast (Singulair), which is usually taken just once daily. Zafirlukast blocks the action of the cysteinyl leukotrienes on the CysLT1 receptors, thus reducing constriction of the airways, build-up of mucus in the lungs and inflammation of the breathing passages. | Moderate | 1 | [
[
[
1560,
24,
522
]
],
[
[
1560,
24,
165
],
[
165,
40,
522
]
],
[
[
1560,
24,
1347
],
[
1347,
62,
522
]
],
[
[
1560,
24,
786
],
[
786,
... | [
[
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zafirlukast"
]
],
[
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolvaptan"
],
... | Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Tolvaptan and Tolvaptan (Compound) resembles Zafirlukast (Compound)
Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Clopidogrel and Clopidogrel may cause a minor interaction that can limit clinical effects when taken with Zafirlukast
Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Rilpivirine and Rilpivirine may cause a moderate interaction that could exacerbate diseases when taken with Zafirlukast
Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Zafirlukast
Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon alfa-2a and Peginterferon alfa-2a may cause a moderate interaction that could exacerbate diseases when taken with Zafirlukast
Pegaspargase may lead to a major life threatening interaction when taken with Infliximab and Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Zafirlukast
Pegaspargase may lead to a major life threatening interaction when taken with Etanercept and Etanercept may cause a moderate interaction that could exacerbate diseases when taken with Zafirlukast
Pegaspargase may lead to a major life threatening interaction when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Zafirlukast
Pegaspargase may lead to a major life threatening interaction when taken with Lomitapide and Lomitapide may lead to a major life threatening interaction when taken with Zafirlukast |
DB00283 | DB00981 | 701 | 1,528 | [
"DDInter395",
"DDInter1462"
] | Clemastine | Physostigmine | An ethanolamine-derivative, first generation histamine H1 antagonist used in hay fever, rhinitis, allergic skin conditions, and pruritus. It causes drowsiness. | A cholinesterase inhibitor that is rapidly absorbed through membranes. It can be applied topically to the conjunctiva. It also can cross the blood-brain barrier and is used when central nervous system effects are desired, as in the treatment of severe anticholinergic toxicity. | Moderate | 1 | [
[
[
701,
24,
1528
]
],
[
[
701,
21,
28751
],
[
28751,
60,
1528
]
],
[
[
701,
24,
508
],
[
508,
24,
1528
]
],
[
[
701,
35,
1511
],
[
1511,
... | [
[
[
"Clemastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Physostigmine"
]
],
[
[
"Clemastine",
"{u} (Compound) causes {v} (Side Effect)",
"Convulsion"
],
[
"Convulsion",
"{u} (Side Effect) is... | Clemastine (Compound) causes Convulsion (Side Effect) and Convulsion (Side Effect) is caused by Physostigmine (Compound)
Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Promazine and Promazine may cause a moderate interaction that could exacerbate diseases when taken with Physostigmine
Clemastine (Compound) resembles Mepenzolate (Compound) and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Mepenzolate and Mepenzolate may cause a moderate interaction that could exacerbate diseases when taken with Physostigmine
Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Tiotropium and Tiotropium may cause a moderate interaction that could exacerbate diseases when taken with Physostigmine
Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Disopyramide and Disopyramide may cause a moderate interaction that could exacerbate diseases when taken with Physostigmine
Clemastine (Compound) resembles Hydroxyzine (Compound) and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Hydroxyzine and Hydroxyzine may cause a moderate interaction that could exacerbate diseases when taken with Physostigmine
Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Tramadol and Tramadol may lead to a major life threatening interaction when taken with Physostigmine
Clemastine (Compound) causes Convulsion (Side Effect) and Convulsion (Side Effect) is caused by Amoxapine (Compound) and Amoxapine may cause a moderate interaction that could exacerbate diseases when taken with Physostigmine
Clemastine (Compound) causes Vomiting (Side Effect) and Vomiting (Side Effect) is caused by Nebivolol (Compound) and Nebivolol may cause a moderate interaction that could exacerbate diseases when taken with Physostigmine |
DB00530 | DB08875 | 1,195 | 1,618 | [
"DDInter667",
"DDInter262"
] | Erlotinib | Cabozantinib | Erlotinib is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase that is used in the treatment of non-small cell lung cancer, pancreatic cancer and several other types of cancer. It is typically marketed under the trade name Tarceva. Erlotinib binds to the epidermal growth factor receptor (EGFR) tyrosine kinase in a reversible fashion at the adenosine triphosphate (ATP) binding site of the receptor. Recent studies demonstrate that erlotinib is also a potent inhibitor of JAK2V617F, which is a mutant form of tyrosine kinase JAK2 found in most patients with polycythemia vera (PV) and a substantial proportion of patients with idiopathic myelofibrosis or essential thrombocythemia. This finding introduces the potential use of erlotinib in the treatment of JAK2V617F-positive PV and other myeloprolifer | Cabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer. In 2016, a capsule formulation (Cabometyx) was approved for the treatment of advanced renal cell carcinoma, and this same formulation gained additional approval in both the US and Canada in 2019 for the treatment of hepatocellular carcinoma in previously treated patients.[L15128,L15133] | Moderate | 1 | [
[
[
1195,
24,
1618
]
],
[
[
1195,
24,
384
],
[
384,
63,
1618
]
],
[
[
1195,
23,
307
],
[
307,
24,
1618
]
],
[
[
1195,
24,
1249
],
[
1249,
... | [
[
[
"Erlotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabozantinib"
]
],
[
[
"Erlotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
],
[
... | Erlotinib may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Cabozantinib
Erlotinib may cause a minor interaction that can limit clinical effects when taken with Modafinil and Modafinil may cause a moderate interaction that could exacerbate diseases when taken with Cabozantinib
Erlotinib may cause a moderate interaction that could exacerbate diseases when taken with Nafcillin and Nafcillin may cause a moderate interaction that could exacerbate diseases when taken with Cabozantinib
Erlotinib may cause a moderate interaction that could exacerbate diseases when taken with Nevirapine and Nevirapine may cause a moderate interaction that could exacerbate diseases when taken with Cabozantinib
Erlotinib may cause a moderate interaction that could exacerbate diseases when taken with Troleandomycin and Troleandomycin may lead to a major life threatening interaction when taken with Cabozantinib
Erlotinib may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin and Epirubicin may lead to a major life threatening interaction when taken with Cabozantinib
Erlotinib may cause a moderate interaction that could exacerbate diseases when taken with Rifabutin and Rifabutin may lead to a major life threatening interaction when taken with Cabozantinib
Erlotinib (Compound) resembles Vandetanib (Compound) and Vandetanib may lead to a major life threatening interaction when taken with Cabozantinib
Erlotinib may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may lead to a major life threatening interaction when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Cabozantinib |
DB01075 | DB01202 | 1,376 | 1,435 | [
"DDInter569",
"DDInter1046"
] | Diphenhydramine | Levetiracetam | Diphenhydramine - perhaps known most commonly as its brand name formulation Benadryl - is a first-generation H1 receptor antihistamine that is used extensively for the treatment of seasonal allergies, insect bites and stings, and rashes [L5263, L5266, L5269, F3379]. However, it also has antiemetic, antitussive, hypnotic, and antiparkinson properties [L5269, F3352]. As histamine receptors exist both peripherally and in the central nervous system, diphenhydramine has been shown to cause sedation due to its competitive antagonism of histamine H1 receptors within the central nervous system [L5263, L5266, L5269, F3379, A174541]. While its use in allergy therapy can sometimes fall out of favor due to its sedative effect, diphenhydramine has been repurposed | Levetiracetam is a drug within the pyrrolidine class that is used to treat various types of seizures stemming from epileptic disorders. It was first approved for use in the United States in 1999 and is structurally and mechanistically unrelated to other anti-epileptic drugs (AEDs).[L8606,L8600,L8615] Levetiracetam possesses a wide therapeutic index[L8615,A185918] and little-to-no potential to produce, or be subject to, pharmacokinetic interactions[L8606,L8600,L8615] - these characteristics make it a desirable choice over other AEDs, a class of drugs notorious for having generally narrow therapeutic indexes and a propensity for involvement in drug interactions. | Moderate | 1 | [
[
[
1376,
24,
1435
]
],
[
[
1376,
21,
28769
],
[
28769,
60,
1435
]
],
[
[
1376,
63,
701
],
[
701,
24,
1435
]
],
[
[
1376,
35,
272
],
[
272... | [
[
[
"Diphenhydramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levetiracetam"
]
],
[
[
"Diphenhydramine",
"{u} (Compound) causes {v} (Side Effect)",
"Feeling abnormal"
],
[
"Feeling abnormal",
... | Diphenhydramine (Compound) causes Feeling abnormal (Side Effect) and Feeling abnormal (Side Effect) is caused by Levetiracetam (Compound)
Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Clemastine and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Levetiracetam
Diphenhydramine (Compound) resembles Chlorpheniramine (Compound) and Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine and Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Levetiracetam
Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Levetiracetam
Diphenhydramine (Compound) resembles Carbinoxamine (Compound) and Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine and Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Levetiracetam
Diphenhydramine (Compound) resembles Alimemazine (Compound) and Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Levetiracetam
Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Metoclopramide and Metoclopramide may cause a moderate interaction that could exacerbate diseases when taken with Levetiracetam
Diphenhydramine (Compound) causes Feeling abnormal (Side Effect) and Feeling abnormal (Side Effect) is caused by Methotrexate (Compound) and Methotrexate may cause a minor interaction that can limit clinical effects when taken with Levetiracetam
Diphenhydramine (Compound) causes Tremor (Side Effect) and Tremor (Side Effect) is caused by Clemastine (Compound) and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Levetiracetam |
DB00434 | DB00794 | 13 | 759 | [
"DDInter459",
"DDInter1521"
] | Cyproheptadine | Primidone | Cyproheptadine is a potent competitive antagonist of both serotonin and histamine receptors. It is used primarily to treat allergic symptoms, though it is perhaps more notable for its use in appetite stimulation and its off-label use in the treatment of serotonin syndrome. | Primidone is an anticonvulsant used to treat essential tremor as well as grand mal, psychomotor, and focal epileptic seizures. Primidone was developed by J Yule Bogue and H C Carrington in 1949. Primidone was granted FDA Approval on 8 March 1954. | Moderate | 1 | [
[
[
13,
24,
759
]
],
[
[
13,
24,
697
],
[
697,
40,
759
]
],
[
[
13,
63,
362
],
[
362,
1,
759
]
],
[
[
13,
24,
157
],
[
157,
1,
... | [
[
[
"Cyproheptadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Primidone"
]
],
[
[
"Cyproheptadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenobarbital"
]... | Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Phenobarbital and Phenobarbital (Compound) resembles Primidone (Compound)
Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Phenytoin and Phenytoin (Compound) resembles Primidone (Compound)
Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Ethotoin and Ethotoin (Compound) resembles Primidone (Compound)
Cyproheptadine (Compound) causes Dizziness (Side Effect) and Dizziness (Side Effect) is caused by Primidone (Compound)
Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Primidone
Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Tripelennamine and Tripelennamine may cause a moderate interaction that could exacerbate diseases when taken with Primidone
Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Cetirizine and Cetirizine may cause a moderate interaction that could exacerbate diseases when taken with Primidone
Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Morphine and Morphine may lead to a major life threatening interaction when taken with Primidone
Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Phenobarbital and Phenobarbital (Compound) resembles Phenytoin (Compound) and Phenytoin (Compound) resembles Primidone (Compound) |
DB00651 | DB00728 | 746 | 1,610 | [
"DDInter613",
"DDInter1612"
] | Dyphylline | Rocuronium | Dyphylline is a theophylline derivative with broncho- and vasodilator properties. It is typically used in the management of asthma, cardiac dyspnea, and bronchitis. | Rocuronium (rapid onset-curonium) is a desacetoxy analogue of vecuronium with a more rapid onset of action. It is an aminosteroid non-depolarizing neuromuscular blocker or muscle relaxant used in modern anaesthesia, to facilitate endotracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation. Introduced in 1994, rocuronium has rapid onset, and intermediate duration of action. It is commonly marketed under the trade names Zemuron and Esmeron. The drug is associated with the risk of developing allergic reactions in some high-risk patients, such as those with asthma. However, there was a similar incidence of allergic reactions associated with other non-depolarizing neuromuscular blocking agents. [Sugammadex] is a γ-cyclodextrin derivative that has been introduced as a novel agent to reverse the action of rocuronium. | Moderate | 1 | [
[
[
746,
24,
1610
]
],
[
[
746,
24,
728
],
[
728,
40,
1610
]
],
[
[
746,
21,
29118
],
[
29118,
60,
1610
]
],
[
[
746,
40,
1031
],
[
1031,
... | [
[
[
"Dyphylline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rocuronium"
]
],
[
[
"Dyphylline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vecuronium"
],
[
... | Dyphylline may cause a moderate interaction that could exacerbate diseases when taken with Vecuronium and Vecuronium (Compound) resembles Rocuronium (Compound)
Dyphylline (Compound) causes Tachycardia (Side Effect) and Tachycardia (Side Effect) is caused by Rocuronium (Compound)
Dyphylline (Compound) resembles Theophylline (Compound) and Theophylline may cause a moderate interaction that could exacerbate diseases when taken with Rocuronium
Dyphylline may cause a moderate interaction that could exacerbate diseases when taken with Vecuronium and Vecuronium (Compound) resembles Pancuronium (Compound) and Pancuronium (Compound) resembles Rocuronium (Compound)
Dyphylline may cause a moderate interaction that could exacerbate diseases when taken with Pancuronium and Pancuronium (Compound) resembles Vecuronium (Compound) and Vecuronium (Compound) resembles Rocuronium (Compound)
Dyphylline (Compound) causes Tachycardia (Side Effect) and Tachycardia (Side Effect) is caused by Vecuronium (Compound) and Vecuronium (Compound) resembles Rocuronium (Compound)
Dyphylline (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Irinotecan (Compound) and Irinotecan may cause a minor interaction that can limit clinical effects when taken with Rocuronium
Dyphylline (Compound) resembles Theophylline (Compound) and Theophylline may cause a moderate interaction that could exacerbate diseases when taken with Vecuronium and Vecuronium (Compound) resembles Rocuronium (Compound)
Dyphylline may cause a moderate interaction that could exacerbate diseases when taken with Mivacurium and Mivacurium (Compound) binds CHRNA2 (Gene) and CHRNA2 (Gene) is bound by Rocuronium (Compound) |
DB00598 | DB09122 | 1,523 | 1,613 | [
"DDInter1013",
"DDInter1409"
] | Labetalol | Peginterferon beta-1a | Labetalol is a racemic mixture of 2 diastereoisomers where dilevalol, the R,R' stereoisomer, makes up 25% of the mixture. Labetalol is formulated as an injection or tablets to treat hypertension.[L7727,L7730] Labetalol was granted FDA approval on 1 August 1984. | Multiple Sclerosis (MS) is a chronic and inflammatory autoimmune disease of the central nervous system, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792] Peginterferon beta-1a is an interferon therapy used for the management of relapsing forms of MS. It was originally approved by the FDA in 2014 for subcutaneous use, and was approved for intramuscular use in January 2021. Currently, it is the only approved pegylated interferon for the management of MS with an proven ability to reduce relapses and delay the progression of disability resulting from MS. | Moderate | 1 | [
[
[
1523,
24,
1613
]
],
[
[
1523,
24,
1274
],
[
1274,
24,
1613
]
],
[
[
1523,
25,
1011
],
[
1011,
24,
1613
]
],
[
[
1523,
63,
1560
],
[
15... | [
[
[
"Labetalol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Peginterferon beta-1a"
]
],
[
[
"Labetalol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flurbiprofen"
... | Labetalol may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen and Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
Labetalol may lead to a major life threatening interaction when taken with Fingolimod and Fingolimod may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
Labetalol may cause a moderate interaction that could exacerbate diseases when taken with Pegaspargase and Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
Labetalol (Compound) resembles Quinapril (Compound) and Quinapril may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
Labetalol may cause a moderate interaction that could exacerbate diseases when taken with Alectinib and Alectinib may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
Labetalol may lead to a major life threatening interaction when taken with Theophylline and Theophylline may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
Labetalol may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may lead to a major life threatening interaction when taken with Peginterferon beta-1a
Labetalol may cause a moderate interaction that could exacerbate diseases when taken with Iohexol and Iohexol may lead to a major life threatening interaction when taken with Peginterferon beta-1a
Labetalol may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen and Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Cannabidiol and Cannabidiol may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a |
DB00524 | DB01069 | 811 | 401 | [
"DDInter1199",
"DDInter1533"
] | Metolazone | Promethazine | A quinazoline-sulfonamide that is considered a thiazide-like diuretic which is long-acting so useful in chronic renal failure. It also tends to lower blood pressure and increase potassium loss. | Promethazine, originally known as 3,277 R.P., is an N-dimethylaminopropyl derivative of [phenothiazine] that was developed in France in 1946. Promethazine antagonizes a variety of receptors, allowing it to be used for a number of indications including allergic reactions, pain, sedation, nausea, and vomiting.[A189907,A190153,A190159,A190150,A190171] Promethazine was granted FDA approval before 29 March 1951.[A190177,L4000] | Moderate | 1 | [
[
[
811,
24,
401
]
],
[
[
811,
24,
1264
],
[
1264,
63,
401
]
],
[
[
811,
24,
104
],
[
104,
24,
401
]
],
[
[
811,
21,
28709
],
[
28709,
... | [
[
[
"Metolazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
]
],
[
[
"Metolazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
],
[
... | Metolazone may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Promethazine
Metolazone may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine
Metolazone (Compound) causes Decreased appetite (Side Effect) and Decreased appetite (Side Effect) is caused by Promethazine (Compound)
Metolazone may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide and Magnesium hydroxide may cause a minor interaction that can limit clinical effects when taken with Promethazine
Metolazone may cause a moderate interaction that could exacerbate diseases when taken with Nabilone and Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Promethazine
Metolazone may cause a minor interaction that can limit clinical effects when taken with Trospium and Trospium may cause a moderate interaction that could exacerbate diseases when taken with Promethazine
Metolazone may cause a minor interaction that can limit clinical effects when taken with Propantheline and Propantheline may cause a moderate interaction that could exacerbate diseases when taken with Promethazine
Metolazone may cause a minor interaction that can limit clinical effects when taken with Mepenzolate and Mepenzolate may cause a moderate interaction that could exacerbate diseases when taken with Promethazine
Metolazone (Compound) resembles Chlorothiazide (Compound) and Chlorothiazide may cause a moderate interaction that could exacerbate diseases when taken with Promethazine |
DB00553 | DB00697 | 92 | 876 | [
"DDInter1177",
"DDInter1821"
] | Methoxsalen | Tizanidine | A naturally occurring furocoumarin compound found in several species of plants, including Psoralea corylifolia. It is a photoactive substance that forms DNA adducts in the presence of ultraviolet A irradiation. | Tizanidine is a fast-acting drug used for the management of muscle spasm, which may result from the effects of multiple sclerosis, stroke, an acquired brain injury, or a spinal cord injury . It may also be caused by musculoskeletal injury . Regardless of the cause, muscle spasticity can be an extremely painful and debilitating condition. Initially approved by the FDA in 1996, tizanidine is an Alpha-2 adrenergic receptor agonist reducing spasticity by the presynaptic inhibition of excitatory neurotransmitters that cause firing of neurons promoting muscle spasm [FDA label]. | Major | 2 | [
[
[
92,
25,
876
]
],
[
[
92,
6,
7950
],
[
7950,
45,
876
]
],
[
[
92,
18,
8386
],
[
8386,
57,
876
]
],
[
[
92,
21,
28882
],
[
28882,
... | [
[
[
"Methoxsalen",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tizanidine"
]
],
[
[
"Methoxsalen",
"{u} (Compound) binds {v} (Gene)",
"CYP1A2"
],
[
"CYP1A2",
"{u} (Gene) is bound by {v} (Compound)",
"Tizan... | Methoxsalen (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Tizanidine (Compound)
Methoxsalen (Compound) downregulates MTHFD2 (Gene) and MTHFD2 (Gene) is downregulated by Tizanidine (Compound)
Methoxsalen (Compound) causes Body temperature increased (Side Effect) and Body temperature increased (Side Effect) is caused by Tizanidine (Compound)
Methoxsalen may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Tizanidine
Methoxsalen may cause a moderate interaction that could exacerbate diseases when taken with Methotrexate and Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Tizanidine
Methoxsalen may cause a moderate interaction that could exacerbate diseases when taken with Thiethylperazine and Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Tizanidine
Methoxsalen may cause a moderate interaction that could exacerbate diseases when taken with Vemurafenib and Vemurafenib may lead to a major life threatening interaction when taken with Tizanidine
Methoxsalen (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Clonidine (Compound) and Clonidine (Compound) resembles Tizanidine (Compound)
Methoxsalen (Compound) downregulates MTHFD2 (Gene) and MTHFD2 (Gene) regulates DLD (Gene) and DLD (Gene) is downregulated by Tizanidine (Compound) |
DB09034 | DB14568 | 1,313 | 982 | [
"DDInter1733",
"DDInter1000"
] | Suvorexant | Ivosidenib | Suvorexant is a selective dual antagonist of orexin receptors OX1R and OX2R that promotes sleep by reducing wakefulness and arousal. It has been approved for the treatment of insomnia. | Ivosidenib is a first-in-class isocitrate dehydrogenase-1 (IDH1) inhibitor. IDH1 is an enzyme that is often mutated and overexpressed in some cancers, leading to aberrant cell growth and proliferation. Ivosidenib inhibits mutated IDH1, blocking the enzymatic activity and further differentiation of cancer cells. Ivosidenib was granted accelerated approval by the FDA in July 2018 for the treatment of relapsed of refractory acute myeloid leukemia in adults. It is currently approved to also treat newly diagnosed acute myeloid leukemia in older adults in combination [azacitidine] or as monotherapy, as well as locally advanced or metastatic cholangiocarcinoma and relapsed or refractory myelodysplastic syndromes in adults. The drug is only effective in patients with a susceptible IDH1 mutation. In February 2023, the EMA's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion of ivosidenib and recommended it be granted marketing authorization for the treatment of acute myeloid leukemia and cholangiocarcinoma. It was fully approved by the EMA in May 2023. | Moderate | 1 | [
[
[
1313,
24,
982
]
],
[
[
1313,
63,
1101
],
[
1101,
23,
982
]
],
[
[
1313,
63,
770
],
[
770,
24,
982
]
],
[
[
1313,
23,
1135
],
[
1135,
... | [
[
[
"Suvorexant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivosidenib"
]
],
[
[
"Suvorexant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
... | Suvorexant may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Ivosidenib
Suvorexant may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Ivosidenib
Suvorexant may cause a minor interaction that can limit clinical effects when taken with Naloxegol and Naloxegol may cause a moderate interaction that could exacerbate diseases when taken with Ivosidenib
Suvorexant may cause a moderate interaction that could exacerbate diseases when taken with Acalabrutinib and Acalabrutinib may cause a moderate interaction that could exacerbate diseases when taken with Ivosidenib
Suvorexant may lead to a major life threatening interaction when taken with Venetoclax and Venetoclax may cause a moderate interaction that could exacerbate diseases when taken with Ivosidenib
Suvorexant may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Ivosidenib
Suvorexant may cause a moderate interaction that could exacerbate diseases when taken with Glasdegib and Glasdegib may lead to a major life threatening interaction when taken with Ivosidenib
Suvorexant may cause a moderate interaction that could exacerbate diseases when taken with Pazopanib and Pazopanib may lead to a major life threatening interaction when taken with Ivosidenib
Suvorexant may lead to a major life threatening interaction when taken with Fluconazole and Fluconazole may lead to a major life threatening interaction when taken with Ivosidenib |
DB00850 | DB09278 | 1,630 | 852 | [
"DDInter1432",
"DDInter24"
] | Perphenazine | Activated charcoal | An antipsychotic phenothiazine derivative with actions and uses similar to those of chlorpromazine. | Activated charcoal, or activated carbon, is an amorphous form of carbon prepared from incomplete combustion of carbonaceous organic matter. It is activated by an oxidizing gas flow at high temperature passed over its surface to make a fine network of pores, producing a material with large surface area and high affinity for various substances. It is used as a gastric decontaminant and emergency medication to treat poisonings following excessive oral ingestion of certain medications or poisons by absorbing most drugs and toxins. However its effects is rendered poor on some compounds including strong acids or bases, methanol and substances with limited absorptive capacity (including iron, lithium, arsenic). It works by binding to the poison in the gastric contents in a reversible fashion thus may be adminstered together with a cathartic to reduce the small intestine transit time. The clinical applications of activated charcoal occured in the early 1800's. While this management for acute poisoning is considered fairly invasive, it is on the World Health Organization's List of Essential Medicines that includes the most important medications needed in a basic health system. | Moderate | 1 | [
[
[
1630,
24,
852
]
],
[
[
1630,
63,
127
],
[
127,
24,
852
]
],
[
[
1630,
24,
1411
],
[
1411,
24,
852
]
],
[
[
1630,
1,
1178
],
[
1178,
... | [
[
[
"Perphenazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Activated charcoal"
]
],
[
[
"Perphenazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Miglitol"
]... | Perphenazine may cause a moderate interaction that could exacerbate diseases when taken with Miglitol and Miglitol may cause a moderate interaction that could exacerbate diseases when taken with Activated charcoal
Perphenazine may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Activated charcoal
Perphenazine (Compound) resembles Trifluoperazine (Compound) and Trifluoperazine may cause a moderate interaction that could exacerbate diseases when taken with Activated charcoal
Perphenazine (Compound) resembles Methdilazine (Compound) and Perphenazine may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Activated charcoal
Perphenazine may cause a moderate interaction that could exacerbate diseases when taken with Miglitol and Miglitol may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Activated charcoal
Perphenazine may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Amitriptyline and Amitriptyline may cause a moderate interaction that could exacerbate diseases when taken with Activated charcoal
Perphenazine (Compound) resembles Trifluoperazine (Compound) and Trifluoperazine may cause a moderate interaction that could exacerbate diseases when taken with Miglitol and Miglitol may cause a moderate interaction that could exacerbate diseases when taken with Activated charcoal
Perphenazine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin (Compound) resembles Amitriptyline (Compound) and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Amitriptyline and Amitriptyline may cause a moderate interaction that could exacerbate diseases when taken with Activated charcoal
Perphenazine (Compound) resembles Methdilazine (Compound) and Perphenazine may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Amitriptyline and Amitriptyline may cause a moderate interaction that could exacerbate diseases when taken with Activated charcoal |
DB00771 | DB00909 | 262 | 306 | [
"DDInter397",
"DDInter1971"
] | Clidinium | Zonisamide | Clidinium is a synthetic anticholinergic agent which has been shown in experimental and clinical studies to have a pronounced antispasmodic and antisecretory effect on the gastrointestinal tract. It inhibits muscarinic actions of acetylcholine at postganglionic parasympathetic neuroeffector sites. It is used for the treatment of peptic ulcer disease and also to help relieve abdominal or stomach spasms or cramps due to colicky abdominal pain, diverticulitis, and irritable bowel syndrome. | Zonisamide is a sulfonamide anticonvulsant used as an adjunctive therapy in adults with partial-onset seizures.[L42530,L42535] Zonisamide may act by blocking repetitive firing of voltage-gated sodium channels, leading to a reduction of T-type calcium channel currents or by binding allosterically to GABA receptors. This latter action may inhibit the uptake of the inhibitory neurotransmitter GABA while enhancing the uptake of the excitatory neurotransmitter glutamate.[L42530,L42535] Zonisamide represents an alternative for patients that remain refractory to established antiepileptic drugs. In 1989, it was approved for commercial use in Japan. The US and Europe approved it in 2000 and 2005, respectively.[A1379,A1383] | Major | 2 | [
[
[
262,
25,
306
]
],
[
[
262,
24,
407
],
[
407,
63,
306
]
],
[
[
262,
63,
475
],
[
475,
24,
306
]
],
[
[
262,
24,
537
],
[
537,
64,... | [
[
[
"Clidinium",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Zonisamide"
]
],
[
[
"Clidinium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
],
[
"Opium",
"{u... | Clidinium may cause a moderate interaction that could exacerbate diseases when taken with Opium and Opium may cause a moderate interaction that could exacerbate diseases when taken with Zonisamide
Clidinium may cause a moderate interaction that could exacerbate diseases when taken with Morphine and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Zonisamide
Clidinium may cause a moderate interaction that could exacerbate diseases when taken with Cyclizine and Cyclizine may lead to a major life threatening interaction when taken with Zonisamide
Clidinium may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may lead to a major life threatening interaction when taken with Zonisamide
Clidinium may cause a moderate interaction that could exacerbate diseases when taken with Dicyclomine and Dicyclomine may lead to a major life threatening interaction when taken with Zonisamide
Clidinium (Compound) resembles Trospium (Compound) and Clidinium may cause a moderate interaction that could exacerbate diseases when taken with Trospium and Trospium may lead to a major life threatening interaction when taken with Zonisamide
Clidinium may cause a moderate interaction that could exacerbate diseases when taken with Opium and Opium may cause a moderate interaction that could exacerbate diseases when taken with Pentoxyverine and Pentoxyverine may cause a moderate interaction that could exacerbate diseases when taken with Zonisamide
Clidinium may cause a moderate interaction that could exacerbate diseases when taken with Metoclopramide and Metoclopramide (Compound) causes Somnolence (Side Effect) and Somnolence (Side Effect) is caused by Zonisamide (Compound)
Clidinium may cause a moderate interaction that could exacerbate diseases when taken with Morphine and Morphine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Zonisamide (Compound) |
DB00619 | DB12147 | 1,419 | 241 | [
"DDInter909",
"DDInter661"
] | Imatinib | Erdafitinib | Imatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001. It was deemed a "miracle drug" due to its clinical success, as oncologist Dr. Brian noted that "complete hematologic responses were observed in 53 of 54 patients with CML treated with a daily dosage of 300 mg or more and typically occurred in the first four weeks of therapy".. The discovery of imatinib also established a new group of therapy called "targeted therapy", since treatment can be tailored specifically to the unique cancer genetics of each patient. Imatinib was approved on February 1st,2001 by the FDA and November 7th, 2001 by the EMA; however, its European approval has been withdrawn in October 2023.[A263036,L49746,L49751] | In early April of 2019, the US FDA approved Janssen Pharmaceutical Companies' brand name Balversa (erdafitinib) as the first-ever fibroblast growth factor receptor (FGFR) kinase inhibitor indicated for patients with locally advanced or metastatic urothelial carcinoma, with susceptible FGFR3 or FGFR2 genetic alterations, that has progressed during or following platinum-containing chemotherapy, including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy. [L5956, L5959] At the same time, the FDA also approved the therascreen FGFR RGQ RT-PCR Kit (Qiagen) for utilization as a companion diagnostic with erdafitinib for selecting patients for the indicated therapy [L5956, L5959]. Erdafitinib is the first personalized treatment targeting susceptible FGFR genetic alterations for patients with metastatic bladder cancer, which demonstrates the development of more personalized and precise medicines tailoring to a patient's specific genetic mutation.[L5956, L5959] Considering urothelial cancer is statistically the fourth most common kind of cancer in the world, the introduction of erdafitinib offers a much-needed new option in the ever-expanding therapeutic tool kit to treat such a prevalent medical condition. | Moderate | 1 | [
[
[
1419,
24,
241
]
],
[
[
1419,
25,
1456
],
[
1456,
24,
241
]
],
[
[
1419,
24,
384
],
[
384,
24,
241
]
],
[
[
1419,
25,
982
],
[
982,
... | [
[
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Erdafitinib"
]
],
[
[
"Imatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Venetoclax"
],
[
"Venetoclax",
... | Imatinib may lead to a major life threatening interaction when taken with Venetoclax and Venetoclax may cause a moderate interaction that could exacerbate diseases when taken with Erdafitinib
Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Erdafitinib
Imatinib may lead to a major life threatening interaction when taken with Ivosidenib and Ivosidenib may cause a moderate interaction that could exacerbate diseases when taken with Erdafitinib
Imatinib may lead to a major life threatening interaction when taken with Cisapride and Cisapride may cause a moderate interaction that could exacerbate diseases when taken with Erdafitinib
Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Vinblastine and Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Erdafitinib
Imatinib (Compound) resembles Nilotinib (Compound) and Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Erdafitinib
Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Erdafitinib
Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone may lead to a major life threatening interaction when taken with Erdafitinib
Imatinib may lead to a major life threatening interaction when taken with Apalutamide and Apalutamide may lead to a major life threatening interaction when taken with Erdafitinib |
DB00365 | DB00653 | 839 | 544 | [
"DDInter842",
"DDInter1120"
] | Grepafloxacin | Magnesium sulfate | Grepafloxacin is an oral broad-spectrum quinoline antibacterial agent used to treat bacterial infections. Due to the QTc-prolonging potential, as indicated by the changes in the QT interval on the electrocardiogram, and the risk for cardiovascular adverse events, grepafloxacin was withdrawn in the United States. | A small colorless crystal used as an anticonvulsant, a cathartic, and an electrolyte replenisher in the treatment of pre-eclampsia and eclampsia. It causes direct inhibition of action potentials in myometrial muscle cells. Excitation and contraction are uncoupled, which decreases the frequency and force of contractions. (From AMA Drug Evaluations Annual, 1992, p1083) | Moderate | 1 | [
[
[
839,
24,
544
]
],
[
[
839,
24,
1473
],
[
1473,
63,
544
]
],
[
[
839,
25,
175
],
[
175,
24,
544
]
],
[
[
839,
25,
167
],
[
167,
6... | [
[
[
"Grepafloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium sulfate"
]
],
[
[
"Grepafloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium gluc... | Grepafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Magnesium gluconate and Magnesium gluconate may cause a moderate interaction that could exacerbate diseases when taken with Magnesium sulfate
Grepafloxacin may lead to a major life threatening interaction when taken with Triamcinolone and Triamcinolone may cause a moderate interaction that could exacerbate diseases when taken with Magnesium sulfate
Grepafloxacin may lead to a major life threatening interaction when taken with Hydrocortisone and Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Magnesium sulfate
Grepafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Lactulose and Lactulose may cause a moderate interaction that could exacerbate diseases when taken with Magnesium sulfate
Grepafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Magnesium gluconate and Magnesium gluconate may cause a moderate interaction that could exacerbate diseases when taken with Deferiprone and Deferiprone may cause a moderate interaction that could exacerbate diseases when taken with Magnesium sulfate
Grepafloxacin may lead to a major life threatening interaction when taken with Triamcinolone and Triamcinolone (Compound) causes Shock (Side Effect) and Shock (Side Effect) is caused by Magnesium sulfate (Compound)
Grepafloxacin may lead to a major life threatening interaction when taken with Deflazacort and Deflazacort may lead to a major life threatening interaction when taken with Gatifloxacin and Gatifloxacin may cause a moderate interaction that could exacerbate diseases when taken with Magnesium sulfate
Grepafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate and Magnesium citrate may cause a minor interaction that can limit clinical effects when taken with Linaclotide and Linaclotide may cause a minor interaction that can limit clinical effects when taken with Magnesium sulfate
Grepafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Irinotecan and Irinotecan (Compound) causes Flushing (Side Effect) and Flushing (Side Effect) is caused by Magnesium sulfate (Compound) |
DB00059 | DB08827 | 1,560 | 990 | [
"DDInter1404",
"DDInter1085"
] | Pegaspargase | Lomitapide | Pegaspargase is a conjugate of monomethoxypolyethylene glycol (mPEG) and L-asparaginase (L-asparagine amidohydrolase), an asparagine-specific enzyme that converts L-asparagine into aspartic acid and ammonia. Asparagine is an amino acid that is vital for cell survival. In humans, most normal tissues can produce asparagine through the action of asparagine synthetase. However, leukemia cells have low levels of this enzyme and depend on exogenous sources. Therefore, the use of pegaspargase results in leukemic cell death.[A103,A255912,L44667] Pegaspargase has the same mechanism of action as [L-asparaginase] derived from _Escherichia coli_, a previously developed enzyme used for the treatment of acute lymphoblastic leukemia (ALL). However, using L-asparaginase derived from _Escherich | Lomitapide is a microsomal triglyceride transfer protein (MTP) inhibitor used in homozygous familial hypercholesterolemia (HoFH) patients. It is marketed under the name Juxtapid (R). | Major | 2 | [
[
[
1560,
25,
990
]
],
[
[
1560,
24,
1409
],
[
1409,
24,
990
]
],
[
[
1560,
24,
1421
],
[
1421,
63,
990
]
],
[
[
1560,
24,
1387
],
[
1387,... | [
[
[
"Pegaspargase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lomitapide"
]
],
[
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apixaban"
],
[
"Apixaban... | Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Apixaban and Apixaban may cause a moderate interaction that could exacerbate diseases when taken with Lomitapide
Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Betrixaban and Betrixaban may cause a moderate interaction that could exacerbate diseases when taken with Lomitapide
Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Terbinafine and Terbinafine may lead to a major life threatening interaction when taken with Lomitapide
Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon alfa-2b and Peginterferon alfa-2b may lead to a major life threatening interaction when taken with Lomitapide
Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Nintedanib and Nintedanib may lead to a major life threatening interaction when taken with Lomitapide
Pegaspargase may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may lead to a major life threatening interaction when taken with Lomitapide
Pegaspargase may lead to a major life threatening interaction when taken with Natalizumab and Natalizumab may lead to a major life threatening interaction when taken with Lomitapide
Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Apixaban and Apixaban may lead to a major life threatening interaction when taken with Conivaptan and Conivaptan (Compound) resembles Lomitapide (Compound)
Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin and Epirubicin (Compound) causes Discomfort (Side Effect) and Discomfort (Side Effect) is caused by Lomitapide (Compound) |
DB09133 | DB12615 | 1,527 | 1,381 | [
"DDInter965",
"DDInter1482"
] | Iothalamic acid | Plazomicin | Iothalamic acid is an iodine containing organic anion used as a diagnostic contrast agent. | Developed by Achaogen biopharmaceuticals, plazomicin is a next-generation aminoglycoside synthetically derived from . The structure of plazomicin was established via appending hydroxylaminobutyric acid to at position 1 and 2-hydroxyethyl group at position 6' . It was designed to evade all clinically relevant aminoglycoside-modifying enzymes, which contribute to the main resistance mechanism for aminoglycoside therapy . However, acquired resistance of aminoglycosides may arise through over expression of efflux pumps and ribosomal modification by bacteria, which results from amino acid or rRNA sequence mutations . Like other aminoglycosides, plazomicin is ineffective against bacterial isolates that produce 16S rRNA methyltransferases [FDA Label]. Plazomicin mediates the antibacterial activity against pathogens including carbapenem-resistant (CRE) and extended-spectrum beta-lactamase (ESBL) producing _Enterobacteriaceae_. It mediates the antibacterial activity by binding to bacterial 30S ribosomal subunit and inhibiting protein synthesis [FDA Label]. On June 28th, 2018, plazomicin sulfate was approved by the FDA for use in adult patients for the treatment of complicated urinary tract infections (cUTI) including Pyelonephritis. It is marketed as Zemdri and is administered via once-daily intravenous infusion. | Major | 2 | [
[
[
1527,
25,
1381
]
],
[
[
1527,
64,
416
],
[
416,
24,
1381
]
],
[
[
1527,
64,
1441
],
[
1441,
25,
1381
]
],
[
[
1527,
64,
416
],
[
416,
... | [
[
[
"Iothalamic acid",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Plazomicin"
]
],
[
[
"Iothalamic acid",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Kanamycin"
],
[
"Kanamycin",
... | Iothalamic acid may lead to a major life threatening interaction when taken with Kanamycin and Kanamycin may cause a moderate interaction that could exacerbate diseases when taken with Plazomicin
Iothalamic acid may lead to a major life threatening interaction when taken with Bacitracin and Bacitracin may lead to a major life threatening interaction when taken with Plazomicin
Iothalamic acid may lead to a major life threatening interaction when taken with Kanamycin and Kanamycin may cause a minor interaction that can limit clinical effects when taken with Lidocaine and Lidocaine may cause a minor interaction that can limit clinical effects when taken with Plazomicin
Iothalamic acid may lead to a major life threatening interaction when taken with Olsalazine and Olsalazine may cause a moderate interaction that could exacerbate diseases when taken with Kanamycin and Kanamycin may cause a moderate interaction that could exacerbate diseases when taken with Plazomicin
Iothalamic acid may lead to a major life threatening interaction when taken with Vancomycin and Vancomycin may cause a moderate interaction that could exacerbate diseases when taken with Kanamycin and Kanamycin may cause a moderate interaction that could exacerbate diseases when taken with Plazomicin
Iothalamic acid may lead to a major life threatening interaction when taken with Acyclovir and Acyclovir may cause a minor interaction that can limit clinical effects when taken with Mycophenolic acid and Mycophenolic acid may cause a moderate interaction that could exacerbate diseases when taken with Plazomicin
Iothalamic acid may lead to a major life threatening interaction when taken with Ibuprofen and Ibuprofen may lead to a major life threatening interaction when taken with Acetylsalicylic acid and Acetylsalicylic acid may cause a moderate interaction that could exacerbate diseases when taken with Plazomicin
Iothalamic acid may lead to a major life threatening interaction when taken with Methotrexate and Methotrexate may lead to a major life threatening interaction when taken with Acetylsalicylic acid and Acetylsalicylic acid may cause a moderate interaction that could exacerbate diseases when taken with Plazomicin
Iothalamic acid may lead to a major life threatening interaction when taken with Sirolimus and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Lidocaine and Lidocaine may cause a minor interaction that can limit clinical effects when taken with Plazomicin |
DB06636 | DB09075 | 1,623 | 498 | [
"DDInter980",
"DDInter621"
] | Isavuconazonium | Edoxaban | Isavuconazonium is a second-generation triazole antifungal approved on March 6, 2015 by the FDA and July 2015 by the EMA for the treatment of adults with invasive aspergillosis and invasive mucormycosis, marketed by Astellas under the brand Cresemba. It is the prodrug form of isavuconazole, the active moiety, and it is available in oral and parenteral formulations. Due to low solubility in water of isavuconazole on its own, the isovuconazonium formulation is favorable as it has high solubility in water and allows for intravenous administration. This formulation also avoids the use of a cyclodextrin vehicle for solubilization required for intravenous administration of other antifungals such as voriconazole and posaconazole, eliminating concerns of nephrotoxicity associated with cyclodextrin. Isovuconazonium has excellent | Edoxaban is a member of the Novel Oral Anti-Coagulants (NOACs) class of drugs, and is a rapidly acting, oral, selective factor Xa inhibitor. By inhibiting factor Xa, a key protein in the coagulation cascade, edoxaban prevents the stepwise amplification of protein factors needed to form blood clots. It is indicated to reduce the risk of stroke and systemic embolism (SE) in patients with nonvalvular atrial fibrillation (NVAF) and for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) following 5-10 days of initial therapy with a parenteral anticoagulant. Traditionally, warfarin, a vitamin K antagonist, was used for stroke prevention in these individuals but effective use of this drug is limited by it's delayed onset, narrow therapeutic window, need for regular monitoring and INR testing, and numerous drug-drug and drug-food interactions. This has prompted enthusiasm for newer agents such as dabigatran, apixaban, and rivaroxaban for effective clot prevention. In addition to once daily dosing, the benefits over warfarin also include significant reductions in hemorrhagic stroke and GI bleeding, and improved compliance, which is beneficial as many patients will be on lifelong therapy. | Moderate | 1 | [
[
[
1623,
24,
498
]
],
[
[
1623,
62,
222
],
[
222,
24,
498
]
],
[
[
1623,
24,
1017
],
[
1017,
63,
498
]
],
[
[
1623,
25,
1476
],
[
1476,
... | [
[
[
"Isavuconazonium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Edoxaban"
]
],
[
[
"Isavuconazonium",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sibutramine"
],
... | Isavuconazonium may cause a minor interaction that can limit clinical effects when taken with Sibutramine and Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Edoxaban
Isavuconazonium may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib and Lorlatinib may cause a moderate interaction that could exacerbate diseases when taken with Edoxaban
Isavuconazonium may lead to a major life threatening interaction when taken with Brigatinib and Brigatinib may cause a moderate interaction that could exacerbate diseases when taken with Edoxaban
Isavuconazonium may lead to a major life threatening interaction when taken with Enzalutamide and Enzalutamide may cause a moderate interaction that could exacerbate diseases when taken with Edoxaban
Isavuconazonium may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib and Dasatinib may lead to a major life threatening interaction when taken with Edoxaban
Isavuconazonium may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib and Fedratinib may lead to a major life threatening interaction when taken with Edoxaban
Isavuconazonium may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib and Ponatinib may lead to a major life threatening interaction when taken with Edoxaban
Isavuconazonium may lead to a major life threatening interaction when taken with Eliglustat and Eliglustat may lead to a major life threatening interaction when taken with Edoxaban
Isavuconazonium may lead to a major life threatening interaction when taken with Neratinib and Neratinib may lead to a major life threatening interaction when taken with Edoxaban |
DB00448 | DB11071 | 1,215 | 1,004 | [
"DDInter1022",
"DDInter1449"
] | Lansoprazole | Phenyl salicylate | Lansoprazole marketed under the brand Prevacid, is a proton pump inhibitor (PPI) and is structurally classified as a substituted benzimidazole. It reduces gastric acid secretion by targeting gastric H,K-ATPase pumps and is thus effective at promoting healing in ulcerative diseases, and treating gastroesophageal reflux disease (GERD) along with other pathologies caused by excessive acid secretion. | Phenyl salicylate is a 2-hydroxybenzoic acid phenyl ester. It is utilized in some manufacturing processes of polymers, lacquers, adhesives, waxes, as well as polishes. It is an active ingredient in some pharmaceutical products as a mild analgesic for pain relief by releasing salicylate (found in ). Phenyl salicylate may also be found in some antiseptic agents . It is synthesized by heating salicylic acid with phenol , [MSDS]. Phenyl salicylate is used as a food additive in the USA . This compound belongs to the class of organic compounds known as depsides and depsidones. These are polycyclic compounds that is either a polyphenolic compound composed of two or more monocyclic aromatic units linked by an ester bond (depside), or a compound containing the depsidone structure (depsidone) . | Minor | 0 | [
[
[
1215,
23,
1004
]
],
[
[
1215,
40,
837
],
[
837,
23,
1004
]
],
[
[
1215,
24,
416
],
[
416,
24,
1004
]
],
[
[
1215,
23,
256
],
[
256,
... | [
[
[
"Lansoprazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Phenyl salicylate"
]
],
[
[
"Lansoprazole",
"{u} (Compound) resembles {v} (Compound)",
"Pantoprazole"
],
[
"Pantoprazole",
"{u} may ca... | Lansoprazole (Compound) resembles Pantoprazole (Compound) and Pantoprazole may cause a minor interaction that can limit clinical effects when taken with Phenyl salicylate
Lansoprazole may cause a moderate interaction that could exacerbate diseases when taken with Kanamycin and Kanamycin may cause a moderate interaction that could exacerbate diseases when taken with Phenyl salicylate
Lansoprazole may cause a minor interaction that can limit clinical effects when taken with Prasugrel and Prasugrel may cause a moderate interaction that could exacerbate diseases when taken with Phenyl salicylate
Lansoprazole (Compound) resembles Pantoprazole (Compound) and Pantoprazole (Compound) resembles Esomeprazole (Compound) and Esomeprazole may cause a minor interaction that can limit clinical effects when taken with Phenyl salicylate
Lansoprazole (Compound) resembles Esomeprazole (Compound) and Esomeprazole (Compound) resembles Pantoprazole (Compound) and Pantoprazole may cause a minor interaction that can limit clinical effects when taken with Phenyl salicylate
Lansoprazole may cause a moderate interaction that could exacerbate diseases when taken with Kanamycin and Kanamycin may cause a moderate interaction that could exacerbate diseases when taken with Pantoprazole and Pantoprazole may cause a minor interaction that can limit clinical effects when taken with Phenyl salicylate
Lansoprazole may cause a minor interaction that can limit clinical effects when taken with Prasugrel and Prasugrel may cause a minor interaction that can limit clinical effects when taken with Pantoprazole and Pantoprazole may cause a minor interaction that can limit clinical effects when taken with Phenyl salicylate
Lansoprazole may cause a moderate interaction that could exacerbate diseases when taken with Kanamycin and Kanamycin may cause a moderate interaction that could exacerbate diseases when taken with Dexlansoprazole and Dex
Lansoprazole may cause a moderate interaction that could exacerbate diseases when taken with Clopidogrel and Clopidogrel may cause a minor interaction that can limit clinical effects when taken with Dexlansoprazole and Dex |
DB00831 | DB01087 | 1,178 | 1,520 | [
"DDInter1866",
"DDInter1520"
] | Trifluoperazine | Primaquine | A phenothiazine with actions similar to chlorpromazine. It is used as an antipsychotic and an antiemetic. | An aminoquinoline that is given by mouth to produce a radical cure and prevent relapse of vivax and ovale malarias following treatment with a blood schizontocide. It has also been used to prevent transmission of falciparum malaria by those returning to areas where there is a potential for re-introduction of malaria. Adverse effects include anemias and GI disturbances. (From Martindale, The Extra Pharmacopeia, 30th ed, p404) | Moderate | 1 | [
[
[
1178,
24,
1520
]
],
[
[
1178,
25,
1487
],
[
1487,
64,
1520
]
],
[
[
1178,
6,
7950
],
[
7950,
45,
1520
]
],
[
[
1178,
21,
28722
],
[
28... | [
[
[
"Trifluoperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Primaquine"
]
],
[
[
"Trifluoperazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Hydroxychloroquine"
],
[... | Trifluoperazine may lead to a major life threatening interaction when taken with Hydroxychloroquine and Hydroxychloroquine may lead to a major life threatening interaction when taken with Primaquine
Trifluoperazine (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Primaquine (Compound)
Trifluoperazine (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Primaquine (Compound)
Trifluoperazine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Primaquine
Trifluoperazine (Compound) resembles Promazine (Compound) and Promazine may cause a moderate interaction that could exacerbate diseases when taken with Primaquine
Trifluoperazine may cause a moderate interaction that could exacerbate diseases when taken with Abarelix and Abarelix may cause a moderate interaction that could exacerbate diseases when taken with Primaquine
Trifluoperazine may cause a moderate interaction that could exacerbate diseases when taken with Romidepsin and Romidepsin may cause a moderate interaction that could exacerbate diseases when taken with Primaquine
Trifluoperazine may cause a moderate interaction that could exacerbate diseases when taken with Granisetron and Granisetron may cause a moderate interaction that could exacerbate diseases when taken with Primaquine
Trifluoperazine (Compound) resembles Clomipramine (Compound) and Clomipramine may cause a moderate interaction that could exacerbate diseases when taken with Primaquine |
DB06228 | DB14975 | 792 | 988 | [
"DDInter1609",
"DDInter1949"
] | Rivaroxaban | Voxelotor | Rivaroxaban is an anticoagulant and the first orally active direct factor Xa inhibitor. Unlike warfarin, routine lab monitoring of INR is not necessary. However there is no antidote available in the event of a major bleed. Only the 10 mg tablet can be taken without regard to food. The 15 mg and 20 mg tablet should be taken with food. FDA approved on July 1, 2011. | Voxelotor is a novel hemoglobin S polymerization inhibitor for the treatment of sickle cell disease. This is a genetically inherited condition most prevalent in the Middle East, Africa, and certain parts of India. Sickle cell disease can lead to excruciating pain, stroke, infection, and various other complications arising from the blockage of blood vessels. Voxelotor was granted accelerated FDA approval on November 25 2019, as it is likely to be a promising treatment for the 100,000 individuals in the U.S. suffering from the disease, in addition to 20 million others worldwide. It was developed by Global Blood Therapeutics, Inc. and is unique from other drugs used to treat sickle cell anemia, such as [hydroxyurea], [L-glutamine], and [crizanlizumab][A188135,A188138] due to its novel mechanism of action. The EMA approved the use of voxelotor for the treatment of hemolytic anemia associated with sickle cell disease in February 2022.[L41419,L41424] | Moderate | 1 | [
[
[
792,
24,
988
]
],
[
[
792,
63,
222
],
[
222,
23,
988
]
],
[
[
792,
24,
466
],
[
466,
23,
988
]
],
[
[
792,
64,
126
],
[
126,
24,... | [
[
[
"Rivaroxaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Voxelotor"
]
],
[
[
"Rivaroxaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
[
... | Rivaroxaban may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Voxelotor
Rivaroxaban may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and Darolutamide may cause a minor interaction that can limit clinical effects when taken with Voxelotor
Rivaroxaban may lead to a major life threatening interaction when taken with Warfarin and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Voxelotor
Rivaroxaban may lead to a major life threatening interaction when taken with Ticagrelor and Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Voxelotor
Rivaroxaban may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib and Gilteritinib may cause a moderate interaction that could exacerbate diseases when taken with Voxelotor
Rivaroxaban may cause a moderate interaction that could exacerbate diseases when taken with Quinine and Quinine may cause a moderate interaction that could exacerbate diseases when taken with Voxelotor
Rivaroxaban may lead to a major life threatening interaction when taken with Apalutamide and Apalutamide may lead to a major life threatening interaction when taken with Voxelotor
Rivaroxaban may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fluconazole may lead to a major life threatening interaction when taken with Voxelotor
Rivaroxaban may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may lead to a major life threatening interaction when taken with Voxelotor |
DB05015 | DB12130 | 1,077 | 1,017 | [
"DDInter174",
"DDInter1094"
] | Belinostat | Lorlatinib | Belinostat is a novel agent that inhibits the enzyme histone deacetylase (HDAC) with a sulfonamide-hydroxamide structure. It was developed as an orphan drug to target hematological malignancies and solid tumors by TopoTarget. The safety and efficacy of belinostat is currently being evaluated for use in combination with traditional front-line therapies for the treatment of PTCL. Intravenous administration of the agent is available as Beleodaq as monotherapy and the dosing regimen involves a 21-day cycle. It was US-approved in July 2014 as a therapeutic agent for relapsed or refractory peripheral T-cell lymphoma. | Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer which was first approved by the US FDA in November of 2018. It was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-positive non-small cell lung cancer, followed by an expanded approval in 2022 to include lorlatinib as a first-line treatment option in advanced ALK-positive NSCLC. | Moderate | 1 | [
[
[
1077,
24,
1017
]
],
[
[
1077,
25,
976
],
[
976,
24,
1017
]
],
[
[
1077,
63,
139
],
[
139,
24,
1017
]
],
[
[
1077,
24,
738
],
[
738,
... | [
[
[
"Belinostat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
]
],
[
[
"Belinostat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tofacitinib"
],
[
"Tofacitin... | Belinostat may lead to a major life threatening interaction when taken with Tofacitinib and Tofacitinib may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Belinostat may cause a moderate interaction that could exacerbate diseases when taken with Zidovudine and Zidovudine may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Belinostat may cause a moderate interaction that could exacerbate diseases when taken with Niraparib and Niraparib may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Belinostat may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib and Gilteritinib may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Belinostat may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Belinostat may lead to a major life threatening interaction when taken with Cladribine and Cladribine may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Belinostat may cause a moderate interaction that could exacerbate diseases when taken with Capmatinib and Capmatinib may lead to a major life threatening interaction when taken with Lorlatinib
Belinostat may cause a moderate interaction that could exacerbate diseases when taken with Erdafitinib and Erdafitinib may lead to a major life threatening interaction when taken with Lorlatinib
Belinostat may cause a moderate interaction that could exacerbate diseases when taken with Atazanavir and Atazanavir may lead to a major life threatening interaction when taken with Lorlatinib |
DB01261 | DB01284 | 170 | 1,042 | [
"DDInter1679",
"DDInter1782"
] | Sitagliptin | Tetracosactide | Sitagliptin is an oral dipeptidyl peptidase-4 (DPP-4) inhibitor used in conjunction with diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus[FDA label,A2260,A2255,A2256]. The effect of this medication leads to glucose dependent increases in insulin and decreases in glucagon to improve control of blood sugar[FDA label,A2255]. Sitagliptin was granted FDA approval on October 16, 2006. | Tetracosactide (also known as Cosyntropin) is a synthetic peptide that is identical to the 24-amino acid segment (sequence: SYSMEHFRWGKPVGKKRRPVKVYP) at the N-terminal of adrenocorticotropic hormone. ACTH (1-24), a segment similar in all species, contains the biological activity that stimulates production of corticosteroids in the adrenal cortex. Tetracosactide exhibits the same activity as natural ACTH with regard to all its biological activities. The complex results in a product whose absorption in man is effected over a longer period of time as compared to corticotropin. Therefore, therapy may be maintained with less frequent administration. | Moderate | 1 | [
[
[
170,
24,
1042
]
],
[
[
170,
63,
455
],
[
455,
23,
1042
]
],
[
[
170,
24,
659
],
[
659,
62,
1042
]
],
[
[
170,
63,
811
],
[
811,
... | [
[
[
"Sitagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetracosactide"
]
],
[
[
"Sitagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salmeterol"
],
... | Sitagliptin may cause a moderate interaction that could exacerbate diseases when taken with Salmeterol and Salmeterol may cause a minor interaction that can limit clinical effects when taken with Tetracosactide
Sitagliptin may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol and Vilanterol may cause a minor interaction that can limit clinical effects when taken with Tetracosactide
Sitagliptin may cause a moderate interaction that could exacerbate diseases when taken with Metolazone and Metolazone may cause a moderate interaction that could exacerbate diseases when taken with Tetracosactide
Sitagliptin may cause a moderate interaction that could exacerbate diseases when taken with Quinestrol and Quinestrol may cause a moderate interaction that could exacerbate diseases when taken with Tetracosactide
Sitagliptin may cause a minor interaction that can limit clinical effects when taken with Dulaglutide and Dulaglutide may cause a moderate interaction that could exacerbate diseases when taken with Tetracosactide
Sitagliptin may cause a moderate interaction that could exacerbate diseases when taken with Paliperidone and Paliperidone may cause a moderate interaction that could exacerbate diseases when taken with Tetracosactide
Sitagliptin may cause a moderate interaction that could exacerbate diseases when taken with Teriflunomide and Teriflunomide may lead to a major life threatening interaction when taken with Tetracosactide
Sitagliptin may cause a moderate interaction that could exacerbate diseases when taken with Salmeterol and Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Racepinephrine and Racepinephrine may cause a minor interaction that can limit clinical effects when taken with Tetracosactide
Sitagliptin may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol and Vilanterol may cause a moderate interaction that could exacerbate diseases when taken with Racepinephrine and Racepinephrine may cause a minor interaction that can limit clinical effects when taken with Tetracosactide |
DB00612 | DB00986 | 1,121 | 1,192 | [
"DDInter216",
"DDInter834"
] | Bisoprolol | Glycopyrronium | Bisoprolol is a cardioselective β1-adrenergic blocking agent used to treat high blood pressure.[A180472,L7219] It is considered a potent drug with a long-half life that can be used once daily to reduce the need for multiple doses of antihypertensive drugs. Bisoprolol is generally well tolerated, likely due to its β1-adrenergic receptor selectivity and is a useful alternative to non-selective β-blocker drugs in the treatment of hypertension such as [Carvedilol] and [Labetalol]. It may be used alone or in combination with other drugs to manage hypertension and can be useful in patients with chronic obstructive pulmonary disease (COPD) due to its receptor selectivity. | Glycopyrronium, also known as NVA237 or glycopyrrolate, is a racemic mixture of two enantiomers. They are both quaternary ammonium compounds and long acting muscarinic antagonists. It is one of the most commonly prescribed anticholinergic medications.[A233535,A233540] Early research into glycopyrronium use was for its indication as an adjunct therapy in the treatment of peptic ulcers.[A233570,L33090] Later research, taking advantage of the systemic distribution of muscarinic receptors through the body, found that glycopyrronium could also be used for reducing sweat gland, oral, airway, and gastric secretions; as well as reducing cardiac inhibitory reflexes; and reducing bronchoconstriction in COPD. Glycopyrronium is commonly prescribed as a first line treatment for a wide variety indications and is considered to have a wider therapeutic window than [tiotropium]. Glycopyrronium was originally granted FDA approval on 11 August 1961. | Moderate | 1 | [
[
[
1121,
24,
1192
]
],
[
[
1121,
24,
1511
],
[
1511,
63,
1192
]
],
[
[
1121,
24,
262
],
[
262,
24,
1192
]
],
[
[
1121,
21,
29231
],
[
292... | [
[
[
"Bisoprolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glycopyrronium"
]
],
[
[
"Bisoprolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepenzolate"
],
... | Bisoprolol may cause a moderate interaction that could exacerbate diseases when taken with Mepenzolate and Mepenzolate may cause a moderate interaction that could exacerbate diseases when taken with Glycopyrronium
Bisoprolol may cause a moderate interaction that could exacerbate diseases when taken with Clidinium and Clidinium may cause a moderate interaction that could exacerbate diseases when taken with Glycopyrronium
Bisoprolol (Compound) causes Cardiac disorder (Side Effect) and Cardiac disorder (Side Effect) is caused by Glycopyrronium (Compound)
Bisoprolol may cause a moderate interaction that could exacerbate diseases when taken with Morphine and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Glycopyrronium
Bisoprolol (Compound) resembles Metoprolol (Compound) and Metoprolol may cause a moderate interaction that could exacerbate diseases when taken with Glycopyrronium
Bisoprolol (Compound) resembles Acebutolol (Compound) and Acebutolol may cause a moderate interaction that could exacerbate diseases when taken with Glycopyrronium
Bisoprolol may cause a moderate interaction that could exacerbate diseases when taken with Trospium and Trospium (Compound) resembles Glycopyrronium (Compound) and Trospium may cause a moderate interaction that could exacerbate diseases when taken with Glycopyrronium
Bisoprolol may cause a moderate interaction that could exacerbate diseases when taken with Mepenzolate and Mepenzolate may cause a moderate interaction that could exacerbate diseases when taken with Clidinium and Clidinium may cause a moderate interaction that could exacerbate diseases when taken with Glycopyrronium
Bisoprolol may cause a moderate interaction that could exacerbate diseases when taken with Clidinium and Clidinium may cause a moderate interaction that could exacerbate diseases when taken with Mepenzolate and Mepenzolate may cause a moderate interaction that could exacerbate diseases when taken with Glycopyrronium |
DB04861 | DB06703 | 1,592 | 619 | [
"DDInter1271",
"DDInter793"
] | Nebivolol | Gadobutrol | Nebivolol is a racemic mixture of 2 enantiomers where one is a beta adrenergic antagonist and the other acts as a cardiac stimulant without beta adrenergic activity. Treatment with nebivolol leads to a greater decrease in systolic and diastolic blood pressure than [atenolol], [propranolol], or [pindolol]. Nebivolol and other beta blockers are generally not first line therapies as many patients are first treated with thiazide diuretics. Nebivolol was granted FDA approval on 17 December 2007. | Gadobutrol is a second-generation extracellular non-ionic macrocyclic GBCA (gadolinium-based contrast agent) used in magnetic resonance imaging (MRI) in adults and children older than 2 years of age. Due to its physicochemical properties, gadobutrol is formulated at twice the gadolinium ion concentration compared to other GBCA and thus requires a lesser injection volume. Like other GBCA, gadobutrol usage carries the risk of nephrogenic systemic fibrosis (NSF) due to the dissociation of gadolinium from the chelates, although gadobutrol tends to have a lower risk of NSF thanks to the macrocyclic structures that limit dechelation of gadolinium. | Moderate | 1 | [
[
[
1592,
24,
619
]
],
[
[
1592,
21,
28810
],
[
28810,
60,
619
]
],
[
[
1592,
24,
1013
],
[
1013,
63,
619
]
],
[
[
1592,
21,
28810
],
[
28... | [
[
[
"Nebivolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gadobutrol"
]
],
[
[
"Nebivolol",
"{u} (Compound) causes {v} (Side Effect)",
"Gastrointestinal pain"
],
[
"Gastrointestinal pain",
"{u}... | Nebivolol (Compound) causes Gastrointestinal pain (Side Effect) and Gastrointestinal pain (Side Effect) is caused by Gadobutrol (Compound)
Nebivolol may cause a moderate interaction that could exacerbate diseases when taken with Tyropanoic acid and Tyropanoic acid may cause a moderate interaction that could exacerbate diseases when taken with Gadobutrol
Nebivolol (Compound) causes Gastrointestinal pain (Side Effect) and Gastrointestinal pain (Side Effect) is caused by Acebutolol (Compound) and Acebutolol may cause a moderate interaction that could exacerbate diseases when taken with Gadobutrol
Nebivolol (Compound) causes Diarrhoea (Side Effect) and Diarrhoea (Side Effect) is caused by Gadoteridol (Compound) and Gadoteridol (Compound) resembles Gadobutrol (Compound)
Nebivolol may cause a moderate interaction that could exacerbate diseases when taken with Tyropanoic acid and Tyropanoic acid may cause a moderate interaction that could exacerbate diseases when taken with Acebutolol and Acebutolol may cause a moderate interaction that could exacerbate diseases when taken with Gadobutrol
Nebivolol may cause a moderate interaction that could exacerbate diseases when taken with Gadodiamide and Gadodiamide (Compound) is included by Magnetic Resonance Contrast Activity (Pharmacologic Class) and Magnetic Resonance Contrast Activity (Pharmacologic Class) includes Gadobutrol (Compound)
Nebivolol may cause a moderate interaction that could exacerbate diseases when taken with Gadodiamide and Gadodiamide (Compound) causes Infection (Side Effect) and Infection (Side Effect) is caused by Gadobutrol (Compound)
Nebivolol may cause a moderate interaction that could exacerbate diseases when taken with Gadofosveset trisodium and Gadofosveset trisodium (Compound) is included by Magnetic Resonance Contrast Activity (Pharmacologic Class) and Magnetic Resonance Contrast Activity (Pharmacologic Class) includes Gadobutrol (Compound)
Nebivolol may cause a moderate interaction that could exacerbate diseases when taken with Gadofosveset trisodium and Gadofosveset trisodium (Compound) causes Infection (Side Effect) and Infection (Side Effect) is caused by Gadobutrol (Compound) |
DB06206 | DB09389 | 1,268 | 517 | [
"DDInter1719",
"DDInter1315"
] | Sugammadex | Norgestrel | Sugammadex is a selective relaxant binding agent indicated for reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide during surgery. Rocuronium bromide and vecuronium bromide are neuromuscular blocking medications that cause temporary paralysis and are especially useful for general anesthesia, ventilation, or tracheal intubation that patients may require for surgery. Sugammadex provides a new treatment option to reverse the effects of those medications and possibly help patients recover sooner post-surgery. Sugammadex (brand name Bridion) is marketed by Merck Sharp and Dohme, and was approved by the United States FDA on December 15, 2015. | Norgestrel is synthetic steroidal progestin that is used in combination with ethinyl estradiol for oral contraception. Norgestrel is composed of a racemic mixture of two stereoisomers, dextronorgestrel and levonorgestrel. However, only the levorotary enantiomer ([levonorgestrel]) is biologically active. | Major | 2 | [
[
[
1268,
25,
517
]
],
[
[
1268,
63,
279
],
[
279,
62,
1647
],
[
1647,
24,
517
]
],
[
[
1268,
63,
11
],
[
11,
24,
723
],
[
723,
24,
... | [
[
[
"Sugammadex",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Norgestrel"
]
],
[
[
"Sugammadex",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anisindione"
],
[
"Anisindio... | Sugammadex may cause a moderate interaction that could exacerbate diseases when taken with Anisindione and Anisindione may cause a minor interaction that can limit clinical effects when taken with Acarbose and Acarbose may cause a moderate interaction that could exacerbate diseases when taken with Norgestrel
Sugammadex may cause a moderate interaction that could exacerbate diseases when taken with Toremifene and Toremifene may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Norgestrel
Sugammadex may cause a moderate interaction that could exacerbate diseases when taken with Anisindione and Anisindione may cause a moderate interaction that could exacerbate diseases when taken with Rosuvastatin and Rosuvastatin may cause a minor interaction that can limit clinical effects when taken with Norgestrel
Sugammadex may cause a moderate interaction that could exacerbate diseases when taken with Argatroban and Argatroban may lead to a major life threatening interaction when taken with Dasatinib and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Norgestrel
Sugammadex may cause a moderate interaction that could exacerbate diseases when taken with Toremifene and Toremifene may cause a moderate interaction that could exacerbate diseases when taken with Pioglitazone and Pioglitazone may cause a minor interaction that can limit clinical effects when taken with Norgestrel
Sugammadex may cause a moderate interaction that could exacerbate diseases when taken with Anisindione and Anisindione may lead to a major life threatening interaction when taken with Miconazole and Miconazole may cause a moderate interaction that could exacerbate diseases when taken with Norgestrel
Sugammadex may cause a moderate interaction that could exacerbate diseases when taken with Lepirudin and Lepirudin may lead to a major life threatening interaction when taken with Fedratinib and Fedratinib may cause a moderate interaction that could exacerbate diseases when taken with Norgestrel
Sugammadex may cause a moderate interaction that could exacerbate diseases when taken with Toremifene and Toremifene may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Norgestrel
Sugammadex may cause a moderate interaction that could exacerbate diseases when taken with Apixaban and Apixaban may cause a moderate interaction that could exacerbate diseases when taken with Miconazole and Miconazole may cause a moderate interaction that could exacerbate diseases when taken with Norgestrel |
DB00850 | DB01124 | 1,630 | 1,411 | [
"DDInter1432",
"DDInter1828"
] | Perphenazine | Tolbutamide | An antipsychotic phenothiazine derivative with actions and uses similar to those of chlorpromazine. | Tolbutamide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It is structurally similar to acetohexamide, chlorpropamide and tolazamide and belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release insulin. Sulfonylureas increase both basal insulin secretion and meal-stimulated insulin release. Medications in this class differ in their dose, rate of absorption, duration of action, route of elimination and binding site on their target pancreatic β cell receptor. Sulfonylureas also increase peripheral glucose utilization, decrease hepatic gluconeogenesis and may increase the number and sensitivity of insulin receptors. Sulfonylureas are associated with weight gain, though less so than insulin. Due to their mechanism of action, sulfonylureas may cause hypoglycemia and require consistent food intake to decrease this risk. The risk of hypoglycemia is increased in elderly, debilitated and malnourished individuals. Tolbutamide appears to be metabolized in the liver. Tolbutamide and its metabolites are excreted in urine (75-85%) and feces. | Moderate | 1 | [
[
[
1630,
24,
1411
]
],
[
[
1630,
24,
959
],
[
959,
40,
1411
]
],
[
[
1630,
63,
245
],
[
245,
40,
1411
]
],
[
[
1630,
6,
10215
],
[
10215,... | [
[
[
"Perphenazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolbutamide"
]
],
[
[
"Perphenazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
],
... | Perphenazine may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide (Compound) resembles Tolbutamide (Compound)
Perphenazine may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride (Compound) resembles Tolbutamide (Compound)
Perphenazine (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Tolbutamide (Compound)
Perphenazine (Compound) causes Erythema (Side Effect) and Erythema (Side Effect) is caused by Tolbutamide (Compound)
Perphenazine may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec and Insulin degludec may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide
Perphenazine (Compound) resembles Trifluoperazine (Compound) and Trifluoperazine may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide
Perphenazine may cause a moderate interaction that could exacerbate diseases when taken with Epinephrine and Epinephrine may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide
Perphenazine (Compound) resembles Methotrimeprazine (Compound) and Methotrimeprazine may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide
Perphenazine may cause a moderate interaction that could exacerbate diseases when taken with Formoterol and Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide |
DB00202 | DB01172 | 190 | 416 | [
"DDInter1716",
"DDInter1004"
] | Succinylcholine | Kanamycin | Succinylcholine is a depolarizing skeletal muscle relaxant consisting of two molecules of the endogenous neurotransmitter [acetylcholine] (ACh) linked by their acetyl groups. It has been widely used for over 50 years, most commonly in its chloride salt form, as a means of neuromuscular blockade during intubation and surgical procedures. Its rapid onset and offset, with effects beginning within 60 seconds of intravenous administration and lasting between four to six minutes, make succinylcholine particularly useful in the setting of short medical procedures requiring brief periods of muscle relaxation. | Kanamycin (also known as kanamycin A) is an aminoglycoside bacteriocidal antibiotic, available in oral, intravenous, and intramuscular forms, and used to treat a wide variety of infections. Kanamycin is isolated from the bacterium Streptomyces kanamyceticus and its most commonly used form is kanamycin sulfate. | Major | 2 | [
[
[
190,
25,
416
]
],
[
[
190,
21,
28680
],
[
28680,
60,
416
]
],
[
[
190,
24,
608
],
[
608,
23,
416
]
],
[
[
190,
24,
91
],
[
91,
2... | [
[
[
"Succinylcholine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Kanamycin"
]
],
[
[
"Succinylcholine",
"{u} (Compound) causes {v} (Side Effect)",
"Rash"
],
[
"Rash",
"{u} (Side Effect) is caused by {v} (Compo... | Succinylcholine (Compound) causes Rash (Side Effect) and Rash (Side Effect) is caused by Kanamycin (Compound)
Succinylcholine may cause a moderate interaction that could exacerbate diseases when taken with Lidocaine and Lidocaine may cause a minor interaction that can limit clinical effects when taken with Kanamycin
Succinylcholine may cause a moderate interaction that could exacerbate diseases when taken with Vancomycin and Vancomycin may cause a moderate interaction that could exacerbate diseases when taken with Kanamycin
Succinylcholine may cause a moderate interaction that could exacerbate diseases when taken with Magnesium sulfate and Magnesium sulfate may lead to a major life threatening interaction when taken with Kanamycin
Succinylcholine may lead to a major life threatening interaction when taken with Polymyxin B and Polymyxin B may lead to a major life threatening interaction when taken with Kanamycin
Succinylcholine may lead to a major life threatening interaction when taken with Streptomycin and Streptomycin (Compound) resembles Kanamycin (Compound) and Streptomycin may cause a moderate interaction that could exacerbate diseases when taken with Kanamycin
Succinylcholine (Compound) causes Rash (Side Effect) and Rash (Side Effect) is caused by Tobramycin (Compound) and Tobramycin (Compound) resembles Kanamycin (Compound)
Succinylcholine may cause a moderate interaction that could exacerbate diseases when taken with Lidocaine and Lidocaine (Compound) causes Paralysis (Side Effect) and Paralysis (Side Effect) is caused by Kanamycin (Compound)
Succinylcholine may cause a moderate interaction that could exacerbate diseases when taken with Magnesium sulfate and Magnesium sulfate may cause a moderate interaction that could exacerbate diseases when taken with Lactulose and Lactulose (Compound) resembles Kanamycin (Compound) |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.